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CHAPTER 1 PART I
General introduction part I and scope of this thesis
The role of pericytes in congenital diaphragmatic hernia
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Pulmonary hypertension associated with CDH is characterized by extensive muscularization 
of the vessels, which is already noticeable early in gestation. This indicates that the structural 
abnormalities start to develop when the lung is very immature. Previously, we have shown 
that the pulmonary vasculature mainly develops through angiogenesis1. The process of 
angiogenesis is described as a mechanism where endothelial cells sprout from pre-existing 
vessels to form new tubules 2. Newly formed tubes need to be stabilized by pericytes and 
this happens in a PDGFβ depended manner3 5. Many studies have studied angiogenesis in the 
vasculature of the systemic circulation and in vascular tumor growth 2, 4. To better understand 
the onset of the pathological features of pulmonary hypertension (PH) associated with 
congenital diaphragmatic hernia (CDH), a detailed analysis of the vascular development and 
organization under normal conditions and under specific pathological conditions is required. 
Understanding the development and organization of pulmonary vascular development in 
the normal condition could help to elucidate the pathological features of PH. The pathology 
of PH is characterized by hypermuscularization of the midsized and large vessels and 
neomuscularization of the small capillaries. Pericytes are prime candidates to underlie and 
eventually modulate the structural changes observed in PH associated with CDH 5, 6. However, 
little is known about the pericyte population during lung development. Pericytes in the 
proximal end of the lung have been shown to originate from a multipotent cardiacpulmonary 
progenitor pool of cells 7.This suggests that pericytes in the proximal end of the lung originate 
from a different progenitor pool than pericytes in the distal end of the lung. The different origins 
of pericytes within the lung indicate the heterogeneous nature of the pericyte population.
Differences in pericyte coverage have been linked to multiple diseases such as diabetic 
retinopathy, cancer and adult pulmonary arterial hypertension8 9 10. Therefore, we 
hypothesized that alterations in pericyte coverage in CDH is the first pathological event in the 
development of hypermuscularisation of the pulmonary vascular wall and neomuscularization 
of the capillaries (Figure 1). Furthermore, alterations in pericyte coverage in combination with 
aberrant expression of the contractile marker ACTA2 indicate the start of aberrant pericyte 
muscularization (Figure1). Muscularization of pericytes in CDH may hamper their function 
in angiogenesis resulting in reduced growth of the pulmonary vasculature, in particular the 
capillary bed. Thus, a cascade of events during the different phases of lung development can 
eventually lead the pathological characteristics of PH (Figure 1). 
Further identification of differences in pulmonary vascular cell populations may help to 
understand how PH associated with CDH arises. Whole transcriptome analysis has been 
proven to be effective in revealing molecular pathways in developmental processes 11.  This 
method provides an excellent opportunity to reveal new differentially expressed markers 
and thereby revealing new molecular mechanisms in the CDH cell populations. Once 
executed these kinds of studies can be very valuable in characterizing not only pathological 
mechanisms but also understanding normal developmental mechanisms.
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Regarding treatment possibilities for CDH, current therapeutic opportunities and treatment, 
which are beneficial for the development of the vasculature should be carefully considered. 
Sildenafil treatment has been effective in pulmonary hypertension associated with congenital 
heart disease 12. It is of high importance to identify the narrow window of opportunity for 
the administration of sildenafil since CDH is usually diagnosed during the 20-week ultra 
sound examination of all pregnancies in the Netherlands
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Figure 1 
Multiple events during the pulmonary vascular development in congenital diaphragmatic hernia lead to fewer 
capillaries and extensive muscularization of the mid-sized vessels and neo-muscularization of the small capillaries. 
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Scope of the thesis
The aim of this thesis is to identify early structural changes and the associated molecular 
mechanism associated with these changes. Together these results should provide new 
insights into the development of PH associated with CDH. 
 
In the first chapter I give an overview of the current state of research towards pulmonary 
vascular abnormalities associated with congenital diseases. Furthermore, I suggest that 
multiple congenital lung diseases show similar changes in the vasculature, which implies 
that these diseases may have some overlap in origin and cause.
In the second chapter I investigate the effect of retinoic acid inhibition on the development 
of the pulmonary vasculature. Delicate immunohistological analysis in combination with 
FACS experiments of pulmonary vascular development could be a first step in understanding 
the vascular changes in CDH. NG2 was identified as a specific pericyte marker during lung 
development. Furthermore immunofluorescent whole mount analysis together with FACS 
analysis showed increased pericyte coverage from the late pseudoglandular phase in the 
CDH mouse model. In addition, alterations in proliferation, migration and differentiation 
were observed after the inhibition of the retinoic acid pathway.
The third chapter describes the whole transcriptome analysis of four different cell populations 
isolated from embryonic lungs of E13 normal and CDH mice. This analysis facilitates to find 
the connection between genes, which are known to be involved in CDH to specific cell 
populations. Additionally, further analysis of RNA sequence data revealed downregulation 
of KLF4 in the endothelial cell population in CDH. KLF4 acts as a upstream regulator of 
NOTCH signaling, which is required for activation of the tip cell and thereby initiates the 
sprouting of endothelial cells to form new tubules. The downregulation of KLF4 therefore 
underlies the simplification of the capillary bed observed in CDH. The downregulation of 
KLF4 was further confirmed with whole mount immunofluorescent analysis.
The fourth chapter describes the effects of treatment with the PDE5 antagonist sildenafil. 
Moreover, time pregnant rats were treated with nitrofen and during the canalicular phase 
treated with sildenafil. This resulted in beneficial effects for the pups with CDH. The body 
weight improved, the lung/kidney ratio improved and the alveolar airspaces increased in 
diameter.
In the fifth chapter, the general discussion, I summarize our own findings of the different 
studies and describe future possibilities to study CDH.

CHAPTER 1 PART II
Pulmonary vascular development goes awry in 
congenital lung abnormalities
Heleen Kool, Daphne Mous, Dick Tibboel, Annelies de Klein and Robbert J. Rottier
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Abstract
Pulmonary vascular diseases of the newborn comprise a wide range of pathological 
conditions with developmental abnormalities in the pulmonary vasculature. Clinically, 
pulmonary arterial hypertension (PH) is characterized by persistent increased resistance 
of the vasculature and abnormal vascular response. The classification of PH is primarily 
based on clinical parameters instead of morphology and distinguishes five groups of PH. 
Congenital lung anomalies such as alveolar capillary dysplasia (ACD) and PH associated 
with congenital diaphragmatic hernia (CDH), but also bronchopulmonary dysplasia 
(BPD), are classified in group three.
Clearly, tight and correct regulation of pulmonary vascular development is crucial 
for normal lung development. Human and animal model systems have increased our 
knowledge and make it possible to identify and characterize affected pathways and 
study pivotal genes. Understanding of the normal development of the pulmonary 
vasculature will give new insights in the origin of the spectrum of rare diseases such 
as CDH, ACD and BPD, which render a significant clinical problem in neonatal intensive 
care units around the world.
In this review we will describe the normal pulmonary vascular development and we 
will focus on four diseases of the newborn in which abnormal pulmonary vascular 
development play a critical role in the morbidity and mortality. In the future perspective 
we indicate the lines of research that seems to be very promising for elucidating the 
molecular pathways involved in the origin of congenital pulmonary vascular disease.
ABNORMAL VASCULAR DEVELOPMENT IN CONGENITAL DISEASES 19
1
The morphology of the pulmonary vasculature
In mammals, blood is transported through the cardiovascular system that can be divided in 
the systemic and the pulmonary circulation. These two types of circulations have histological 
similarities but differ in their physiological function and anatomic position to the heart. 
Oxygenated blood is transported and distributed throughout the body by the systemic 
circulation, whereas oxygen depleted blood is transported to the lungs by the pulmonary 
circulation. The blood supply in the lung can be divided into the bronchial circulation and 
the pulmonary circulation. The bronchial circulation is mainly separated from the pulmonary 
circulation, although some overlap exists in the pre capillary region. The bronchial circulation 
comprises arteries, which align with the bronchial tree. A third of the blood in the bronchial 
circulation returns to the right atrium through the bronchial vein. The pulmonary circulation 
transports oxygen deprived blood to the gas exchange areas and oxygen-rich blood back 
to the left atrium. The bronchial circulation is part of the systemic circulation and delivers 
oxygen rich blood to the cells of the lung at high systemic pressure.
The pulmonary vasculature comprises anatomically and functionally different compartments: 
the arterial tree, the capillary bed and the venular tree. The pulmonary arteries also support 
the intrapulmonary structure and ultimately regulate gas exchange via the capillary bed. 
Prenatally, the pulmonary circulation is characterized by high pulmonary vascular resistance 
(PVR) and low blood flow (compared to the ventricular output). The thick wall and high 
vasomotor tone contribute to the high PVR. The majority of the blood flow of the cardiac 
output is diverted to other organs than the lung through the foramen ovale and the ductus 
arteriosus. This process is facilitated by the relative high resistance in the pulmonary 
circulation compared to the systemic circulation. After birth, there is a large transition from 
relative hypoxic conditions to normoxic condition. This transition induces dramatic changes 
in the PVR leading to physiological adaptations in the lung. This adaption of the lung is 
required to exerts its important function exchange gas and oxygenate the blood.
The cellular composition of the pulmonary vascular wall varies depending on the functionality 
of the vessel. The outer layer of the pulmonary arteries, the adventitia, is a loosely organized 
structure consisting of an extracellular matrix with fibroblasts, vasa vasorum and a neuronal 
network 1, 2. There is gradual change in structure from the proximal to distal end of the lung, 
which corresponds with the maturation of the developing airways. The large pulmonary 
arteries at the proximal end of the lung have a media consisting of a layer of smooth muscle 
cells in between the lamina elastic interna and externa. Towards the distal area of the lung, 
the arteries have a smaller lumen with a thinner smooth muscle cell layer and no lamina 
elastica. The smooth muscle cells in the tunica media form a heterogeneous population, 
ranging from cuboidal, synthetic cells to the characteristic elongated contractile cells. The 
contractile smooth muscle cells have more contractile fibers, have less proliferation and 
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less migration activity compared to the synthetic phenotype 3, 4. The pulmonary capillaries 
are the most distal compartment of the pulmonary vasculature and are the site where gas 
exchange takes place. Capillaries exist of a monolayer of endothelial cells, which are in direct 
contact with perivascular cells. The structure of the pulmonary veins is comparable to the 
structure of small arteries. Pulmonary veins consist of a thin intima, smooth muscle cell 
containing media in the larger veins and an adventitia containing a vaso vasorum, nerves 
and bundles of collagen and elastin fibers 2.
The development of the pulmonary vasculature
Understanding the process of normal pulmonary vascular development is a prerequisite 
to comprehend the origin of pulmonary hypertension and its associated diseases of the 
newborn. The pulmonary vasculature develops in close relation with the airways and 
has extensively been studied in rodent models. In mice, the first molecular sign of lung 
development is around embryonic day 8 when the expression of Nkx2-1 starts in the ventral 
wall of the anterior foregut (see table 1 for lung developmental stages of human and mouse). 
At embryonic day 9.5 (E9.5) in the mouse, a primitive bud evaginates from the ventral side 
of the foregut and invades the surrounding mesenchyme 5. This bud splits into two buds, 
which will form the right and left lung, but this embryonic phase is very short and rapidly 
turns into the pseudoglandular phase when the primary buds expand into the mesenchyme 
and start budding and branching until E16.5. After E16.5, when the bronchial tree is formed, 
development of the lung goes into a new stage, the canalicular phase. In mice it is very short 
(E16.5-E17.5) and during this period the terminal buds narrows. From E17.5 until postnatal 
day 5 (P5) lung development goes into the saccular stage and the precursors of the alveoli 
are formed. And finally from postnatal life onwards alveolarization starts and ends around 
P14. In humans, lung development follows a similar sequence of stages, but with a different 
timetable. Budding starts at four weeks of gestation, the pseudoglandular stage ends around 
week 6, followed by the canalicular (week 16-26), saccular (week 26-36) and alveolarisation 
(postnatal until 3 years of age) stages (Table 1).
Table 1 Overview of stages in lung development in mouse and human
Stage I Embryonic II Pseudoglandular III Canalicular IV Saccular V Alveolar
Mouse E9-12 E12-15 E15-17 E17-Birth Birth-P20
Human Wk 3-7 Wk5-17 Wk16-26 Wk26-36 Wk36-3Years
The lung endoderm and mesoderm are interacting during all these developmental stages 
via multiple molecular pathways. These molecular pathways controlling these stages have 
been discussed in extensively in two recent reviews 6 5. In this review we focus on congenital 
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diseases associated with pulmonary abnormalities and only describe the molecular players 
that have been associated with these diseases.
The past two decades new insights into the development of the pulmonary vasculature have 
been obtained. It was suggested that pulmonary vasculature in mice developed through two 
main mechanisms: the central vasculature through angiogenesis and the distal vasculature 
through vasculogenesis and either angioblasts from the mesenchyme or blood lakes would 
provide endothelial cells for vessel development 7. These two structures would fuse around 
embryonic day E13/E14 through a lytic process and circulation would start 8. A histological 
and morphological study seemed to confirm this hypothesis and the same processes would 
underlie pulmonary vascular development in human 9. The results from these studies were 
mainly obtained by histological analysis. However, fixation artifacts have led to inappropriate 
conclusion and analysis of lung development using transgenic mice expressing a lacZ 
reporter gene under the control of an early marker for endothelial cells (fetal liver kinase 1 
(Flk1)) 10, showed that the proximal and distal pulmonary vasculature was already connected 
at embryonic day 10.5 11. In addition, detailed analysis of lung samples of transgenic mice 
expressing the lacZ reporter under the control of the endothelium specific Tie2 promoter 
showed that already at day E9.5 the presence of a vascular network surrounded the 
primitive lung bud connected to the systemic circulation. This network mainly expands as 
the lung develops through angiogenesis, a process called distal angiogenesis 12. It is still not 
completely understood how the pulmonary vasculature develops and where progenitor cells 
involved in angiogenesis in the lung come from. Lineage trace experiments, instrumental 
in deciphering the origin and the fate of early precursor cells in the lung, indicate that 
specific, cardiopulmonary, progenitor cells differentiate into both cardiac and pulmonary 
mesenchymal cells. Moreover, these progenitor cells can differentiate into vascular smooth 
muscle cells and pericyte-like cells, but were only observed in the proximal end of the lung 
13. It remains unclear what the progenitors are for the perivascular cells and endothelial cells 
in the distal end of the lung. Proper lineage trace studies throughout pulmonary vascular 
development could serve to answer these questions.
Important molecular players in pulmonary vascular development
Normal pulmonary vascular development requires tight regulation of cell migration, 
proliferation and differentiation. The family of Vascular endothelial growth factors (Vegf), 
and their receptors Fetal liver kinase1 (Kdl1 or Vegfr1) and Kinase domain receptor (Kdr or 
Vegfr2), are one of the most potent angiogenic factor signaling cascades and are required 
for vascular growth and endothelial cell proliferation 14, 15. Early during lung development, 
Vegf is expressed by the epithelium and mesenchyme, but later its expression is restricted 
to the epithelium 16 where it is required for epithelial branching and morphogenesis 17. 
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In response to hypoxic conditions, as in the prenatal lung, Vegf expression is induced by 
Hypoxia-inducible transcription factor-1 and 2  (Hif1/Hif2). Hif1 and Hif2 are heterodimers 
existing of an oxygen sensitive subunit, Hif1α or Hif2α, and a constitutive Arnt/Hif1β 
subunit. At normoxic conditions, specific prolyl hydroxylases (Phd) hydroxylate the Hifα 
subunit, which is subsequently ubiquitinated and targeted for degradation via the Von-
Hippel-Lindau tumour suppressor protein pathway 18-20. Under hypoxic conditions, the Hifα 
subunit is not hydroxylated and the Hifα/Hifβ complex translocates to the nucleus where it 
binds to hypoxic responsive elements in the regulatory unit of target genes to induce the 
transcription of these genes. Among the genes that are activated under hypoxic conditions 
are several angiogenic genes, such as Vegf, which results in the growth and expansion of the 
vasculature.
Vascular development is consists of vasculogenesis and angiogenesis: vasculogenesis is the 
process where the vascular plexus is formed de novo from mesodermal progenitor cells 21, and 
angiogenesis is the process where endothelial cells sprout from preexisting vessels to form 
new tubes. There is constant competition between the leading cell, the tip cell, and the trailing 
cell, the stalk cell, to become or to stay on the tip of the sprout. Endothelial cells of the newly 
formed tubes recruit pericytes in a Platelet-derived growth factorβ (Pdgfβ) depended manner 
(Figure 1). Pericytes wrap around the newly formed endothelial tubes and induce stabilization 
and maturation 22 23 and the interaction between these two cells is crucial for normal vascular 
development. This interaction is regulated by different growth factors and their receptors, 
such as Pdgf(r) and Tgfb(r) 24. Tight regulation of this interaction is required for normal vascular 
development and disruption of this process may lead to pathological conditions. However, 
pericytes comprise a very heterogenic population in the lung and therefore they are rather 
difficult to identify. New, specific markers are required to better understand the interaction of 
pericytes and endothelial cells in both health and disease.
The specification of arteries and veins is one of the first events that take place in the 
development of the circulatory system. Arteries and veins can be distinguished from each 
other by the expression of members of a tyrosine kinase family Ephrin2 and Eph4 25. However, 
the specification of the pulmonary network occurs relatively late and the expression of 
Ephrin2 and Eph4 is not restricted to artery endothelial or vein endothelial cells, respectively 
until late in the pseudoglandular stage (Figure 1). In mice, at E13.5 endothelial cells still 
express both Ephrin2 and Eph4, but from E15.5 onwards the endothelial cells express 
either Ephrin2 or Eph4 when they become committed to arteries or veins, respectively. 
Furthermore, Ephrin expression in the lung is not restricted to endothelial cells but is also 
highly expressed by mural cells 26. Modulation of the Notch pathway results in arterial 
defects and can lead, depending on which member of the pathway is affected, to early 
prenatal death,.. For example, heterozygous Dll4 embryos suffer from remodeling defects in 
the yolk sac and have a smaller dorsal aorta 27 while the full Dll4-deficient embryos die due 
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to early lethal loss of arterial identity at E9.528. To study the lung developmental phenotype, 
tissue specific inhibition of the Notch pathway is necessary and may give new insights in the 
specification of pulmonary arteries and veins. Specification of venous endothelium includes 
expression of the nuclear receptor Chicken ovalbumin upstream transcription factor II 
(CouptfII), which is expressed in venous and lymphatic endothelium (Figure 1). CouptfII is 
highly expressed in the foregut mesenchyme at the site where later in development the lung 
will be formed. CouptfII knock-out mice die at E10 from heart defects and loss of venous 
identity in the vasculature 29. Lung specific deficient CouptfII mice show a Bochdalek-type 
congenital diaphragmatic hernia (CDH) 30, lung hypoplasia associated with CDH indicates the 
importance of CouptfII in normal lung development. 
Figure 1: Simplified scheme of pulmonary vascular compartments
Schematic overview of pulmonary vasculature, with veins (A), arteries (B) and capillaries (C). Endothelial cells 
recruit pericytes in a Pdgfβ dependent manner in the distal end of the lung(C). The pulmonary arteries are 
characterized by the expression of Eph2 and Notch family member Dll4 (A). Specification of the pulmonary veins 
includes expression of Ephrin4 and CouptfII (B).
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Fibroblast growth factors (Fgf) belong to a family of mitogens that are identified as regulators 
of lung development 31. Early during lung development Fgf10 is expressed in the mesoderm 
around the budding lung endoderm, which expresses its receptor Fgfr2. Knockout mice of 
Fgf10 32 or Fgfr2 33 resulted in mice without lungs, indicating the crucial role for this signaling 
pathway in the development of the lung. 34. However, recently it was shown that Fgf10 is not 
just inducing budding and branching of the lung during development, but that expression 
of Fgf10 is also important for the maintenance of epithelial progenitor cells by preventing 
these cells to differentiate 35. Another member of the fibroblast growth family, Fgf9, is 
important for lung mesenchyme growth and proliferation 36. More specific, Fgf9 stimulates 
proliferation of mesenchymal cells and regulates mesenchymal Sonic hedgehog signaling 
(Shh). 37. Furthermore, it is also shown that Fgf9 and Shh regulate Vegfa expression what is 
required for capillary development in the distal end of the lung 17.
Retinoic acid (RA) signaling has been shown to be of high importance for lung development 
38. Vitamin A in the blood plasma is transported by Retinol binding protein 4 (Rbp4), it binds 
to the extracellular receptor Stimulated by retinoic acid 6 (Stra6) and then through several 
enzymatic reactions it is converted into its active form RA. Active retinoic acid is secreted 
and taken up by retinoic acid responsive cells. In the cytoplasm RA binds to one of the 
three Retinoic acid receptor (RAR), Rarα, Rarβ or Rarγ 39. These complexes bind to a Retinoic 
Acid active Responsive Element (RARE) in the regulatory elements of their target genes 
and modulate transcription of these genes 40, 41. Targeted deletions of members of Rar and 
Rxr family have different effects. Double knockouts of Rarα and Rarβ result in failure to 
separate the esophagus and trachea and hypoplasia of the left and right lung. However, 
deletion of other members of the RAR and RXR family did not result in an obvious lung 
phenotype 42. Binding of retinoic acid to its receptor directly affects the target genes either 
by inducing or repressing gene expression. Many genes regulated by the RA pathway are 
involved in embryogenesis 39. However, it is possible that still many target genes have yet 
to be discovered. Tracing the activity of RARE’s in embryonic development revealed high 
activity of the RA pathway in multiple developing organs, for example in heart, hindbrain 
and diaphragm 43 44. Activity of the retinoic acid receptors is important for proper lung 
development and at E9 in mice, when the first lung buds start to develop from the foregut, RA 
signaling is highly active 38. Furthermore, in absence of retinoic acid, levels of Fgf10 decrease 
and levels of Tgfβ increase, and there is reduced budding and branching of the lung 45. More 
specific, molecular processes required for formation of the lung primordium from the 
foregut are controlled by RA receptor activity. RA is a major regulator of Wnt signaling and 
the Tgfβ pathway and thereby controls Fgf10 expression, early in lung development 46. The 
role of RA signaling in vascular development has so far only been shown in the development 
of the systemic blood circulation. In RA deficient embryos endothelial cell growth and 
proliferation is uncontrolled, indicating a role for RA in suppression of endothelial cells 
during vasculogenesis 47. Although there is no direct evidence yet that the RA pathway is 
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involved in the development of the pulmonary vasculature, it may be that this pathway is 
involved based on the intimate relation between the airways and the vasculature.
Abnormal pulmonary vascular development
Perturbations of the described molecular pathways in the pulmonary vascular development 
may cause congenital anomalies, like pulmonary hypertension (PH), in newborns, infants 
and children 48. PH is characterized by persistent increased resistance of the vasculature and 
abnormal vascular tone, which is regulated by the contraction of smooth muscle cells. Five 
groups of PH can be distinguished: pulmonary arterial hypertension, pulmonary hypertension 
due to left heart disease, pulmonary hypertension due to lung diseases and/or hypoxia, 
chronic thromboembolic pulmonary hypertension and pulmonary hypertension with unclear 
multifactorial mechanisms 49, 50(Table 2). Normally the PVR is high antenatally and decreases 
immediately after birth, reaching levels that are comparable to adult values within 2 months 
after birth. PH has an incidence of approximately 63.7 per million children 51 and can be 
idiopathic or associated with other diseases. It can cause significant morbidity and mortality. 
In children, idiopathic pulmonary arterial hypertension (iPAH) and PH due to congenital heart 
disease comprise the majority of cases. Other important causes include persistent pulmonary 
hypertension of the newborn (PPHN), bronchopulmonary dysplasia (BPD) and developmental 
lung diseases, like congenital diaphragmatic hernia (CDH), alveolar capillary dysplasia (ACD) 
and lung hypoplasia and surfactant protein abnormalities 48, 49. Mutations in specific genes have 
been reported (Table 3), but PH in children can also be associated with genetic syndromes, like 
Down syndrome, DiGeorge syndrome, VACTERL syndrome, CHARGE syndrome and Noonan 
syndrome 52. Perinatal care and prognosis in pediatric PH has improved over the last years, but 
despite the fact that there are significant differences in pulmonary vascularity between adults 
and children, most  treatment is based on experimental research or trials in adults 53. We will 
focus on iPAH, CDH, ACD and BPD which are all characterized by an abnormal pulmonary 
vascular development and in which PH plays an important role in the mortality and morbidity.
Idiopathic pulmonary arterial hypertension
iPAH is characterized by restricted blood flow through the pulmonary arterial circulation, 
elevated pulmonary vascular resistance and progressive right heart failure 54. iPAH, previously 
known as primary pulmonary hypertension, has an incidence of approximately 0.7 per million 49 
with hypertensive vasculopathy exclusively in the pulmonary circulation without a demonstrable 
cause. Young children have a reduction in arterial number and a failure of the vasculature to 
relax, whereas in older children intimal hyperplasia, occlusive changes and plexiform lesions 
are found (Figure 2). In contrast to adults, children with iPAH have more pulmonary vascular 
medial hypertrophy and less intimal fibrosis and fewer plexiform lesions 55, 56. Younger children 
have a more reactive pulmonary vascular bed with an increased prevalence of acute pulmonary
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Table 2 Classification of pulmonary hypertension*
Pulmonary arterial hypertension
Idiopathic PAH (iPAH)
Heritable PAH
BMPR2
ALK-1, ENG, SMAD9, CAV1, KCNK3
Unknown
Drug and toxin induced
Associated with other diseases
Connective tissue disease
HIV infection
Portal hypertension
Congenital heart diseases
Schistosomiasis
Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
Persistent pulmonary hypertension of the newborn (PPHN)
Pulmonary hypertension due to left heart disease
Left ventricular systolic dysfunction
Left ventricular diastolic dysfunction
Valvular disease
Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
Pulmonary hypertension due to lung diseases and/or hypoxia
Chronic obstructive pulmonary disease
Interstitial lung disease
Other pulmonary diseases with mixed restrictive and obstructive pattern
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Developmental lung diseases
Congenital diaphragmatic hernia (CDH)
Bronchopulmonary dysplasia (BPD)
Alveolar capillary disease (ACD)
Lung hypoplasia
Surfactant protein abnormalities
Pulmonary interstitial glycogenosis
Pulmonary alveolar proteinosis
Pulmonary lymphangiectasia
Chronic thromboembolic pulmonary hypertension (CTEPH)
Pulmonary hypertension with unclear multifactorial mechanisms
Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
*Adapted from the updated Dana point classification 50
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hypertensive crises 55, 57. Possible mechanisms that play a role in PAH development are endothelial 
cell dysfunction, smooth muscle cell migration and dysfunction, and abnormal apoptosis. In 
adult iPAH, in-vitro studies showed increased expression of endogenous vasoconstrictors and 
decreased expression of vasodilators 58-61. The same vasoactive factors could play a role in pediatric 
iPAH. An increased expression of thromboxane and endothelin-1 (ET-1) , both vasoconstrictive 
and proliferative mediators, are elevated in both adults and children 57, 62, 63. However, besides 
these two factors, this might also be the case for other vasoactive factors.
Heritable forms of pulmonary hypertension are caused by mutations in several genes. Point 
mutations and deletions in the bone morphogenetic protein receptor 2 (BMPR2) have been 
identified in approximately 10-40% of all patients with iPAH and are the major cause of 
heritable PAH 64. Both pediatric and adult patients with BMPR2 mutations appeared to 
have more severe disease compared to those without this mutation 57. Pfarr et al. found 
mutations in BMPR2 and two receptors of the TGFβ/BMP pathway, activin receptor-like 
kinase 1 (ACVRL1) and endoglin (ENG), in 8/29 (27.6%) of the pediatric iPAH patients 65. A 
genetic polymorphism detected in the serotonin 5-hydroxy tryptamine transporter (5HTT) 
gene is associated with iPAH in adults and might also play a role in iPAH in children. This 
polymorphism leads to elevated levels of 5HT and results in increased smooth muscle cell 
proliferation 66. Most of the genetic mutations in iPAH are only studied in adults and in 
contrast to adults, PAH in children is often associated with genetic syndromes. However, 
not all patients with a mutation in the same gene will develop severe PAH, suggesting that 
modifiers and or epigenetic regulation of expression could also play a role.
Congenital diaphragmatic hernia
Congenital diaphragmatic hernia (CDH) has an incidence of approximately 1 in 2500-3000 
live births. Beside a diaphragmatic defect, CDH is characterized by pulmonary hypoplasia and 
pulmonary hypertension, which may be due to an altered development of the pulmonary 
vasculature and a disordered process of pulmonary vascular remodeling 67, 68. Previous 
studies showed excessive muscularization of the pulmonary arteries and maladaptive 
pulmonary vascular remodeling in CDH patients 4, 67-70 (Figure 2). In contrast to the positive 
effect of inhaled NO in preterms with PH, the effectiveness of this treatment is only around 
30-40 % of patients with CDH.
Over the last years several factors involved in the abnormal pulmonary vascular development 
in CDH have been identified. Expression levels of these factors have been analyzed both in 
lung tissue of CDH patients and experimental animal models. We studied the role of the 
Von Hippel-Lindau protein (pVHL) and HIF1α and found a decrease of pVHL and HIF1α 
expression in the arterial endothelium and an elevated expression of pVHL in the pulmonary 
arterial media of human CDH cases compared to age matched controls 71. Shehata et al. 
showed increased VEGF expression in the bronchial epithelium and medial smooth muscle 
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cells and positive VEGF staining in endothelial cells, which were negative in age-matched 
controls 72. However, we have found lower expression of VEGF mRNA in the alveolar stage 
in CDH patients 73. In the process of normal remodeling of the pulmonary vasculature, 
extracellular matrix membrane proteins (MMPs) are of fundamental importance. Altered 
expression of certain MMPs and tissue inhibitors of MMPs (TIMPs) was found in human CDH 
lungs compared to control 74. Decreased expression of VEGF and its receptors is also seen 
in the nitrofen rat model of CDH 75, 76. In summary, an increase in pVHL may downregulate 
HIFα, leading to decreased expression of VEGF and a disturbance of vascular growth and 
endothelial cell proliferation during development. It would be interesting to investigate the 
oxygen concentration during the development of the (CDH) lung, to evaluate whether this 
may contribute, through HIFα, to the structural changes that contribute to the hypertension.
Abnormal RA signaling contributes to the etiology of CDH, and the first evidence of its 
involvement in CDH came from observations of pups born to rat dams with vitamin A deficient 
diets. In 25-40% of these pups a diaphragmatic hernia was present 77. This finding is supported 
by the development of a diaphragmatic defect, pulmonary hypoplasia and pulmonary vascular 
abnormalities after disruption of the retinoid signaling pathway by nitrofen 78. Furthermore, 
retinoic acid receptor (RAR) α/β double knock-out mice were found to have offspring with a 
diaphragmatic hernia 79. In addition to the animal models, measurements of the levels of retinol 
and retinol-binding protein (RBP) in de first hours after birth in human CDH newborns showed 
a significant reduction compared to matched controls, independent of maternal retinol status 
80, 81. As described above, Chen et al. showed that lower levels of RA could cause an increase 
in TGFβ and a decrease in Fgf10 45. Increased expression of TGFβ1 with immunostaining at 
the midpseudoglandular, late pseudoglandular and saccular stage of lung development is 
detected in the nitrofen rat model of congenital diaphragmatic hernia 82. Also increased mRNA 
levels of TGFβ and TGFβRII are observed in the same model 83. Teramoto et al. described a 
decrease in gene expression of Fgf10 in the nitrofen rat model 84. Since TGFβ plays a role in the 
airway branching and muscularisation of the pulmonary vasculature and Fgf10 was thought 
to regulate lung budding and branching, this might implicate that the neomuscularization and 
reduced branching in CDH may be caused by disturbances in the RA-TGFβ-Fgf10 interactions. 
Over 450 chromosomal aberrations have been reported in CDH 85 Some of the recurrent 
genetic changes are found in retinoid related genes. In autosomal recessive conditions as 
Matthew-Wood syndrome (Microophthalmia syndromic 9 (MCOPS9) or Donnai-Barrow 
syndrome; OMIM #222448 mutations in the STRA6 and LRP2 genes have been reported. 
STRA6 is the membrane receptor for retinol binding protein (RBP1) and mutations of the 
LRP2 gene leads to proteinuria with spillage of retinol-binding proteins. Deletions of COUP-
TFII on chromosome 15q26.1-26.2 86, and of FOG2 (ZFPM2; chromosome 8q23.1) or SOX7 
(8p23.1) lead to an autosomal dominant form of CDH with variable penetrance 87, 88. Beck et 
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al. showed that a deletion of the FRAS1-related extracellular matrix 1 (FREM1) gene, which 
encodes an extracellular matrix protein, can cause CDH in both human and mice 89. 
Several CDH animal models have been developed, such as the surgical models in lambs and 
rabbits, several knockout models in mice and teratogenic models in rats 78, 90. Surgical animal 
models are useful for the investigation of interventional therapies, but are less informative 
in studying the etiology and pathogenesis of CDH 90. The nitrofen model is the most 
commonly used teratogenic model for CDH. When administered to pregnant rat dams at 
gestational day 9.5, the herbicide nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether) causes 
diaphragmatic defects, lung hypoplasia and pulmonary hypertension in pups, strikingly 
similar to the human condition 90, 91.
#
*
Control
BPDiPAH
ACD CDH
Figure 2: Characteristic histology of four pulmonary vascular disease samples
Hematoxylin and eosin staining of human lungs: control, idiopathic pulmonary hypertension (iPAH), congenital 
diaphragmatic hernia (CDH), alveolar capillary dysplasia (ACD) and bronchopulmonary dysplasia (BPD). Scale bars 
100µm.
iPAH: thickening of the arteries (arrows), CDH: excessive muscularisation of the arteries (arrows), ACD: medial 
hypertrophy and muscularisation (#), malpositioning of the pulmonary veins (*) and central positioning of the 
capillaries in the alveolar septa ,BPD: fibrosis with widening of the alveolar septa.
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Alveolar capillary dysplasia
Alveolar capillary dysplasia (ACD) is a rare lethal developmental lung disorder with failure of 
alveolar capillary formation, often accompanied by misalignment of the pulmonary veins. 
This results in abnormal gas exchange, severe hypoxemia and pulmonary hypertension. The 
prevalence and incidence is not known, but the mortality rate approaches 100%. ACD is 
characterized by premature growth arrest with immature lobular development, reduced 
capillary density, thickened alveolar septa, medial hypertrophy and muscularization of small 
pulmonary arteries and distal arterioles and malposition of pulmonary veins (Figure 2). In 
50-80% of patients, ACD is associated with other congenital anomalies. Although at the 
moment a definitive diagnose can only be obtained by histological examination of lung tissue 
92, the detection of genetic changes of the Forkhead Box F1( FOXF1) locus on chromosome 
16q24 can aid the diagnosis.
Mutations of FOXF1 and deletions of the 5’ regulatory region of this transcription factor 
gene have been reported in most patients with ACD 93, 94. FOXF1 deficiency is associated with 
reduced numbers of pulmonary capillaries in patients with ACD and similar observations 
have been made studying Foxf1 heterozygous knockout mice. Conditional deficient Foxf1 
mouse models showed that loss of Foxf1 in the endothelial lineages resulted in an impaired 
angiogenesis, endothelial proliferation and VEGF signaling 95. Involvement of the FOXF1 
protein in SHH signaling has been shown both in vitro and in vivo in human and mice 92, 93, 95. 
Mahlapuu et al. showed that SHH induces the transcriptional activation of Foxf196. This may 
imply that other genes from this pathway are involved in the etiology of ACD. In addition 
to the large phenotypic overlap between human ACD and the mouse Foxf1mutant mice, 
overlapping expression profiles of lung specimens indicate that the Foxf1 mouse model is 
an excellent animal model for ACD.
Table 3 Genes involved in pulmonary vascular disease in newborns
Gene Chromosome Reference
iPAH BMPR2 2q33 65, 97, 98
ACVRL1 12q13 65, 97
ENG 9q34.11 65
5HTT 17q11.2 66
BMPR1B 4q22.3 99
CDH FOG2 8q22.3-23.1 100
COUP-TFII 15q26.1-26.2 86
STRA6 15q23-25.1 101
FREM1 9p22.3 89
WT1 11p12-15.1 102
ACD FOXF1 16q24.1 93, 94
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In addition to the Foxf1 ACD mouse model other knock-out models show similarities to ACD 
and may potentially be used to study ACD. For example, the pulmonary phenotype and 
associated congenital defects observed in endothelial nitric oxide synthase (eNOS)-deficient 
mice are strikingly similar to the pathological features seen in ACD 103. NO plays a role in the 
downstream signaling of angiogenic factors and the regulation of angiogenic gene expression 
in the developing lung. Furthermore, mice lacking the phosphatase and tensin homologue 
deleted from chromosome 10 (Pten) showed defects in the pulmonary microvasculature 
similar to those seen in ACD. Pten inactivation caused increased expression of Fgf9, Fgf10 
and Fgf7 and decreased expression of Shh, Ptch1 and Gli1. They also found a decreased 
expression of FOXF1 in these mice 104, which might indicate a role for Pten in the regulation 
of FOXF1. 
As described above, Fgf9 signaling, SHH signaling and Vegfa expression in lung mesenchyme 
are required for the pulmonary capillary formation. In an in vitro study in mice it was 
observed that Fgf9 and SHH regulate each other and the expression of angiogenic factors 
such as Vegfa 17. Fgf9 and SHH might play a possible role in the development of ACD. 
It is important to improve our knowledge of the pathology of ACD. The discovery of mutations 
in the FOXF1 gene locus has been a great improvement in the research on ACD. However 
not in all patients with ACD a mutation in this gene locus can be found, indicating that there 
might be other genetic or etiological factors involved in the genesis of this disease. Since 
the HIF1 and HIF2 complexes are involved in vascular expansion during development of the 
lung, alterations in HIF1/HIF2 may play a role in the premature growth arrest and vascular 
abnormalities in ACD. However, no altered expression of HIF1α in lungs of human ACD 
patients has been observed 105, but other genes in this pathway like HIF2α could play a role. 
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is a chronic lung disease associated with preterm 
newborns that weigh <1000g and receive respiratory support with mechanical ventilation 
and/or prolonged oxygenation 106. More than 30% of preterm infants born before 30 
weeks of gestation develop BPD and the incidence is still rising 107. It is characterized by 
decreased or arrested alveolarization and pulmonary microvascular development (Figure 
2). The definition of BPD changed over the past 50 years. It was last redefined in 2000 by 
the National Institute of Child Health and Human Development (NICHD). 108 The current 
definition is graduated by the severity of the disease, where mild BPD is defined as the need 
for supplemental oxygen at ≥28 days but not at 36 weeks of gestation, moderate BPD as 
the need for supplemental oxygen at 28 days in addition to supplemental oxygen at ≤30% 
at 36 weeks of gestation, and severe BPD as the need for supplemental oxygen at 28 days 
and the need for mechanical ventilation and/or oxygen >30% at 36 weeks of gestation 109. 
Since the alveolar and distal vascular development in premature born infants are still in 
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a crucial state, BPD results from the need for the lung to develop while continued injury 
and repair are occurring 109, 110. The vascular pathology in BPD shows immature vessels 
with a dysmorphic structural configuration of the distal microvasculature and an abnormal 
distribution of alveolar capillaries with more distance from the air surface 111. Just like in 
CDH, intrapulmonary shunting through precapillary arteriovenous anastomotic vessels was 
found in the lungs of patients with severe BPD 112. This dysmorphic growth and impaired 
function of the pulmonary vasculature can be caused by various prenatal and postnatal 
factors and can result in pulmonary hypertension 113.
Mechanical ventilation and oxygen therapy in preterm infants can result in impaired 
angiogenic signaling with an increased expression of antiangiogenic genes and a decreased 
expression of proangiogenic genes 113. After short periods of ventilation fewer arteries and 
endothelial cells are seen, whereas longer periods of ventilation can cause decreased vessel 
branches and increased endothelial cell proliferation 114. Changes in VEGF expression are 
observed in lungs of human BPD patients and in an experimental animal model. Where most 
of the in vitro studies in humans and animals showed a decrease in VEGF expression 115-117, 
one in vitro study in a baboon model of BPD showed an increase in VEGF protein 118. Levels 
of soluble VEGFR1 (sVEGFR1), an endogenous antagonist of VEGF, were found to be elevated 
in amniotic fluid and maternal blood in preeclampsia and intra-amniotic administration of 
sVEGFR1 to pregnant rats resulted in pups with blunted alveolarization and reduced lung 
vessel density 119, 120. This implicates a role for preeclampsia by perturbations in VEGF levels 
in the development of BPD. During fetal lung development, levels of HIF1α are high and 
are important for the expression of VEGF and other angiogenic factors. In premature born 
children, levels of HIFα decline rapidly 118, possibly because of the absence of a hypoxic 
environment or even because of the use of oxygen therapy. This may cause a decrease in 
angiogenic factors resulting in less vascular expansion. Also HIF2α is a regulator of VEGF 
and is critical for fetal lung maturation. However, it plays a more important role in the 
alveolar epithelial cells than in the vascular cells 121. We showed earlier that Hif2α is a key 
regulator in the maturation of type II pneumocytes and that ectopic expression of an oxygen 
insensitive, constitutive active form of Hif2α leads to a severe surfactant deficiency in the 
newborn 122, which is also seen in BPD patients. In contrast to the downregulated angiogenic 
factors found by others, Paepe et al. found an upregulation of endoglin mRNA and protein 
levels in ventilated preterm infants. Endoglin is a hypoxia-inducible TGFβ coreceptor and 
is an important regulator of angiogenesis. They speculated that there might be a shift in 
angiogenic regulators which contributes to the dysangiogenesis in BPD. Furthermore, the 
upregulated endoglin possibly modulates vascular permeability resulting in interstitial 
edema, which is a morphological feature of early BPD 123. As such BPD forms an interesting 
model of postnatal injury and repair showing similarities in expression profiles of a number 
of transcription factors involved in normal development. This disease can thus be used to 
gain knowledge on these processes and can be implemented in our developmental studies.
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Besides the angiogenic factors, there may be a possible role for the retinoid signaling 
pathway in the development of BPD. As already shown in CDH, a shortage in vitamin A can 
disrupt the retinoid signaling pathway. Preterm infants have low vitamin A levels at birth and 
supplementing very low birth weight infants with vitamin A was found to be associated with 
a reduction in incidence of BPD 124. The shortage in vitamin A could possibly be a cause of 
impaired pulmonary vascular development and pulmonary hypertension in BPD.  
Many genes with a putative role in the development of BPD have been investigated in 
genotype association studies. These genes have been described in a recent review 125. Many 
of these studies have tested polymorphisms in potential candidate genes such as surfactant 
proteins or cytokines but only weak associations implicating susceptibility to the disease 
have been reported 126. 
Over the last decades many animal models have been developed to study the impairments 
in lung development in BPD. These models are based on hyperoxia, mechanical ventilation 
and inflammation. Since newborn rodents are born during the saccular stage of lung 
development, they are well suited to model BPD. The hyperoxia animal model is most 
commonly used and results in acute lung injury, disrupted lung structure and impaired 
alveolarization and vascularization, resembling the pathology seen in BPD. However, in 
contrast to the used animal models, preterm infants normally receive lower concentrations 
of oxygen with a lot of fluctuations, possibly resulting in differences in molecular signaling. 
Over the last years animal models gave us a better insight in the pathogenesis of BPD 
and resulted in the development of new therapies 107. Since HIF1α and its expression of 
angiogenic factors seem to play an important role in the development of BPD, this may be a 
good target for the treatment of BPD.
Conclusion and future perspectives
Over the past decades, human studies focusing on abnormal pulmonary vascular 
development have primarily been descriptive and molecular players have been investigated 
in archival and resection material. Human cell cultures have been instrumental in describing 
molecular pathways that may contribute to specific aspects of these congenital anomalies. 
Although these studies have been very valuable for generating hypotheses about the 
origin of congenital pulmonary diseases, the majority of the studies fail to identify the 
underlying mechanisms. Human studies linking molecular mechanisms to diseases remain 
rare, because the limited number and quality of human material prevents the initiation of 
large-scale studies. The combination of human studies with animal models facilitates the 
analysis of molecular mechanisms and pathways, although the different animal models 
only partly reflect and phenocopy the human pathology. For instance, the mouse model for 
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BPD is induced by exposing mice to much higher levels of oxygen than the levels that are 
used in the clinical situation. The surgical CDH rabbit model is sufficient to explore surgical 
techniques, but cannot be used to study the etiology and pathogenesis of the disease.
 
The –omics era has opened new ways to generate and analyze large data sets, which 
facilitated discovery and characterization of specific chromosomal locations, SNPs, 
associated with specific diseases by Genome Wide Association Studies (GWAS). However, 
it remains unclear in the majority of cases how the identified loci or SNP are involved in the 
origin of diseases. In the near future, it will be interesting to investigate whether these SNPs 
harbor specific binding sites for transcription factors or other DNA associating proteins, like 
DNA methylases. Alterations in binding efficiency may have a huge impact on downstream 
processes, such as transcription, leading to changes in developmental processes. It may also 
be that these loci SNPs are involved in spatial and or temporal long-range chromosomal 
interactions, which may be investigated with specific techniques, such as 3C-Seq 127.
Another putative approach is to investigate the interaction network between proteins, which 
may identify specific partners that are involved in developmental processes. Searching for 
Sox2 binding partners in neural stem cells, we recently showed that SOX2 interacts with 
CHD7. Mutations in SOX2 cause Anophthalmia-Esophageal-Genital (AEG) syndrome and 
mutations in CDH7 are associated with CHARGE syndrome (Coloboma of the eye, Heart 
defects, Atresia of the nasal choanae, Retardation of growth and/or development, Genital 
and/or urinary abnormalities, and Ear abnormalities and deafness). AEG and CHARGE have 
overlapping clinical features, and disturbing the interaction between SOX2 and CHD7, or 
other members of this cascade, may cause a variety of clinical symptoms 128. Moreover, 
several genes that are implicated in related syndromes, like JAG1 and GLI3), were shown 
to be activated by SOX2/CHD7. In addition, we showed that the HMG domain of SOX2 and 
SRY contains a binding site for the nuclear-cytoplasmic shuttling protein Exportin4. Several 
mutations have been described in the human SRY gene, which were shown to be involved 
in XY sex reversal. These mutations prevented SRY from associating with EXP4, leading to a 
block in its translocation to the nucleus and thus its transcriptional activity 129. So, the study 
of protein-protein interactions may provide mechanistic insights in specific disease.
Aside from (familial) genetic studies, epigenetics has become a major field of interest, 
and encompasses three classes: chromatin modifications (DNA methylation), histone 
modifications (methylation, acetylation, phosphorylation) and noncoding RNA molecules 
(lncRNA, miRNA). Recently, microRNA-206 (miR-206) was found as a possible triggering 
factor of early stage hypoxia-induced PH by targeting the Hif-1α/Fhl-1 pathway 130. Others 
have identified epigenetic changes in adult patients suffering from COPD, Asthma and 
interstitial lung disease (reviewed by 131), and it would be interesting to analyze pulmonary 
vascular diseases with these whole genome epigenetics techniques to establish the full 
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methyl-Cap-RNA Sequence, miRNA or lncRNA profiles of the congenital pulmonary vascular 
diseases.
Fetal lung explants have been studied for a long time, and have generated ample evidence 
for branching morphogenesis in the developing lung. Human lung explants have been used, 
but these cultures also suffer from technical limitations 132. As human samples are very 
scarcely available, and mostly derived from end-stage disease, it is mandatory to investigate 
alternative ways of setting up culture systems beyond the classical cell culture. Currently, 
several emerging 3-D culture systems, such as tracheospheres 133, alveolar spheres 134, 
lung organoids 135, decellularized lungs 136, bioartificial lung 137 and lung on a chip 138, 139, 
are being employed to address specific developmental mechanisms or to optimize systems 
for regenerative medicine (for reviews, see 140-142). Moreover, the generation of hiPS cells 
has become a standard technique in most institutes, and the use of patient specific cells 
in combination with protocols to differentiate these cells into cells representing the three 
germ layers has provided new ways to explore human (pulmonary vascular) diseases 143-148. 
Especially the development and employment of bioartificial lungs, such as the lung on a 
chip and related cultures, with patient derived hiPS cells will contribute significantly to the 
understanding of how different cell layers interact during development and disease. We 
believe that the use of these systems in combination with patient specific hiPS cells will also 
benefit the testing of putative therapeutic agents. 
In summary, understanding lung development and the molecular pathways leading to the 
mature gas exchanging organ is necessary to decipher the underlying causes of congenital 
pulmonary vascular diseases. It is obvious from the above perspectives that the interaction 
between different scientific disciplines, such as development, cell science, genetics, 
bioengineering, bioinformatics, will be a prerequisite to take the next steps in this process.
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Abstract 
Rationale
The mortality and morbidity of patients with congenital diaphragmatic hernia (CDH) 
is primarily caused by a treatment-resistant, persistent pulmonary hypertension. 
Structural vascular changes, exemplified by extensive muscularization, are already 
present early in gestation, but the origin of these abnormalities is unknown.
Objective–the purpose of the study
Understanding the origin of the vascular defects of CDH patients is important to improve 
treatment modalities. We therefore aimed to delineate the origin of this extensive 
muscularization by focusing on the pericytes.
Methods and Results
Using a mouse model of CDH by inhibiting retinoic acid (RA) signaling, we showed 
by immunohistochemistry and FACS analysis the early origin and expansion of the 
pericyte population in normal and abnormal development. Pericytes revealed a 
reduced migratory potential after inhibition of RA signaling in vitro. Analysis of 
immunofluorescently labeled embryonic lungs showed reduced expansion of the 
capillary bed at gestational age 15 (E15) and E18 in CDH, and a significant increase 
of the pericyte coverage. Furthermore, both pericytes and endothelial cells showed 
less proliferation and elevated expression of a-smooth muscle actin (ACTA2) in CDH-
pericytes. In addition, CDH samples had reduced collagen IV expression from E15 
onwards, which was also observed in human CDH patients. 
Conclusions
One of the earliest pathogenic signs leading to the structural vascular changes in CDH 
is the increased pericyte coverage, resulting in reduced angiogenic activity and fewer 
capillaries. Furthermore, the reduced proliferation and migration activity of pericytes 
observed in CDH, as well as the increased expression of ACTA2 indicates that pericytes 
in CDH lungs are well differentiated. Reduced collagen IV expression in CDH indicates 
a loss of basal membrane integrity between pericytes and endothelial cells. Taken 
together, the pericyte population in CDH lungs starts to differentiate much earlier in 
gestation as a result of reduced RA signaling, leading to aberrant vascular development.
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Introduction
Persistent pulmonary hypertension in the newborn is characterized by high pulmonary 
vascular resistance after birth with structural changes in the cardio-pulmonary circulation 1. 
Pulmonary hypertension in the newborn may occur as a primary disease or in association 
with a congenital disease such as congenital diaphragmatic hernia (CDH) 2. CDH is a severe 
congenital anomaly characterized by a variable defect of the diaphragm, different gradations 
of pulmonary hypoplasia and pulmonary hypertension 3 4. Previously, we showed that CDH 
patients have already pathological changes in the vascular smooth muscle cell layer in 
the tunica media from early stages onwards, indicating that these changes are result of 
disturbed development of the pulmonary vasculature 5.
The first step of lung development is the patterning and separation of the foregut. Shortly 
after this separation, the first lung buds appear and start to grow and expand, this is in 
the pseudoglandular phase (in human week 4-17 and mice E9.5-E16.5). A capillary network 
that is connected to the central circulation surrounds the newly formed lung buds 6. The 
development of the airways and pulmonary vasculature remain closely connected during 
the canalicular stage (in human week 16-26 and in mice E16.5-E17.5) and the saccular stage 
(in human week 26-36 and in mice E18.5-P5) 7.We and others revealed that the expansion 
of the pulmonary vasculature is required for normal lung development, since disturbances 
in normal growth of the vasculature leads to improper development of the airways and the 
lungs remain hypoplastic 8 9, 10. The pulmonary vasculature develops predominantly by the 
expansion of the existing vascular network, a process we described as distal angiogenesis 6. 
Angiogenesis is characterized by the sprouting of endothelial cells from pre-existing vessels 
to form new, unstable tubules 11. These primitive tubules are stabilized by cells from the 
surrounding mesenchyme, the perivascular cells or pericytes. The endothelial cells of the 
newly formed tubule release Platelet derived growth factor β (PDGFβ) which binds to 
the PDGF receptor β (PDGFRβ) expressed by pericytes 12-14. As a result, the pericytes are 
recruited to the neo-vessel and interact with the endothelial cells via direct contact or 
paracrine cross-stimulation, thereby stabilizing the primitive tubule and causing maturation 
of the vessel 12 15. As a consequence of the interaction between pericytes and endothelial 
cells, the pericytes start to release collagen IV (COLIV), a key component of the basement 
membrane (BM). Through the BM the endothelial cells and pericytes interact and allow 
stabilization and growth of the micro vascular bed 16.
Altered pericyte function is related to multiple pathological conditions such as fibrosis, 
diabetic renopathy and cancer biology 17. Pericyte coverage differs per organ and fluctuation 
in this ratio indicates malignancies.17 Furthermore, in pulmonary arterial hypertension 
(PAH) increased pericyte coverage was found in both PAH mouse and human PAH samples18, 
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indicating that increased pericyte coverage may be associated with structural changes 
observed in adult pulmonary hypertension.
As mentioned above, in a previous study we observed already early in lung development 
structural changes in the vasculature of CDH patients 5. Based on our data and other 
studies, pericytes are prime candidates to underlie these vascular changes. However, 
characterization of pericytes remains difficult and fundamental knowledge about pericytes 
during lung development is still missing. Although a range of markers for pericytes have 
been described, each marker depends on the type of tissue, developmental age and 
location17, 19-21. Therefore, we first analyzed the expression of the different perivascular 
markers during normal and abnormal lung development in mice to identify which of the 
known markers of pericytes would serve as an appropriate marker for pericytes during 
pulmonary development. Furthermore, we analyzed the pericyte coverage at different 
gestational ages with Fluorescence-activated cell sorting (FACS) and by immunofluorescently 
labeling complete embryonic lungs. Lastly, we linked a decreased proliferation and a higher 
expression of alpha smooth muscle actin (ACTA2) of pericytes in CDH to be the source of the 
hyper-muscularization in CDH, and we translated our findings to human patient material.
Taken together, we found that increased pericyte coverage is an important factor in the 
pathogenesis of CDH and a lack of Collagen IV in the BM leads to reduced stabilization of the 
vessel bed and therefore insufficient development of the pulmonary vasculature.
Methods
Mouse CDH model
Different compounds to inhibit the retinoic acid pathway have been tested in different doses 
based on literature 22. This pilot showed that the combination of nitrofen (2,4-dichlorophenyl-
p-nitrophenylether) and Biphenyl carboxylic acid (BPCA, Sigma) resulted in the most 
consistent way of inducing CDH in the offspring of pregnant mice (Table 1). Thus, timed-
mated pregnant mice received 20 mg nitrofen and 5 mg BPCA in 500 μl olive oil (Sigma) 
per 25 grams of body weight at day 8.5 of gestation. At different gestational ages pregnant 
mice were sacrificed, fetal lungs were isolated and their morphology was used to divide 
the phenotypic appearance of the fetuses into severely affected and mildly affected. 
Subsequently, both samples were analyzed with Immunohistochemistry (IHC) and showed 
comparable pathology.
2INCREASED PERICYTE COVERAGE HAMPERS PULMONARY VASCULAR DEVELOPMENT                         51
Table 1: Compounds tested to induce CDH in mice
Concentration Compount Pups (N) CDH (N) Deaths (N) (N)
5 mg / kg BMS493 72 4 1 8
25 mg / 0,5 ml BPCA 74 19 13 23
25 mg / 0,5 ml Nitrofen 72 7 1 12
25 mg / 0,5 ml Bisdiamine 26 4 1 4
25 mg / 0,5 ml BPCA/Nitrofen 20 9 0 7
25 mg / 0,5 ml Nitrofen/Bisdiamine 42 21 0 8
Immunohistochemistry and Immunofluorescence 
IHC was performed on 5 µm thick paraffin sections of lungs according to standard protocols, 
using the DAKO EnvisionTM amplification kit. Primary and secondary antibodies used for IHC 
and for Immunoflourescence (IF) are listed in supplementary table 1. Antigen retrieval was 
performed with Tris-EDTA buffer (pH 9.0) on the first day and on the second day for signal 
detection and amplification the Envision™ detection system (DakoCytomatic) 23 was used. 
The protocol used for IF staining was similar to the IHC protocol, with small adjustments 
on the second day since Alexa Fluor secondary anti-bodies were used (Table 2). Negative 
controls were performed by omitting the primary antibody. Analysis of the proliferating 
cells was performed by counting all the endothelial cells and the NG2+ cells around the 
endothelial cells. The percentages of Ki67 positive cells from all the counted cells were 
statistically analyzed using two tailed T-test in Graphpad.
Table 2: Primary and secondary antibodies used for IHC and IF
Antibody name Dilution Company Specie
NG2 1:500 Merck KGaA Rabbit
NG2 1:500 Prof. W.Stallcup Guinea pig
αSMA 1:1200 Thermo Fisher Mouse
αSMA-FITC 1:250 Sigma Mouse
SMMHCII
PDGFRβ
1:800
1:250
Abcam
Cell Signal
Mouse
Rabbit
KI67 1:500 Thermo Fisher Rat
COLIV 1:500 Millipore Rabbit
COLIV 1:100 AbD Serotec Rabbit
CD31 1:50 Thermo Fisher Biothynilated
Alexa488 1:500 Jackson Donkey
Alexa594 1:500 Jackson Donkey
Alexa647 1:500 Jackson Streptavidin
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Whole mount immunofluorescence and analysis
Whole mount immunofluorescence staining of total fetal lungs was based on Yokomizo et 
al., 2012 24. Shortly, the left lung lobe was dissected of freshly isolated lungs and fixed in 
4% paraformaldehyde (PFA) overnight. The next day, the lungs were gradually dehydrated 
with methanol and could be stored in pure methanol at -20°C for up to 3 months. The next 
day, the lungs were re-hydrated and blocked in PBS, 0.4% triton X-100 and 1% skimmed 
milk powder for 4 hours, blocking buffer was refreshed every hour. Subsequently, the lungs 
were incubated with primary anti-body diluted in blocking buffer (CD31 R&D 1:100, NG2 
generously provided by Prof. W. Stallcup 1:500, SMA-FITC labeled, Sigma 1:250) for at 
least 4 days at 4⁰C. The samples were washed with PBS-0.4% Triton for at least 48 hours, 
washing solution was refreshed every 4 hours and at the end of the day. Secondary anti-
bodies conjugated with Alexa Fluor 594 or biotinylated Alexa Fluor 647 appropriate for the 
choice of primary antibody were diluted in blocking buffer and incubated for at least 48 
hours. After this incubation, the lungs were washed, cleared with benzyl alcohol/benzyl 
benzoate (BABB). Samples were imaged using a Tile Scan option in the Leica application Suit 
(LAS) on the Leica SP5 confocal microscope. 3D reconstructions were made using AMIRA 6.3 
software.
Lung explant culture and confocal time- lapse imaging
Embryonic lung explants were grown based on previous published studies 25, 26. Briefly, time 
pregnant NG2DsRedBAC transgenic 27 mice were sacrificed at E10.5 and the embryonic 
lungs were isolated and placed on a floating, porous membrane inserts (0.4 μm pore size) 
on DMEM/F12, 10% FCS. Lung explant cultures were kept in a 37 OC incubator until imaging. 
Imaging and analysis of explant cultures
Explants cultures were placed on the stage of the climate controlled Leica SP5 microscope. 
The reflection of the 633 laser (625-640 nm; 0,5% laser power, 650V) by the culture filters 
was used to autofocus with the matrix screening option of the microscope software provided 
in the Leica Application Suite software (LAS). DsRed fluorescent signal was detected with the 
561 laser (520-558 nm; 8% laser power, 950V) using the HCX PL Fluotar 5 X dry objective. 
Image capturing was done using the 1,5x zoom factor. Images were analyzed with Fiji software 
by importing data of the complete imaging period to make hyperstacks with multiple 
variables (Z for depth of tissue, T for time, C for fluorescent channels). First, a Z-projection 
of the Z-stacks were made and the different channels were split. The background noise in 
the red channel was reduced using the Gaussian blur filter. Next, the size of a positive, red 
cell was measured (“particle”) and subsequently used to automatically count the cells in 
the multiple stacks of each time point using the function “analyze particles”. This number of 
particles was plotted with Microsoft Excel.
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Imaging and analysis of the immunofluorescent images
Images were made using a Leica SP5 microscope. The lasers that were used for all pictures 
were 405 (415-480nm), 488 (500-550), 561 (571-630 nm) and the 633 (643-700 nm). Laser 
power was kept under 20% and the gain between 650V-750V for all images. The 20X HCX PL 
APO CS was used to image the whole mount stained lung samples and the 40X HCX PL APO 
CS oil objective for sections. Analysis of images of both whole mount and sections started 
of with setting the threshold using the auto threshold “moments”. A region of interest (ROI) 
was selected for each section and the threshold was set for the NG2 and ACTA2 channels. 
Colocalization of NG2 and ACTA2 was calculated using the AND function in the image 
calculator in Fiji.
Human lung samples
Human lung samples were retrieved from the archives of the Department of Pathology of the 
Erasmus MC, Rotterdam, following approval by the Erasmus MC medical Ethical Committee. 
Lung samples were selected of CDH patients by different gestational ages and which did not 
show severe hemorrhage or necrosis. To circumvent the problem of secondary changes due 
to exposure to high oxygen concentrations and shear forces in all specimens the survival was 
less than 12 hours thus representing the most severe cases.
FACS experiment and analysis
Lungs were isolated at different gestational ages, and collected in 1 ml DMEM (Lonza) in 
Eppendorf tubes. Collagenase I, Collagenase II and Collagenase IV were (10 μg/ml) added 
and incubated at 37 O C for 10 minutes in an Eppendorf shaker at 1000 rpm. Then, the 
mixture was mixed vigorously to completely disrupt the tissue and the cell suspension was 
put through a 40 μm cell strainer. The filter was rinsed with 1ml DMEM 10% FCS and spun 
down at 4O C for 10 minutes at 400 g. Supernatant was removed and the pellet was washed 
with PBS 10% FCS and resuspended in 300 μl PBS 10% FCS, of which 10 μl was taken to 
count the number of cells and to check for doublets and cell aggregates. Samples were 
centrifuged at 4O C for 10 minutes at 400 g and cells were resuspended in 100 μl of CD31-
PE-Cy7 (1:100,Thermo Fisher), CD45-PE-Texas Red (1:100, Thermo Fisher), NG2-488 (1:100, 
Merck KGaA) PDGFRβ-APC (1:100, Thermo Fisher) in PBS-10%FCS, for 40 minutes at 4o C. 
Additionally, a part of the sample was only incubated with a single antibody to set the laser 
voltages. Samples were then washed by adding 150 μl PBS-10%FCS and gently mixed and 
centrifuged. Pellets were re-suspended in live/dead mix (Thermo fisher Scientific) in 100 
μl PBS and incubated for 20 minutes at 4 o C. Samples were then washed by adding 150 μl 
PBS 10% FCS, mixed gently and centrifuged. Pellets were resuspended in 400 μl and kept in 
darkness at 4o C until analyzed on the LSR Fortessa II FACS machine (B&D). Analysis of the 
data was done using FlowJo.
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Cell culture and Migration assay
Human Brain Vascular Pericytes (ScienCell) were cultured on gelatin coated plates in DMEM 
(supplemented with 100U/ml penicillin/streptomycin; Lonza, and 10% FCS; Lonza) , in 5% 
CO2 at 37 ̊C. Pericytes were plated at a density of 0.5 x 10
5 cells/well in an OrisTM Universal 
Cell migration Assembly Kit (Platypus Technologies) derived 96 well plate with cell seeding 
stoppers. Twenty-four hours post sub culturing, the cell stoppers were removed and cells 
were allowed to migrate into the cell free region for 16 hours in 5% CO2 at 37 ̊C. Subsequently, 
the cells were washed in PBS and stained by Calcein-AM followed by visualization using 
fluorescence microscopy. Wells in which cell seeding stoppers were not removed, were used 
as a negative control. Fluorescent colors were adjusted using ADOBE Photoshop and data 
was analyzed by Clemex Software.
Statistical analysis
Statistical analysis was done using Graphpad Prism V7 and for all measurements two-tailed 
T-test was performed.
Results
Perivascular cells during normal and abnormal development
Pregnant female mice were treated at gestational age E 8.5 with a single dose of different 
combinations of teratogens to test which retinoic acid inhibitors induced a consistent CDH-
like phenotype (Table 1). Morphological analysis of the fetal lungs isolated at E18.5 revealed 
that the combinatory treatment with nitrofen and BPCA resulted in a similar lung and 
diaphragm phenotype as the well-known nitrofen-induced rat model 28, 29. Moreover, at all 
of the examined gestational ages the pups of the mothers treated with the combination of 
nitrofen/BPCA showed lung hypoplasia (Fig. 1A). Subsequent histological analysis showed an 
increased staining of ACTA2 in the small capillaries and a prominent expression of Smooth 
muscle myosin heavy chain II (SMMHCII) in the CDH samples, comparable to the CDH rat 
model and human CDH 4, 29 (Fig. 1B).
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Figure 1
Pathology of the mouse congenital diaphragmatic hernia (CDH) model and distribution of perivascular markers 
during lung development. A Representative images of lungs from mothers who retrieved the combination of 
retinoic acid inhibitors Nitrofen/BPCA at E8.5. The complete litter of the treated mothers showed lung hypoplasia, 
lungs were isolated at E12, E15 and E18. B Lungs of CDH mice show the pathological characteristics for CDH. 
Increased expression ACTA2 in the small capillaries and expression of SMMHCII, which is barely expressed in the 
pulmonary vessels of control pups. Scale bar is 200 μM. C Distribution of pulmonary vascular markers PDGFRβ, 
NG2 and ACTA2 analyzed at E12, E15 and E18. PDGFRβ is expressed throughout the mesenchyme at E12 and 
E15, the expression becomes more restricted to the vasculature at E18. NG2 expression is observed around the 
small and mid-sized vessels throughout development (E12, E15 and E18). Scale bar is 20 μM. D At E10 lungs from 
NG2DsRedBAC mice were put on a filter. After 12 hours the first NG2 positive cells were observed. The number of 
cells expanded rapidly. 
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We showed that vascular abnormalities associated with CDH are already present early during 
gestation in patient samples 5, which are here mimicked by the CDH mouse model (Fig 1A, 
B). As perivascular cells are associated with angiogenesis and may contribute to the smooth 
muscle cell layer, we next investigated the emergence and distribution of perivascular cells, 
which are not well described during lung development. Therefore, analysis of the temporal 
and spatial expression patterns of NG2, PDGFRβ and ACTA2 at embryonic days E12, E15 
and E18 in lungs of control and CDH pups was performed. At E12 the expression of ACTA2 
is found in cells around the large airways, and at E15 and E18 in cells around the mid-
sized and large vessels and airways. However, significant more ACTA2 positive cells were 
detected around the capillaries in CDH samples at E18 (arrow heads in Fig. 1C). In the early 
pseudoglandular phase of lung development, at E12, the expression of PDGFRβ is observed 
in cells surrounding the larger vessels (>50 μm) and distributed throughout the mesenchyme 
(Fig 1C). This pattern is consistent at E15 but diminishes at E18 in the mesenchyme and 
becomes more restricted to vasculature (arrowheads in Fig 1C).
At E12, the cells which surround the small capillaries are NG2 positive and this pattern 
continues at E15 and E18, at which stage of development the mid-sized (40-50 μm) and 
larger vessels (>50 μm) also become positive (arrowheads in Fig. 1C). To explore the 
emergence, invasion and distribution of perivascular cells in the lung during the initial 
phases of lung development, time-lapse imaging was performed using explants of fetal 
lungs from NG2DsRedBAC transgenic mice. This transgenic mouse line harbors a bacterial 
artificial chromosome that specifically expresses DsRed in NG2 positive cells 27. Therefore, 
time-lapse experiments were performed with lungs isolated at E10 and images showed that 
12 hours after isolation the first NG2 positive cells appeared and the number of NG2 positive 
cells expanded rapidly in time (Fig. 1 D). The early presence in the development of the 
lung and the swift expansion of the number of cells indicates the potential importance of 
NG2 positive cells. The rapid emergence of the NG2 positive cells in the early stage of lung 
development coincides with the expansion of the capillary network at the same time.
Increased pericyte coverage in the pulmonary vasculature CDH in mouse results in an 
impaired capillary bed 
The cellular composition of the pulmonary vascular wall varies depending on the size and 
functionality of the vessel. The large pulmonary arteries exist of an adventitia (the outer 
layer) where fibroblast are loosely organized and a vasa vasorum where smooth muscle cells 
are present 30. The smaller arteries, the arterioles do not have a distinguished vasa vasorum 
as an outer layer but discrimination can be made between the outer perivascular cell layer 
and the layer which is in direct contact with the endothelial cells, the more inner perivascular 
cell layer. The capillaries which are present in the distal end of the lung consist of a layer 
endothelial cells with a monolayer of perivascular cells around them. Immunofluorescent 
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double labeling with PDGFRβ and ACTA2 specific antibodies at different gestational ages 
revealed that at E12 and E15 PDGFRβ (Fig 2A) is expressed throughout the mesenchyme 
and outer layer of the perivascular wall of the arterioles. No difference in expression of 
PDGFRβ and ACTA2 was observed between control and CDH at E12. The expression pattern 
of PDGFRβ becomes more restricted to the vasculature at E18, however only the cells in 
the outer layer of the arteries and arterioles are PDGFRβ positive (indicated by white arrow 
heads in Fig 2A). CDH samples showed a decrease in PDGFRβ expression in the mesenchyme 
at E15, which could indicate that there are fewer PDGFβ responsive cells in CDH and thus 
possibly explaining the reduced expansion of the pulmonary vasculature. Double labeling of 
fetal lung samples with NG2 and ACTA2 specific antibodies revealed that the pericytes which 
are in direct contact with the endothelial cells are NG2 positive in the arterioles (indicated 
by white arrowheads; Fig 2A). Furthermore the expression of NG2 is consistent during 
pulmonary development and based on this expression and the location of the positive cells 
close to the endothelial cells we concluded that NG2 more specifically marks perivascular 
cells in the developing lung than PDGFRβ. 
To further understand the structural differences in the pulmonary vasculature in CDH, whole 
mount immunofluorescence staining was performed. The left lobe of lungs isolated at E15 and 
E18 were stained with antibodies against CD31, NG2 and ACTA2 to get a better insight of the 
entire three dimensional (3D) structure of the pulmonary vessels and the perivascular cells. 
Besides the evident lung hypoplasia, the pulmonary vasculature of lungs of CDH pups was 
highly affected. Although the number of large vessels and their branches seemed comparable 
to the control, a major difference was observed in the capillary beds. The capillary network in 
the CDH samples appeared to be less dense and the number of capillaries was also reduced 
at E15 and E18 (Fig. 2B). CDH samples showed a simplification in the structure because of a 
decreased number of capillaries. The decreased numbers of capillaries observed at E15 was 
consistent throughout development and was also clearly visible at E18 (Fig 2B). The 3D images 
revealed a simplification of the capillary bed from E15 onwards and this raised the question 
whether we could detect more structural differences in lungs of CDH pups. Therefore, the NG2 
positive area was measured of the second large branch of the left lung lobe was performed 
in control and CDH at E15 (Fig 2C). This revealed a significant increase of pericyte coverage in 
the CDH samples in the second large (>70 μm) branch of the pulmonary vasculature tree. So, 
besides structural differences in the capillary bed, lungs of CDH pups showed also increased 
pericyte coverage in the large pulmonary vessels. The observed increase in pericyte coverage 
may be the first cellular change in CDH eventually leading to the hyper-muscularization. To 
further understand the differences in the capillary bed, high resolution imaging was performed 
on the whole mount samples (Fig 2D). The high magnification images further confirmed 
the increase of NG2 expression in the capillary bed at E15 and E18 (Fig. 2D). The increase 
in the number of pericytes resulted in an incorrect development of the capillary bed at E15 
and became even more pronounced at E18 (Fig. 2D). The capillaries in the CDH samples at
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E18 appear to be loosened from each other resulting in an impaired capillary bed (Fig. 2D). 
Taken together, we show here for the first time increased pericyte coverage in pulmonary 
hypertension associated with CDH as early as from E15 onwards in both the large pulmonary 
vessels and the capillaries. The simplified network of capillaries observed in CDH may the 
results of this increased pericyte coverage and the shift in the number of endothelial and 
perivascular cells may be the basis for the impaired angiogenesis.
Fluctuation of Ng2 positive pericytes in the lung during normal and abnormal 
development
The whole mount analysis of the pulmonary vasculature at E15 and E18 showed a highly 
affected capillary bed in CDH and significant increase in pericyte coverage. These results 
gave rise to the hypothesis that the angiogenic process is affected in CDH, or more precisely, 
that an increased number of pericytes is the potential source of these angiogenic defects 
observed in CDH. To further confirm this increase and in order to assess and more precisely 
quantify this putative difference at E12, E15 and E18, we performed a FACS analysis of 
three different cell populations: CD45-/ CD31-/ PDGFRβ+ (hereafter PDGFRβ+), CD45-/ CD31-/ 
NG2+ (here after NG2+) and CD45-/ CD31-/ NG2+/PDGFRβ+ (hereafter PDGFRβ+ /NG2+) (Fig 
3A). At E12 there were no significant differences between control and CDH in the different 
cell populations. However at E15 we observed a significant decrease in PDGFRβ+ and a 
significant increase in NG2+ cell populations in lungs of CDH pups (Fig. 3A). The difference in 
the PDGFRβ + population diminished at E18, but the significant increase in NG2+ population 
continued (Fig. 3A). At all time points examined we analyzed the NG2+/PDGFRβ+ population, 
but we did not detect any differences in this population between control and CDH (Fig. 3A). 
Plotting the percentages of NG2+ and PDGFRβ+ populations at different time points revealed 
an antagonistic behavior of these populations (Fig 3B). Thus, the NG2+ cell population 
expanded during development, while the PDGFRβ+ cell population decreased, indicating 
that NG2 possibly marks more established perivascular cells and that PDGFRβ marks more 
uncommitted perivascular cells. Taken together, no significant differences were observed at 
E12 between control and CDH samples in any of the investigated populations. In contrast, 
from E15 onwards a decrease in the number of PDGFRβ + is observed. The FACS data further 
confirmed that the significant increase in the number of NG2 + cells, indicating increased 
pericyte coverage in CDH.
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Increased NG2 positive pericytes coverage of the pulmonary vasculature in CDH
The observation that the number of pericytes is increased during pulmonary development 
in the CDH mouse model raised the question whether this may underlie the pathological 
changes observed in CDH. So far, it has remained unclear what precursor cells could lead 
to this extensive muscularization and whether there are differences in this cell population 
between CDH and control lungs. Pericytes are suitable candidates to underlie these 
perivascular changes given the timing of their appearance and their function in angiogenesis. 
Therefore, the ratio of the NG2 + pericytes per CD31+ endothelial cell was determined as an 
indication for pericytes coverage per vessel. The pulmonary vasculature of control and CDH 
lungs isolated at E15 and E18 was visualized and clearly showed difference in the complexity 
(Fig 2 and 4A). Although the gross appearance of the vessels in CDH appeared different from 
controls, we aimed to analyze the individual vessels to ascertain the cellular composition of 
the vascular wall and study their development. Therefore, a FACS analysis was performed 
at gestation day E12, E15 and E18 to select the CD45-/ CD31+ population (Fig 4 B). The 
percentage of CD31+ cells was significantly decreased in the CDH samples compared to 
controls, corresponding with the whole mount analysis. The pulmonary vasculature of 
both the control and CDH lungs rapidly expands in time, although this expansion is more 
prominent in control lungs, as indicated by the steeper curve (Fig 4C).
Next, the vascular coverage was determined at E12, E15 and E18 by measuring the ratio of 
the PDGFRβ+, NG2+ and PDGFRβ+/NG2+ populations over the CD31+ population (Fig 4D). At 
E12 no overt differences in pericyte coverage between control and CDH was noted, but at 
E15 a significant increase in NG2+ coverage in the CDH samples was detected. This difference 
is continuous and also observed at E18. The other cell population ratios did not show any 
significant differences. Thus, although CDH lungs have a simplified vascular tree, a significant 
increase of the inner perivascular layer was observed from E15 onwards in CDH lungs, which 
may trigger the pathological muscularization defects observed in pulmonary hypertension 
associated with CDH.
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Reduced proliferation of endothelial cells and pericytes during pulmonary vascular 
development in CDH
The apparent differences in the perivascular layer between control and CDH lungs could 
result from differences in the cell cycle. Thus, control and CDH lungs were stained with Ki67 
and NG2 to analyze the proliferation and cell division of endothelial cells and pericytes. 
The vasculature was divided into small vessels (20-70 μm) (Fig. 5A) and large vessels (>70 
μm) (Fig. 5A). At E15 we observed a non-significant decrease in number of proliferating 
endothelial cells in the small vessels, but a significant decrease in proliferating pericytes 
in the small vessels (Fig. 5B). No significant differences in proliferation of pericytes and 
endothelial cells were observed in the large vessels between control and CDH at E15 (Fig. 
5B). At E18, both the small and large vessels showed a significant decrease in number of 
proliferating endothelial cells in CDH (Fig. 5B). No difference was observed in the number of 
proliferating pericytes in CDH in both the large and the small vessels at E18 (Fig. 5B) aside 
from differences in proliferation, the changes in the vascular wall in CDH lungs may also be 
related to migration of proliferating progenitor cells. Therefore, human brain pericytes were 
cultured with or without the retinoic acid inhibitor BMS493 (figure 5C), which significantly 
inhibited the migration potential of the pericytes (Fig 5C). This suggests that the pericytes in 
the lungs of CDH may have a reduced migratory potential.
These results imply that the balance of proliferating pericytes and endothelial cells in CDH is 
disrupted, which may lead to disordered angiogenesis and a simplification of the pulmonary 
capillary bed in CDH.
64 INCREASED PERICYTE COVERAGE HAMPERS PULMONARY VASCULAR DEVELOPMENT 
0
10
20
30
40
C CDH
%
0
10
20
30
40
50
C CDH
%
C CDH
0
20
40
60
%
0
20
40
60
80
%
C CDH
*
CDH
E18
Control 
E15
CDHControl 
0
10
20
30
%
C CDH
*
0
5
10
15
20
C CDH
% *
0
10
20
30
40
50
C CDH
%
0
20
40
60
C CDH
%
A
Ki67  endothelial cells+
Vessels20-70 uM 
Vessels > 70 uM
Ki67   NG2 cells
+
Vessels20-70 uM 
Vessels > 70uM 
B
E15 E15
Ki67  endothelial cells+
Vessels 20-70 uM 
E18
Vessels > 70 uM
Ki67   NG2 cells
+
Vessels 20-70 uM 
E 18
Vessels > 70 uM 
C
D
E
F
G
0
0.2
0.4
0.6
*
C BMS493
Cell Culture
+ BMS493
NG2
Ki67
Vessels20-70 uM 
NG2
Ki67
Vessels > 70 uM
uM
2
Figure 5
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Decreased collagen IV production of pericytes leads to altered differentiation and 
simplification of the capillary bed in CDH
The increase of pericyte coverage and the simplification of the pulmonary capillary bed led 
to the conclusion that the interaction between endothelial cells and pericytes is affected 
in CDH. Therefore, we analyzed the presence of COLIV, which is the main constituent of 
the basement membrane forming between the endothelial cell and the pericytes. The 
production of COLIV is a parameter for the BM integrity is. Moreover, the BM between 
pericytes and endothelial cells is important in the communication between these two cell 
types.
At E12 we did not observe apparent differences in COLIV expression between control and 
CDH (Data not shown). However, at E15 a reduced level of collagen was observed throughout 
the mesenchyme in CDH and we noticed discontinued basement membranes around the 
midsized vessels indicated by the white arrow (Fig 6A). The reduced expression of COLIV in 
the BM was also detected at E18 throughout the mesenchyme and the basement membrane 
of the midsized vessels was also discontinued indicated by the white arrow (Fig 6B).
The reduced proliferation and migration (Fig 5) and an affected basement membrane (Fig 
6A-6B) suggested that pericytes in CDH are different and that there may be changes in 
the expression of pericyte-specific genes. Therefore the double positive area for NG2 and 
ACTA2 at the proximal (large vessels >70 μm) and distal side (small vessels 20-70 μm) of the 
pulmonary vasculature was quantified (Fig. 6C). At E15 there was no significant difference 
in co-localization of NG2 and ACTA2 in CDH. However, at E18 there was a significant 
increase in co-localization of NG2 and ACTA2 in the large and in the small vessels in CDH. 
This indicates that pericytes in lungs in CDH contain more ACTA2 fibers, leading to more 
contractile pericytes. To test whether this was an effect of the inhibition of the retinoic 
acid pathway, pericytes were cultured in the presence or in the absence of the retinoic acid 
pathway inhibitor BMS493. Pericytes that were cultured in the presence of BMS493 clearly 
expressed more ACTA2 than the pericytes that were cultured in absence of BMS493 (Fig. 
6D). This indicates that the increase of ACTA2 expression in CDH is an effect of the inhibition 
of retinoic acid pathway and may be the result of up regulation of other signaling pathways. 
Taken together, these data show that pericytes in cell culture and in the lungs of CDH pups 
are more contractile and that altered differentiation of pericytes in the distal end of the lung 
leads to neo-muscularization observed in pulmonary hypertension associated with CDH.
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Figure 6
Reduced Collagen IV production in CDH and an increase of ACTA2 expressing pericytes. A COLIV is expressed 
throughout the mesenchyme at E15. Decreased expression the CDH samples was observed in the mesenchyme and 
around the vessels (indicated with white arrow). This effect hold true until E18. Scale bar is 20 μM. B The number of 
αSMA expressing pericytes in the small and in the large vessels was significant higher in CDH samples at E18. Scale 
bar is 20μM C Human brain pericytes were cultured in for 24 hours with the addition of the retinoic acid inhibitor 
BMS493. Pericytes cultured in the presents of the inhibitor expressed more αSMA than the pericytes in the control 
conditions. Two-sided T-test was performed.
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Human CDH patients show imbalance in PDGFRβ and Collagen IV expression during late 
pseudo-glandular phase in lung development
To test whether the findings in the CDH mouse model could be extrapolated to human CDH 
patients, the expression of PDGFRβ and COLIV was analyzed. Since pericyte markers may 
be different per organ, gestational age and also per species, we first examined different 
pericyte markers in human tissue. This indicated that PDGFRβ is the most reliable and specific 
pericyte marker in the late pseudoglandular phase of human lung development. Since the 
first differences in COLIV and PDGFRβ appeared in the pseudoglandular phase of lung 
development in the CDH mouse model, lungs of CDH patients and age-matched controls at 
the pseudoglandular phase were analyzed. Increased expression of PDGFRβ was observed 
in CDH patients, which correlates with a lower COLIV expression (Fig. 7A and Fig. 7B). This 
result is in line with the findings in the CDH mouse model, so increased coverage of pericyte 
in the pulmonary vasculature leads to aberrant pericyte attachment and maturation. The 
BM showed reduced expression of COLIV in CDH, this could indicate that the attachment 
or cross-signaling between pericytes and endothelial cells is inadequate. This may lead to 
decreased angiogenesis and a simplification of the capillary bed in the distal end of the lung 
in CDH. The current findings together with our previous work where we have shown the 
importance of the interaction between the vasculature and the growth of the lung 8, the 
simplification of the capillary may be the cause of the hypoplastic lungs in CDH.
Discussion
Pulmonary hypertension associated with CDH results in high mortality and morbidity 31. 
Studies concerning the structural vascular anomalies have mainly focused on the increased 
thickening of the tunica media of the vascular wall. In this study we dissected the events 
before this thickening occurs and what may be the source of the hyper-muscularization and 
neo-muscularization. Pericytes may be good candidates to cause these pathogenic defects.
However characterization of pericytes during lung development has not been studied 
intensively and therefore we firstly analyzed the expression of multiple pericyte markers. 
Based on their expression patterns we showed that NG2 and PDGFRβ are the most specific 
markers for mouse and human pericytes during lung development, respectively. The 
establishment of the most useful pericytes marker in mouse development allowed us to 
further analyze potential differences between control and CDH lung samples. Although the 
CDH lung displays a simplified vascular tree, we also demonstrate that the pericyte coverage 
was increased in CDH lungs already in the late pseudoglandular stage of lung development 
at the individual vessels. 4D analysis of pericytes and endothelial cells revealed that the 
pulmonary vasculature in the CDH mouse model is highly affected. Specifically, the micro 
vascular bed lacks an organized structure and exists of a reduced number of capillaries. 
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Additionally, less proliferating pericytes and endothelial cells were observed in CDH, which 
could direct into a deficiency of sufficient numbers of pericytes to support extensive vascular 
growth by angiogenesis. We found that the BM in CDH was affected due to decreased 
COLIV expression of pericytes in lungs of CDH pups. This indicates that the establishment of 
newly formed vessels is interrupted by reduced expression and thus deposition of COLIV by 
pericytes. As a result, endothelial cells do not receive inhibitory signals and therefore keep 
recruiting pericytes, which is supported by the observed increased pericyte coverage in CDH. 
To be more specific, there are less cells expressing PDGFRβ in the mesenchyme of E15 lungs 
in CDH, indicating that these cells do not respond to PDGF secreted by the endothelial cells. 
This may explain why endothelial cells continue to recruit pericytes, resulting in a reduced 
pulmonary vascular growth and a thickening of the perivascular wall. Moreover, there was 
not only an increase in pericyte coverage, but also pericytes in CDH expressed more ACTA2, 
which indicates that they may be more contractile and could therefore be the source of the 
neo-muscularization observed in CDH.
Fluctuations and alterations in pericytes coverage and interaction with their surrounding 
cells have been linked to multiple pathological conditions such as diabetic renopathy, cancer 
biology and pulmonary hypertension in the adult 16, 18, 32-34. Especially the finding of increased 
pericyte coverage in pulmonary hypertension in the adult is in line with our findings 18. We 
are the first to show during lung development in CDH an increase in pericyte coverage which 
has not been demonstrated before. We show by FACS analysis and extensive IF experiments 
that more pericytes are detected in the CDH mouse model, which was surprisingly linked to 
reduced expression of COLIV. Previously, increased pericyte coverage of the micro-vasculature 
has been linked to pulmonary hypertension in the hyperoxia rat model for pulmonary 
arterial hypertension 35. However this has not been linked to altered COLIV production. 
Aberrant COLIV expression by pericytes has been described in literature before, but mainly 
cases of increased COLIV production such as in wound healing processes 36, 37. The observed 
reduced expression of COLIV in CDH, however, explains the reduced capillary bed since a 
reduced expression of COLIV leads to less stabilization of the newly formed tubules and 
therefore could lead to inefficient tubule maturation what is required for further sprouting 
and thereby growing of the capillary network 38. Additionally, increased pericyte coverage 
in the lungs of CDH pups was observed and these pericytes also significantly expressed 
more ACTA2. Increased pericyte coverage and increase of ACTA2 expressing pericytes is 
linked to pulmonary arterial hypertension in adults before 18. Furthermore it has also been 
shown that resident fibroblasts and pericytes express more ACTA2 in idiopathic fibrosis 34. 
These studies highlight the importance of pericytes in pathological conditions in the lung in 
addition, these alterations in pericyte coverage and pericyte contractility lead to inhibited 
angiogenesis and therefore less extensive capillary bed in CDH underlining the concept that 
CDH is a developmental disorder which occurs already early during lung development 39 40.
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Furthermore, lung samples of human CDH patient show more expression of PDGFRβ 
indicating more pericytes and reduced COLIV expression early in lung development. This 
confirms that CDH is an early developmental disease and the focus of the treatment 
should shift from postnatal to prenatal. We have shown before that prenatal treatment of 
the nitrofen induced CDH rat model results in reduced muscularization of the pulmonary 
vasculature 29. However, current results show that treatment of CDH should even occur 
earlier in lung development aiming at modulation of pulmonary vascular development 
primarily
CDH is a complex disease and is still difficult to treat while the underlying “natural history” 
of the disease is still not well understood. The pathology has been known for decades based 
on morphological descriptions only. This study confirms that CDH is an early developmental 
disease and that pericytes are the source of alterations in muscularization of the vasculature 
observed in pulmonary hypertension associated with CDH. The observation that CDH is 
an early developmental abnormality can be used as an argument for prenatal treatment. 
Moreover, early intervention could help to diminish vascular abnormalities and may result 
in reduced lung hypoplasia and less severe muscularization defects. Further understanding 
of the interaction of endothelial cells and pericytes may help to understand the aberrant 
development of the pulmonary vasculature in CDH. 
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Introduction
Congenital diaphragmatic hernia (CDH) is a severe birth defect characterized by 
diaphragmatic structural defects, pulmonary hypoplasia and pulmonary hypertension (PH). 
The incidence of CDH is 1:2500 live births and the associated pulmonary hypertension is 
unpredictable regarding the response to current treatment modalities. PH is the major 
cause of death in a newborn with CDH, and the cause of long-term hospitalization and 
sometimes lifelong morbidity 1, 2. The pathology of the vascular abnormalities of CDH are 
characterized by extensive thickening of the smooth muscle cells in the medial layer and 
neo-muscularization of the small capillaries. The understanding of how these pathological 
characteristics of CDH occur is very complex because of the heterogeneity of the disease 1. 
In contrast to the well-described morphological changes in CDH lungs, little is known about 
the molecular pathways that are involved in the onset of CDH.
Several studies in rodents and humans have contributed to the identification of potential 
genes that could be involved in the pathogenesis of CDH. Numerous lines of evidence 
show that the retinoic acid (RA) pathway contributes to the occurrence of this disease 3-5. 
Moreover, studies in the rat model where CDH is induced by Nitrofen, an inhibitor of the 
retinoic acid pathway, have strengthened the role of the RA pathway in the development of 
CDH 6, 7 8. Furthermore, studies in neonates with CDH have shown significant lower levels of 
retinol and retinol-binding protein9, 10. In addition, whole genome sequencing studies of CDH 
patients have identified chromosomal changes in genes such as COUPTFII, TCF7L2, FOXP4 
and GATA6 and although valuable, these studies did not analyze the molecular and cellular 
effects of these mutations with respect to the pathogenesis of CDH11 12 13. Thus, human 
and animal studies hint to a role of the retinoic acid pathway in the onset of CDH, but 
it remains unclear what the downstream signaling cascade is that ultimately leads to this 
severe disease.
Previously, we observed structural changes in the pulmonary vasculature of CDH patients 
and in the CDH mouse model already early in development 14 (Chapter 2). In order to get 
a better insight in the cellular origin of CDH and in the interactions between the different 
cell types, we analyzed the gene expression of different cell populations in the CDH 
mouse model. Therefore, the transcriptome of four different cell populations isolated by 
Fluorescent activated cell sorting (FACS) were analyzed to reveal new candidates involved 
in the early events of the development of CDH. Revealing genes involved in CDH could help 
to understand how interactions between cell types are affected and how this relates to the 
onset of the pathological conditions associated with CDH.
The analysis of the whole transcriptome data showed a high similarity in GO terms between 
the NG2 positive pericyte population and the CD31 endothelial cell population. This 
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suggests a disturbed interaction between endothelial cells and pericytes. The disturbed 
interaction is the basis for the aberrant development of the pulmonary vasculature in 
CDH at the cellular level. Detailed analysis of the RNA sequence data revealed that altered 
expression of the Kruppel like factor 4 (Klf4) gene is involved in the abnormal developed 
pulmonary vasculature in CDH. The reduced expression of KLF4 was confirmed with whole 
mount fluorescent analysis. Previously, KLF4 was shown to be an up stream regulator of 
NOTCH signaling and thereby important for proper angiogenesis 15. We further found that 
several members of the NOTCH signaling pathway are differentially expressed, indicating 
that NOTCH signaling is disturbed in CDH. Indicating that the aberrant vascular development 
in CDH is a result of decreased KLF4 expression what result in disturbed NOTCH signaling.
Material and Methods
Mouse CDH model
Timed-mated pregnant mice received 20 mg nitrofen and 5 mg BPCA in 500 μl olive oil 
(Sigma) per 25 grams of body weight at day 8.5 of gestation. At different gestational ages 
pregnant mice were sacrificed, fetal lungs and diaphragms, if possible given the gestational 
age, were isolated and their morphology was used to divide the phenotypic appearance of 
the fetuses into severely affected and mildly affected.
Immunohistochemistry and Immunofluorescence
IF with the FACS antibodies was performed on 5 µm thick cryo-sections. Tissue was isolated 
and immediately embedded in OCT. Five μm thick sections were fixed in ice-cold methanol 
for 10 minutes. Blocking was performed using 5% heat inactivated donkey serum in PBS-
0.5% Tween incubated for 1 hour on room temperature. Slides were washed and incubated 
with the primary antibody overnight. The next day, slides were washed and incubated with 
a fluorescent secondary antibody for 2 hours on room temperature. IHC was performed on 
5 µm thick paraffin sections of lungs according to standard protocols. Antigen retrieval was 
performed with either Tris-EDTA buffer (pH 9.0) or citric acid (pH 6.0) on the first day and 
on the second day the Envision™ detection system (DakoCytomatic ) was used. Primary and 
secondary antibodies used for IHC and for IF are listed in supplementary table 1
Negative controls were performed by omitting the primary antibody.
FACS
Lungs were isolated at different gestational ages, and were collected in 1 ml DMEM (Lonza) 
in Eppendorf tubes. Collagenase I, Collagenase II and Collagenase IV were added and 
incubated at 37OC for 10 minutes in an Eppendorf shaker at 1000 rpm. Then, the mixture 
was mixed vigorously to completely disrupt the tissue and the cell suspension was put 
through a 40 μM cell strainer. The filter was rinsed with 1ml DMEM 10% FCS and spin down 
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at 4O C for 10 minutes at 400 g Supernatant was removed and the pellet was washed with 
PBS-10% FCS and resuspended in 300 μl PBS 10% FCS, of which 10 μl was taken to count 
the number of cells and to check for doublets and cell aggregates. Samples centrifuged at 
4O C for 10 minutes at 400 g and cells were re-suspended in 100 μl of staining mix (CD31, 
EPCAM, CD45 and NG2) or single stains, to set the laser voltages, for 40 minutes at 4o C. 
Samples were then washed by adding 150 μl PBS-FCS and gently mixed and centrifuged. 
Pellets were re-suspended in 200 μl PBS-FCS and kept in darkness at 4o C until sorted and 
just prior to sorting 0.1 μl DAPI solution was added and samples were measured on the ARIA 
FACS machine (B&D). A 100 micron nozzle was used and the gap was kept around 8. Cells 
were caught up in RNA later (Thermofisher) and kept in RNA later at 4o C until RNA isolation 
was performed. Analysis of the data was done using FlowJo
RNA isolation, sequencing, amplification and qpcr
RNA was isolated using the mirVana Paris kit (Thermosfisher). Samples in RNA later were 1 
on 1 diluted with ice-cold PBS and spin down on 15000 rpm. RNA sequencing was performed 
following the Smarter-2Seq protocol with small adjustments 16. 
Analysis of RNA sequencing results
The RNA sequences (demultiplexed) were mapped using TopHat. The RNA profiles in FPKM 
values (Fragments Per Kilobase of transcript per Million mapped reads) were generated by 
Cufflinks. This output was further analyzed using R. A log2 fold change cut off of 0.6 was used 
for the upregulated genes and a -0.6 was used for the downregulated genes. Downstream 
pathway analysis was done using Inguinity pathway analysis (IPA).
Whole mount immunofluorescence
Whole mount immunofluorescence staining of total fetal lungs was based on Yokomizo et al., 
(2012). Shortly, freshly isolated lungs were fixed in 4% paraformaldehyde (PFA) overnight. 
The next day, the lungs were gradually dehydrated through washes in increasing methanol 
and could be stored in pure methanol at -20°C for up to 3 months. The next day, the lungs 
were re-hydrated by sequential steps of decreasing concentration of methanol and blocked 
in PBS, 0.4% triton X-100 and 1% skimmed milk powder for 4 hours, blocking buffer was 
refreshed every hour. Subsequently, the lungs were incubated with primary anti-body for at 
least 4 days at 4oC. Then samples were washed with PBS-0.4% Triton for at least 48 hours, 
washing solution was refreshed every 4 hours and at the end of the day. Secondary anti-
bodies appropriate for the choice of primary antibody were conjugated with Alexa 488, 
Alexa 594, biotinylated 647 and were incubated for at least 48 hours. After this incubation, 
several washes were performed and the lungs were cleared with benzyl alcohol/benzyl 
benzoate (BABB). Samples were imaged using a Tile Scan option on the Leica Sp5 confocal 
microscope. Pictures were processed using FiJi, pictures were adjusted with brightness/
contrast option and background was reduced in Photoshop using Levels function
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Figure 1. Expression analysis of the four different cell populations used for RNA sequence 
A E13 lung tissue stained for EPCAM (magenta, open arrow heads), CD31 (red, arrows) and NG2 (green, closed 
arrow heads), showing the epithelial cells in the airways and the endothelial cells and perivascular cells in the 
vasculature (V). B Representative FACS plots of sorted endothelial (CD45- CD31+), epithelial (CD45-, CD31-, 
EPCAM+), perivascular cells (CD45-, CD31-, EPCAM-) and mesenchymal cells (CD45-, CD31-, EPCAM-, NG2-) at 
E13 Control versus CDH. The table shows the average of the percentages of the four different cell populations in 
control and CDH. C Total numbers of sorted cells of control and CDH at E13 according to the FACS sort. D Heatmaps 
with the average number of Fragments Per Kilobase of transcript per Million mapped reads (FPKM) for the three 
homogenous cell populations for the specific markers; upper for endothelial cells, middle for perivascular cells and 
bottom for epithelial cells.
Results
The distinctive cell populations present in the E13 mouse lung
Previously, we and others showed that the CDH mouse model17 (unpublished data) showed 
comparable pathological characteristics to the well-established nitrofen rat model and to 
human CDH patients18. In order to not only delineate the molecular pathways, but also the 
differences at the cellular level in CDH we focused on individual cell populations involved in 
vascular and airway development. Therefore, the spatial distribution of the individual cell 
populations was analyzed by immunofluorescent labeling of early mouse lungs (E13) (Fig. 
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1A). The immunofluorescent labeling revealed that the EPCAM antibody specifically labeled 
the epithelial cells of the airways (indicated by open arrow heads Fig. 1A). Furthermore, 
endothelial cells were specifically labeled with the CD31 antibody (indicated with white 
arrows Fig. 1A) and perivascular cells were specifically labeled with NG2 (indicated with 
closed arrow heads Fig. 1A). 
Since the antibodies appeared very specific, they were subsequently used to isolate the 
various cell populations from early pseudoglandular stage lungs of control and CDH mouse 
embryos. The CD45- fraction was subsequently used to purify the endothelial (CD31+), 
epithelial (EPCAM+) and perivascular (NG2+) cells, while also the, heterogeneous CD31-
, EPCAM-, NG2- population was collected (subsequently referred to as the mesenchymal 
population). FACS plots showed that the size of these cell populations was variable between 
control and CDH samples (Fig 1B). The cell percentages of the endothelial, epithelial and 
perivascular cells varied between 2.8% - 5.86%, whereas the mesenchymal cell population 
was around 86 %. An increase in the number of perivascular cells and in the ratio pericyte/
endothelial cell was observed, which further verified our previous study (manuscript in 
preparation) (Fig 1B and Fig. 1C). The transcriptome of these isolated populations was 
generated and the purity of the populations was determined by the analysis of genes 
specific for endothelial, epithelial and perivascular cells, leading to heatmaps with the 
specific gene expression for each population (Fig. 1D). This revealed that the endothelial 
specific markers CD34, CDH5, PECAM1 and VEGFR2 had the highest number of reads in the 
CD31+ endothelial cell population (Fig. 1D). The FPKM values of the perivascular markers 
Desmin, NG2, PDGFRβ and PDGFRα showed the highest expression in the NG2+ perivascular 
population, while the gene expression levels of DR1, EPCAM, FOXA1 and NKX2-1 revealed 
that these markers were expressed the highest by the epithelial (EPCAM +) population (Fig. 
1D). Taken together, we identified specific populations in situ and subsequently isolated 
these different cell populations with high purity as indicated by the heatmaps for the 
different markers. We furthermore detected a significant lower cell number of each sorted 
populations in the CDH samples, reflecting the clear pulmonary hypoplasia in the CDH lungs.
Expression of CDH-associated genes assigned to specific cell populations
Until now, several studies have focused on identifying genes that may be involved in the 
pathogenesis of CDH, either identified by exome studies in CDH patient or they have been 
linked to CDH in mouse studies 12, 19 19, 20. Therefore, we first focused the analysis of the 
transcriptomes on those genes that have previously been associated with CDH in human 
and mouse studies. A heatmap was generated for these so-called CDH -associating genes 
in order to elucidate the cell populations that differentially expressed these genes (Fig. 2A). 
For example, previously identified de novo mutations were found in the transcriptional co 
activators EYA1, EYA2 and transcription factor ZFPM2 (FOG2) of CDH patients 21. Sequencing 
studies of CDH patients furthermore revealed mutations in the genes STRA6, GPC3, CHD7 and 
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GATA4 (Reviewed in Holder et al)11. The broad variety of genes indicates the heterogeneous 
nature of CDH and the difficulty of understanding the onset of CDH. CHD7 was expressed 
higher in the endothelial and epithelial cell population but had a lower fold change in the 
perivascular population (Fig. 2A). Mutations in EYA1 and EYA2 have not only been shown in 
patient studies, but also mice lacking two alleles of the transcriptional co-activators Eya1 
and one allele of Eya2 show diaphragmatic defects, indicating the importance of appropriate 
expression levels of these genes22. The transcriptome analysis showed that Eya1 expression 
was decreased in the epithelial and perivascular population. Additionally, Eya2 was higher 
expressed in CDH samples in the epithelial cell population but did not show differences in 
expression in the other populations. An imbalance in the expression levels of Eya1 and Eya2 
can thus be related to the development of CDH.
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Figure 2 Heatmap of fold changes of CDH related genes for different cell populations 
A FPKM values of genes of which are known to be involved in CDH from previous studies in mouse or human 
samples. Colors indicate the degree of fold change, green indicates downregulation and red indicates up regulation. 
B qPCR validation of RNA sequence results of selected CDH genes in the NG2 and CD31 population.
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Genes of the Roundabout (ROBO) -SLIT pathway have also been implicated in CDH23, 24. 
The expression of Robo is increased in the endothelial and epithelial cell population and 
decreased in the mesenchymal and perivascular population in CDH. Slit3 was expressed 
differentially higher in the epithelial and mesenchymal population and lower in the 
endothelial and perivascular cell population. 
To further confirm the RNA sequence results, the expression of PDGFRα, SLIT2, ALDH1A2, 
RARB and CRAPB2 was quantified by qPCR in independent samples (Fig. 2B). The same 
expression patterns between control and CDH samples were observed with the RNA 
sequence results and the qPCR analysis.
Taken together, assigning genes that are involved in CDH to specific cell population is 
a step forward in understanding how CDH develops. The RNA sequence data of the four 
different cell populations isolated at E13 from the CDH mouse model showed that CDH-
causing genes are differently expressed. These genes can now be assigned to specific cell 
populations, which may contribute to understand the role of these genes in CDH. Moreover, 
the up regulation of Robo1 in the endothelial population in combination with the down 
regulation of Slit3 in the perivascular population could lead to changes in migration and 
guidance of these cells and thereby leading to impaired angiogenesis and the alterations in 
the pulmonary vasculature.
Highly differentially expressed genes of molecular pathways assigned to specific cell 
populations in CDH
To further analyze specific changes in gene expression in the cell populations, an evaluation 
of transcriptional regulators was performed using Ingenuity pathway analysis (IPA). The 
complete overview of the transcription factor encoding genes that are either upregulated 
or downregulated in the four different cell populations is shown in a Venn diagram (Fig. 3A.). 
Very little overlap was observed between the populations in both situations, indicating that 
the observed changes were population specific.
Next, we performed a Gene Ontology (GO) analysis using IPA to further investigate which 
pathways were differentially regulated in early development. The GO terms for the 
mesenchymal and epithelial cell populations did not overlap with each other and had very 
little overlap with the other two cell populations. The top 3 GO terms for the mesenchymal 
population were EIF2 Signaling, mitochondrial dysfunction and regulation of elF4 and 
p7056K signaling. The top 3 GO terms for the epithelial cell population were GNRH signaling, 
Molecular mechanism of Cancer and B Cell Receptor Signaling (SFig. 1).
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Figure 3 Canonical pathway analysis of RNA sequence of four cell populations
A Venn diaghrams of top 5 fold changes upregulated and downregulated transcription factors in the four different 
cell populations. Each cell population has its unique top5 indicating the purity of the cell populations. B Top 10 of 
canonical pathways with the highest number of differentially expressed genes in the NG2 population and the CD31 
population showing overlap in the canonical pathways. C Detailed analysis of part of the axonal guidance signaling 
and the angiopoietin signaling. Part of the proteins belonging to these pathways are differentially expressed by 
pericytes (indicated in magenta), part by endothelial cells (blue) and part by both populations (blue/magenta).
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The top 10 differentially regulated pathways of the NG2 and CD31 population showed high 
similarity in their GO terms. Two GO terms which were in the top 10 of the endothelial 
cell population and the perivascular cell population were axonal guidance and angiopoietin 
signaling pathways (Fig. 3B). These two pathways could explain the vascular abnormalities 
observed in CDH. Moreover, detailed analysis of segments of the molecules which are 
part of the axonal guidance pathway revealed that SLIT2/3 and ROBO2 were differentially 
expressed by both populations but ROBO1 and PXN only by the endothelial population 
(Fig. 3C). Large circles indicate the more central nodes in the pathway and thicker edges 
indicate interactions with high confidence. Collectively, this shows that signaling between 
endothelial and perivascular cells is affected and that a lack in migration and guidance in 
these populations could lead to the abnormal pulmonary vasculature of CDH pups and 
in that manner eventually lead to lung hypoplasia.  A similar analysis was executed for 
angiopoietin signaling, which acts through the tyrosine kinase 2 receptor (TIE2) and its 
ligand angiopoetin-1. The ANG-1/TIE2 signaling is controlled by angiopoietin-2 and in this 
manner the responsiveness of endothelial cells towards cytokines is regulated25. Analysis 
of the molecules of this pathway showed that part of the proteins was only differentially 
expressed in the endothelial population while other proteins were differentially expressed 
by the perivascular cell population. The genes FGFR2, FGFR1 and STAT5 were differentially 
expressed by the endothelial cell population whereas AKT3, NKFB1 and PAK6 were only 
differentially expressed by the perivascular population and TEK and ANGPT2 were 
differentially expressed by both populations (Fig. 3C). This supports the hypothesis that the 
process of angiogenesis is affected in CDH through the angiopoietin signaling and could 
furthermore explain the inadequate pulmonary vasculature of CDH pups.
CDH lungs have significant alterations in endothelial cell markers
Significant overlap between the GO terms of the endothelial population and the NG2 
population was observed. Therefore the differentiated genes of these populations were 
compared in more detail starting with the comparison of the Disease & Function terms 
in IPA (Fig. 4A). This could further reveal which processes underlie the abnormal signaling 
between endothelial cells and NG2 positive pericytes resulting in the incomplete pulmonary 
vascular development observed in CDH.
We showed before that increased pericyte coverage leads to abnormal vessel development 
in CDH. Given the close association between endothelial cells and pericytes,26 it is likely 
that the endothelial cell population is also different in CDH. Therefore, a more detailed 
analysis of the gene expression of the endothelial cell population was performed. This 
analysis showed that the transcription factors Kruppel like factor 4 (Klf4) and Forkhead box 
F1 (Foxf1), as well as the G protein-coupled receptor Sphingoside-1-phosphate receptor 3 
(S1pr3) were differentially regulated in the endothelial population (Fig. 4B). These proteins 
have previously been linked to endothelial cell behavior and angiogenesis15, 27, 28. KLF4 has 
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been linked as an upstream regulator of NOTCH signaling. Moreover, increased expression 
of KLF4 leads to reduced expression of NOTCH genes in tumors15. NOTCH signaling is known 
for being important in the competition between the tip and stalk cells during sprouting of 
endothelial cells to form new tubes in the process of angiogenesis29.
Taken together, the analysis of the transcriptome of the different cell populations revealed 
differential expression of Klf4 (Fig. 4B).
Expression of KLF4 is down regulated in CDH and results in malformation of the 
capillary network in CDH
The RNA sequence data showed a decrease of KLF4 expression in the CDH endothelial cell 
population. Therefore, the spatial and temporal expression pattern of KLF4 was analyzed 
to evaluate its potential involvement in the occurrence of pulmonary hypertension in CDH. 
KLF4 expression was decreased in the CDH lung samples isolated at E15 compared to control 
lungs, and remained lower until E18 (Fig5 A indicated with white arrow heads). To get a better 
insight of the exact location and effect of reduced KLF4 expression on the vasculature, high 
resolution images were made of total embryonic lungs stained with specific antibodies. This 
procedure leaves the lung structure completely intact and the small capillaries can easier be 
traced back than in lung sections. At E15 a significant lower number of KLF4 positive signal 
was detected in CDH (Fig. 5B), indicating an early defect in the vascular development in 
the lungs of CDH pups. The decrease of KLF4 signal was consistent through development, 
although they were no longer significant (Fig. 5B). 
As mentioned in the above section the expression levels of KLF4 have been related to NOTCH 
signaling 15. Therefore the expression levels of genes that are part of the NOTCH signaling 
pathway were analyzed and plotted in a heatmap (Fig 5. C), indeed showing that multiple 
genes of the NOTCH signaling pathways were differently expressed in the endothelial cell 
population at E13 in the mouse CDH model. qPCR for HEY2, NOTCH1 and NUMBL1 showed 
the same expression trends as the RNA sequence analysis. Indicating that disturbed NOTCH 
signaling caused by downregulation of Klf4. The disturbed NOTCH signaling leads to a 
decreased number of sprouting endothelial cells what results in a reduced number of newly 
formed tubules in the vascular bed in CDH.
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Figure 4 Disease and function analysis of CD31 and NG2 population leads to specific pathway analysis of the 
CD31 population 
A Disease and function analysis of the CD31 and NG2 population showed that both populations appear to have 
differentially expressed genes in the same terms. B Pathway analysis of the CD31 population of transcription factors 
and G-coupled proteins showed KLF4, FOFXF1 and S1PR3 are part of the same pathway and all three had a high fold 
change and are involved in regulation endothelial cells in angiogenesis.
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Figure 5  KLF4 expression in the developmental lung vasculature and the expression of its downstream targets of 
the NOTCH pathway in RNA sequence data 
A Expression pattern analysis of KLF4 suggest reduced expression of KLF4 at E15 and E18 in the CDH mouse model. 
B High magnification analysis of whole mount immunofluorescent labeled embryonic lung samples at E15 show 
a significant decrease in KLF4 expression and a trend in reduced KLF4 expression at E18, as indicated in the bar 
diagrams.  C The fold change in expression of different members of the NOTCH signaling pathway in the CD31 
population. The diversity in the fold change of the affected members of the NOTCH signaling pathway emphasizes 
the broad underlying mechanism in the developmental defects of the pulmonary vasculature in CDH
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Discussion
CDH is a rare disease, which, however, remains difficult to treat. More specifically, the 
pulmonary hypertension associated with this disease results in long hospitalization and 
potential life-long problems. The onset of the vascular changes that correspond with the 
disease are still not well understood. Studies towards genes involved in CDH have mainly 
been focused on either patient sequencing or mouse knockout studies30 31.A number of 
sequencing studies revealed mutations in CDH patients but the used input is from late 
stages in lung development. In these studies it often remains unclear what the effect of the 
mutations is on the number of cells and their behavior32. Our study shows for the first time 
that differences in gene expression are related to individual cell populations. How structural 
changes associated with PH arise and how this is related to changes in gene expression and 
how this relates to different cell types appeared in this study for the first time. Previously we 
showed that the NG2 positive pericytes are the underlying cause of the structural vascular 
changes that accompany CDH. In this study, we further confirm the strong endothelial/
pericyte interaction and how this interaction is affected in CDH. Moreover, the endothelial 
and pericyte populations revealed high similarity in GO terms. This suggests that the genes 
of certain signaling pathways are differentially expressed in CDH, resulting in aberrant 
communication between pericytes and endothelial cell. More specifically, the appearance 
of the ROBO/SLIT pathway in the GO term analysis indicated that the guidance signaling of 
the endothelial cells and perivascular cells was affected which could be an explanation for 
the simplification of the pulmonary vasculature observed in CDH.
Besides the changes in genes that are involved in both cell populations, we also found new 
genes in the endothelial cell population, namely FOXF1 and KLF4, which have not been 
shown before to be involved in CDH. Mutations in the FOXF1 gene or in the regulatory 
elements of FOXF1 have been associated with Alveolar Capillary Dysplasia (ACD). ACD is a 
severe and lethal congenital lung disease with misalignment of the pulmonary veins 33-35.
It has been demonstrated that there is increased KLF4 expression in SMC in the pulmonary 
arterioles of pulmonary hypertension patients without CDH. It has been hypothesized that 
this increase is required for dedifferentiation and clonal expansion of SMCs in the pulmonary 
hypertension mouse model36. This study showed no difference in the expression of KLF4 in 
the perivascular population but a significant decrease in KLF4 expression in the endothelial 
population. The observed difference further suggests that pulmonary hypertension of the 
newborn and pulmonary hypertension secondary to cardiac malformations are intrinsically 
different from each other. 
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Figure 6 Summary of developmental events that happen during the pulmonary vascular developmen in the 
mouse model for CDH.  
Early inhibition of the retinoic acid pathway (E8.5) results in downregulation of KLF4 at E13. The downregulation of 
KLF4 leads to disturbance in NOTCH signaling which leads to a reduction in the formation of the lung capillary bed.
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The role of KLF4 in angiogenesis has been linked to NOTCH signaling. KLF4 is thought to 
be an upstream regulator of NOTCH and in that way a regulator of angiogenesis 15. The 
importance of KLF4 in the regulation of NOTCH signaling, and thereby the number of 
sprouting endothelial cells during angiogenesis, together with the observed decrease 
in KLF4 expression in the CDH mouse model could explain the vascular abnormalities 
associated with CDH. Since a reduced number of capillaries was observed in the lungs of the 
CDH mouse model we assume that this could be the result of decreased KLF4 expression 
by endothelial cells leading to disturbed NOTCH signaling leading to a decrease in active 
sprouting cells during angiogenesis (Fig. 6).
In summary, this study shows whole trancrtiptome analysis of four different populations of 
lungs of control and CDH samples. Analysis of these data showed high similarity between 
the endothelial and pericyte populations, which could explain the altered pulmonary 
vascular development in CDH. Furthermore, we identify two new candidates involved in 
angiogenesis and impaired during the development of the pulmonary vasculature in CDH. 
Taken together, revealing involved genes in these mechanisms could help to early intervene 
with pulmonary vascular growth in CDH patients.
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Clinically relevant timing of antenatal sildenafil 
treatment reduces pulmonary vascular 
remodeling in congenital diaphragmatic hernia
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Abstract
Patients with congenital diaphragmatic hernia (CDH) suffer from severe pulmonary 
hypertension due to altered development of the pulmonary vasculature, which is often 
resistant to vasodilator therapy. Current treatment starts postnatally even though 
significant differences in the pulmonary vasculature are already present early during 
pregnancy. We examined the effects of prenatal treatment with the phosphodiesterase-5 
inhibitor sildenafil on pulmonary vascular development in experimental CDH starting at 
a clinically relevant time. The well-established, nitrofen induced CDH rodent model was 
treated daily with 100 mg/kg sildenafil from day 17.5 until day 20.5 of gestation (E17.5-
20.5). Importantly, this timing corresponds perfectly to the developmental stage of the 
lung at 20 weeks of human gestation, when CDH is detectable by 2D-ultrasonography 
and/or MRI. The lungs were isolated at E21.5 and analyzed using immunostaining, real-
time PCR and volume measurements. Prenatal treatment with sildenafil improved lung 
morphology and attenuated vascular remodeling with reduced muscularization of the 
smaller vessels. Pulmonary vascular volume was not affected by sildenafil treatment. 
We show that prenatal treatment with sildenafil within a clinically relevant period 
improves pulmonary vascular development in an experimental CDH model. This may 
have important implications for the management of this disease and related pulmonary 
vascular diseases in human.
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Introduction
Congenital diaphragmatic hernia (CDH) is a developmental defect characterized by an 
incomplete diaphragm and lung hypoplasia 1. CDH patients have a high risk of mortality 
and morbidity due to the associated pulmonary hypertension, which is the result of altered 
development of the pulmonary vasculature and disordered pulmonary vascular remodeling 
2-4. Advancement has resulted in early detection of CDH by ultrasonography at 20 weeks 
of gestation, but the severity of clinical symptoms postnatally remains poorly predictable 
at this stage due to significant differences in pulmonary vascular resistance and flow after 
birth. In addition, the pulmonary hypertension in CDH is often unaffected by standard 
vasodilator therapy and the lack of randomized controlled trials prevents the implementation 
of alternative drugs. Trials with Nitric Oxide (NO), one of the most commonly used drugs 
in newborns, failed to show consistently positive effects in CDH patients 5. The impaired 
responsiveness to NO may be due to rapid degradation of the intracellular messenger cyclic 
guanosine monophosphate (cGMP) by phosphodiesterase-5 (PDE5) 6. Binding of cGMP to 
PDE5 stimulates the phosphorylation and activation of PDE5 by cGMP dependent protein 
kinase G (PKG), which results in the conversion of cGMP into GMP 7. Sildenafil is a potent 
PDE5 inhibitor, leading to an accumulation of cGMP and thus the continuous activation of 
PKG. PKG has several physiological substrates, which are involved in smooth muscle cell (SMC) 
relaxation by lowering intracellular calcium 8, 9. Sildenafil also reduces inflammation, improves 
early postnatal survival and prevents pulmonary vascular remodeling in different experimental 
animal models of pulmonary hypertension without CDH 10-12 and prolongs survival and 
improves lung structure in a neonatal hyperoxia rat model 13. It has been successfully used in 
the postnatal treatment of persistent pulmonary hypertension of the newborn (PPHN) 14-19 and 
pulmonary hypertension in patients with congenital heart disease 20. There are no randomized 
controlled trials of sildenafil in CDH patients, but there are case reports showing positive 
effects after postnatal treatment 21, 22. Previously, we showed thickening of the smooth muscle 
cell layer in arterioles, neomuscularization of small capillaries and phenotypic changes of the 
smooth muscle cells in the vascular wall in lungs of CDH patients at 30 weeks of gestation, 
indicating that significant differences in vascular structure are already present in unborn 
children that will develop PH after birth 23. The premature differentiation of vascular smooth 
muscle cells and the early structural changes in pulmonary vascular development suggest 
that antenatal treatment of CDH patients could be beneficial. Recently, Luong et al. showed a 
reduced pathology in experimental CDH after prolonged antenatal treatment with sildenafil 
24. However, they started the daily treatment with sildenafil already at day 10.5 of gestation, 
when the lung bud is just emerging from the primitive foregut. At this embryonic phase of 
lung development there are no signs of CDH pathology, yet. Hence, it is unclear whether 
the prophylactic treatment prevented the development of pathological features, or that the 
sildenafil indeed regressed the clinical signs. Since human CDH can be diagnosed at 20 weeks 
of gestation, the canalicular phase of lung development, we analyzed the therapeutic effects 
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of sildenafil in the nitrofen induced rat CDH model starting at the corresponding gestational 
age (E17.5). In rat, the CDH pathology is already noticeable from E13.5 on with a defective 
diaphragm and affected lungs 25-27. We show that starting the treatment of the CDH rat model 
with sildenafil at the clinically relevant time point improved lung morphology and attenuated 
or reversed the vascular remodeling of the smaller vessels. These findings may directly be 
valuable for future treatment modalities of severe CDH patients. 
Methods
Animal Model
Pregnant Sprague-Dawley rats received either 100 mg nitrofen dissolved in 1 ml olive oil or just 
1 ml olive oil by gavage on gestational age day E9.5. Nitrofen induces CDH in approximately 
70% of the offspring, while all pups have pulmonary hypertension. Administration of nitrofen 
at this time point results in mainly left sided hernias 28. Pregnant rats were divided into 4 
groups: control, nitrofen (CDH), control+sildenafil and nitrofen+sildenafil (CDH + sildenafil). 
Sildenafil (100 mg/kg/day, Pfizer, New York, USA) dissolved in water was administered 
via oral gavage for 4 consecutive days from day E17.5 to day E20.5. At day E21 pups were 
delivered by caesarean section and euthanized by lethal injection of pentobarbital.
All animal experiments were approved by an independent animal ethical committee and 
according to national guidelines.
Plasma Sildenafil Concentration
Maternal and fetal rat blood samples were collected directly after caesarian section. Fetal 
blood samples were pooled, and plasma (50 µl) from 6 maternal and 9 fetal samples was 
isolated by centrifugation (10.000 RPM, 15 minutes) and sildenafil and its metabolite 
N-desmethyl-sildenafil (DMS) concentrations were analyzed using ultra-performance liquid 
chromatography with tandem mass spectrometry (UPLC-MS/MS).
Lung Morphology
Fetal rat lungs were isolated, fixed overnight in 4% PFA and embedded in paraffin. Serial 5 µm 
thick sections were made through the middle of the left lobe and stained with haematoxylin 
and eosin (HE). Sections were imaged at 40x magnification using a BX41 research 
stereomicroscope system (Olympus; Tokyo, Japan). Four non-overlapping images in different 
parts of each lung were acquired. Major airways and vessels were excluded from the analysis. 
The airspace size was automatically quantified using an index (D2-score) that is based on the 
alveolar airspace diameter and takes into account the first three central moments of the 
airspace size distribution. This measurement is designed to account for airspaces of different 
sizes by assigning them different weights. Compared to the well-known mean linear intercept 
(L
m
), this method is more reliable in the presence of a large variability in airspace sizes 29, 30.
4SILDENAFIL TREATMENT REDUCES VASCULAR REMODDELING IN CDH  101
Immunohistochemistry and Immunofluorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraffin sections of the lungs 
according to standard protocols, using the Envision™ detection system (Dako Cytomatic, 
Glostrup, Denmark) 31. Primary antibodies used for IHC were smooth muscle actin (α-SMA; 
MS-113-P1; 1:1200, Thermo Scientific, Fremont, CA, USA), phosphodiesterase-5 (PDE5A; 
PD5A-101AP; 1:300, Fabgennix, Frisco, TX, USA) and phosphorylated phosphodiesterase-5 
(phospho-PDE5; PPD5-140AP; 1:100, Fabgennix). Antigen retrieval with Tris-EDTA buffer (pH 
9.0) was used for α-SMA.
Primary antibodies used for immunofluorescence (IF) staining on 5 µm paraffin sections 
were smooth muscle actin (α-SMA; MS-113-P1; 1:500, Thermo Scientific), smooth muscle 
actin (clone 1a4) (α-SMA direct labelled FITC; 1:200, Sigma, The Netherlands) and platelet 
derived growth factor β (PDGFrβ; 1:100). Secondary antibodies against mouse (α-SMA) 
and rabbit (PDGFrβ) were used. Negative controls were performed by omitting the primary 
antibody.
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation, cDNA synthesis and subsequent qPCR analysis was performed as previously 
described 31. The gene-specific primers were custom designed using PerlPrimer 1.1.21 32 and 
all retrieved sequences were blasted using Ensembl (RLS 84) 33. The primer combinations 
used in our qPCRs are listed in Table 1. Both Actb and Hprt were used as housekeeping genes 
and all represented data are based on Actb.
Table 1: Primer sequences
Gene Sequence (forward 5’- 3’) Sequence (reverse 5’- 3’)
Pde5 TCAACAACGGATAGCAGAACTC CCCTGTTCATTAGATCAGCGG
Prkg1 AACTATGCAGGGACAACCCA CCTTCCCAGTTAAAGCCCTC
Prkg2 ACTAGGCATTATCTACAGAGACC TCCAAAGTCAACCAACTTAAGG
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Pdgfr-β AACGACCAGTTCTACAATGCC CATGATCTCATAGATCTCGTCGG
Pecam-1 GCAGTCCCACTTCTGAACTC GTTCTGGGAGTCGTAATGGC
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Hprt AGACTGAAGAGCTACTGTAATGAC CAACAATCAAGACGTTCTTTCCAG
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Volume Measurements Pulmonary Vascularity
Lungs of pups were perfused through the right ventricle with Microfil contrast agent (Microfil, 
Flow Tech; Carver, MA, USA) and imaged with a micro Computed Tomography (micro-CT) 
scanner (Quantum FX, PerkinElmer; Waltham, MA, USA; pixel size 10–295 µm). Subsequently, 
the images were analyzed with the I-Space (Barco, Kortrijk, Belgium), a CAVETM-like Virtual 
Reality system in which 3D holograms can be viewed with depth perception by wearing a 
pair of stereo glasses with polarizing lenses. Volumes were calculated by semi-automatic 
region growing using the V-Scope volume-rendering software (Department of Bioinformatics, 
Erasmus MC, Rotterdam, The Netherlands) as previously described 34, 35. Volume of the 
pulmonary vasculature was measured in relation to the total lung volume. Results obtained 
with the I-Space were validated using a computer program, Analyze Direct (Kansas City, US).
Statistical Analyses
Data are presented as percentages, means (SD) and univariate analyses were performed 
using two-way ANOVA tests for normally distributed variables. The analyses were performed 
using SPSS 21.0 for Windows (Armonk, NY, USA: IBM Corp.). All statistical tests were two-
sided and used a significance level of 0.05.
Results 
Sildenafil Effectively Crosses the Placental Barrier
In order to investigate potential effects of oral sildenafil on fetuses, we first analyzed the 
levels of sildenafil and its major metabolite N-desmethyl-sildenafil (DMS) in blood plasma 
of the mothers and pups approximately 24 hours after the last dose of sildenafil. These 
measurements showed that the oral application facilitated efficient uptake of sildenafil 
in the bloodstream and subsequent passage through the placental barrier into the fetal 
circulation (Table 2, Figure 1A). 
Table 2: Plasma level of sildenafil and N-desmehtyl-sildenafil (DMS)
Mothers Pups
Sildenafil (ng/ml) DMS (ng/ml) Sildenafil (ng/ml) DMS (ng/ml)
7.00 14.30 15.00 1.80
1.60 4.40 19.80 1.60
1.30 2.70 4.60 1.50
2.70 3.70 4.70 1.90
0.90 2.80 13.20 1.40
1.30 10.80 7.70 0.90
5.00 1.20
6.70 3.10
5.20 1.70
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Since the administration of sildenafil to the rats was started late in gestation after the 
development of the diaphragm, we did not observe a reduction in the incidence of CDH after 
treatment (Figure 1B). The effect of sildenafil on the general development of the fetuses 
was analyzed by assessing the body weight. Fetuses of nitrofen treated mothers (CDH) had 
a significantly lower body weight compared to control at E21.5, but antenatal treatment 
with sildenafil resulted in a significant increase in body weight in control and CDH fetuses 
(Figure 1C). The lung weight-to-kidney weight ratio (LW/KW) was used as an indicator for 
lung hypoplasia, since the kidney weight is less affected by treatment with sildenafil than 
the body weight. This LW/KW ratio was significantly reduced in CDH fetuses compared to 
control, indicating severe lung hypoplasia in the CDH fetuses. Antenatal sildenafil treatment 
reduced the hypoplasia as indicated by the significant improvement of the LW/KW ratio in 
CDH fetuses. 
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Figure 1: Effects of maternal sildenafil on pups.
(A) Levels of sildenafil and its metabolite desmethylsildenafil (DMS) measured in plasma of mother rats and 
her fetuses indicate effective placental passage of sildenafil, median (IQR), n=6 (mothers), n=9 (pups). (B) The 
incidence of CDH is not affected by sildenafil treatment (63% vs 59%, p=0.665); n=5 for all groups. (C) Bodyweight 
is decreased in pups with CDH (3.0 gr vs 3.8 gr, p<0.001), which is reversed by treatment with sildenafil (3.5 gr, 
p<0.001). Sildenafil also caused an increase in bodyweight in control pups (4.0 gr, p<0.05); n=13 (control), n=23 
(CDH), n=16 (control + sildenafil), n=24 (CDH + sildenafil). (D) LW/KW is decreased in CDH (3.0 vs 4.4, p<0.001), 
and slightly improves after sildenafil treatment in CDH (3.5, p<0.001). Sildenafil caused a decrease in the ratio 
in controls (3.9, p<0.001); n=33 (control), n=38 (CDH), n=23 (control + sildenafil), n=28 (CDH + sildenafil). 
*p<0.05, **p<0.01, ***p<0.001. Error bars represent standard error (SD). LW Lung Weight, KW Kidney Weight.
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However, sildenafil induced a mild hypoplasia in control fetuses (Figure 1D). 
Sildenafil inhibits PDE5, so we analyzed if sildenafil had an effect on the expression of its 
target. RNA expression of Pde5 was increased in fetal CDH lungs, but sildenafil did not 
reduce this elevated expression. In addition, the downstream targets of Pde5, Prkg1 and 
Prkg2, were not affected in any of the groups (Figure 2A). Since we did not find differences 
in expression level, we analyzed the distribution of Pde5 in the lungs of the fetuses. The 
expression pattern of Pde5 was primarily in the very large (>100 µm) vessels in some of 
the control samples, but this pattern was expanded in the CDH lungs to a number of small 
(<50 µm) and larger (50-100 µm) vessels (Figure 2B). Remarkably, treatment with sildenafil 
resulted in a reduction of the number of Pde5 positive vessels in CDH, and the staining 
pattern was comparable to control lungs, being primarily around some of the larger vessels. 
The activated, phosphorylated Pde5 was detected in part of both small and larger vessels of 
all samples with no clear differences between all groups.
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Figure 2: Expression of phosphodiesterase-5 (Pde5) in the lungs of rat fetuses. 
(A) Expression of Pde5, Prkg1 and Prkg2 RNA shows no significant differences. For all groups 6 independent lung 
samples were used. Error bars represent SE. (B) Representative images of immunohistochemistry staining show 
expression of Pde5 around the vessels of CDH lungs (top) and phosphorylated Pde5around the vessels in all groups 
(bottom). Arrows indicate vessels, A indicates airways. Scale bars represent 20 µm. For all groups 3 independent 
lung samples were used.
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Sildenafil Improves Lung Morphology and Attenuates Pulmonary Vascular 
Remodeling in CDH
We analyzed the histology of the lungs of the different treated pups, which clearly showed 
differences in cellular density of the lung structure, with thicker septa and smaller alveolar 
airspaces in CDH (Figure 3A). The alveolar airspace diameter (D2-score) was used to quantify 
the alveolar airspaces. Both alveolar density and the number of alveoli were significantly 
increased in CDH rats compared to control and returned to normal after treatment with 
sildenafil (Figure 3B,C). 
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Figure 3: Prenatal sildenafil improves alveolar development in CDH.
(A) Representative images of HE stained sections show a significant decreased mean alveolar airspace diameter in 
CDH rats compared to control. Scale bars represent 50 µm. (B) Quantification of alveolar development in control 
and CDH using the D2-score (49.3 µm (7.8) and 25.9 µm (2.2), respectively, p=0.002). Sildenafil clearly showed an 
increase in alveolar airspace diameter in CDH (52.9 µm (17.6), p=0.001), taking into account the D2-score (in µm) 
that incorporates the first three central moments of airspace distribution. (C) The number of alveoli is significantly 
increased in CDH (p=0.003), while treatment with sildenafil reverted the alveolar abnormality to normal (p=0.001). 
For all groups 4 non-overlapping images were used of 5 independent lung samples. *p<0.05, **p<0.01, ***p<0.001. 
Error bars represent SD. 
We and others have previously shown that the nitrofen rat model phenocopies the vascular 
defects observed in human CDH patients with increased muscularization of the arterioles 23. 
To analyze whether nitrofen and/or sildenafil would affect the development of the vascular 
tree, we measured the total pulmonary vascular volume. Three dimensional volume 
measurements done in the I-Space showed a significant decrease in total lung volume (LV), 
in pulmonary vascular volume (PVV) and in the ratio of PVV to LV in CDH fetuses compared 
to controls (Figure 4A,B). We observed no significant improvement of the vascular volume in 
CDH fetuses treated with sildenafil, but antenatal sildenafil decreased pulmonary vascular 
volume and PVV/LV in control fetuses (Table 3). This indicates that starting sildenafil 
treatment at a clinical relevant time point did not improve the vascular tree. 
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Table 3: Pulmonary vasculature volume in rat fetuses
Control  
(n=7)
CDH  
(n=5)
Control + sildenafil 
(n=9)
CDH + sildenafil 
(n=8)
Lung volume mm3 (SD) 134.0 (22.8) 95.2 (22.3)* 110.4 (22.8) 93.4 (8.3)***
Vasculature volume mm3 (SD) 11.3 (3.3) 4.8 (2.3)** 6.9 (3.1)* 3.6 (0.5)***
Ratio vasculature/lung 0.084 (0.019) 0.048 (0.019)** 0.060 (0.017)* 0.039 (0.005)***
Results are shown as mean (SD). * p<0.05, ** p<0.01, *** p<0.001 compared to control.
Control CDH
P
la
ce
bo
S
ild
en
af
il
A B
Va
sc
ul
ar
 v
ol
um
e 
/ 
lu
ng
 v
ol
um
e 
(R
at
io
) **
**
CDH 
Sildenafil
        -        -        +       +
        -        +         -       +
0.00
0.05
0.10
0.15
Figure 4: Sildenafil does not affect vasculature volume. 
(A) Representative images of computed tomography scans of microfil-injected pulmonary vessels analyzed 
with the I-Space. Scale bars represent 2 mm. (B) The ratio of the pulmonary vasculature volume to total 
lung volume is significantly decreased in CDH rats (0.048 vs 0.084, p=0.001) and control rats treated with 
sildenafil (0.060, p=0.005); n=7 (control), n=5 (CDH), n=9 (control + sildenafil), n=8 (CDH + sildenafil). 
*p<0.05, **p<0.01, ***p<0.001. Error bars represent SD. 
Previously, we showed a thickening of the smooth muscle cell layer in small capillaries in rats 
with PH 36, and a more extensive peripheral distribution of contractile vascular smooth muscle 
cells in human CDH 23. Based on these results, we analyzed gene and protein expression of 
several vascular-associated markers to study the effects of sildenafil treatment on vascular 
remodeling. Gene expression analysis of α-Smooth Muscle Actin (α-Sma) and Platelet-
Derived Growth Factor receptor β (Pdgfr-β, pericyte marker) in relation to endothelial 
cells (Pecam-1/CD31) showed a significant increase of Pdgfr-β in CDH lungs compared to 
control, indicative for an increase of differentiating perivascular cells in the CDH lungs. 
Treatment with sildenafil significantly reduced these markers, suggesting a restoration of 
normal pulmonary vascular development. However, the expression of Pdgfr-β did not revert 
completely to the control levels (Figure 5A,B). Analysis of the distribution pattern showed 
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an increased thickening of the α-Sma+ smooth muscle cell layer in small pulmonary vessels 
(<50 µm) in CDH fetuses. Sildenafil treatment reduced this thickening of the media in CDH 
lungs, corresponding with the RNA expression data. Remarkably, sildenafil slightly increased 
the media in control rats (Figure 5C,
D).
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Figure 5: Sildenafil decreases pathological muscularization in CDH.
(A) RNA expression of smooth muscle actin (Sma) in relation to platelet endothelial cell adhesion molecule (Pecam1) 
shows no significant changes between the groups. (B) RNA expression of platelet derived growth factor β (Pdgfr-β) 
in relation to Pecam1 shows a significant increase in CDH (p<0.001), which is slightly improved after treatment 
with sildenafil (p=0.009). (C,D) Representative images of immunohistochemistry staining (C) and quantitation (D) 
show increased expression of Sma and a significant thickening of the vessel wall of small pulmonary vessels (<50 
µm) in CDH (12.96 µm vs 6.55 µm, p<0.001), which is completely reversed by antenatal treatment with sildenafil 
in CDH (6.91 µm, p<0.001) and thickened in control (9.21 µm, p=0.030). Arrows indicate vessels, A indicates 
airways. Scale bars represent 20 µm. For all groups 15 to 20 vessels of 3 independent lung samples were measured. 
*p<0.05, **p<0.01, ***p<0.001. Error bars represent SD.
Immunofluorescence staining of control lungs showed expression of α-Sma almost 
exclusively in the media of the large vessels and in the subepithelial layer of the airways, and 
a peripheral, parenchymal staining of Pdgfr-β (Figure 6). Interestingly, α-Sma and Pdgfr-β 
co-localized around the smallest vessels in CDH lungs, most likely staining differentiating 
perivascular cells. Thus, in contrast to control lungs, the small capillaries are muscularized 
in CDH fetuses. Sildenafil treatment of CDH fetuses resulted in a reversion of the staining 
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pattern of α-Sma and Pdgfr-β to the control situation, indicating that sildenafil may reduce 
the pulmonary hypertension. This would suggest a beneficial effect of sildenafil on reducing 
the pulmonary hypertension at the cellular level (Figure 6).
Control CDH
P
la
ce
bo
S
ild
en
af
il
A
V V
V
Sma
Pdgfr-β
Figure 6: Abnormal smooth muscle cells surround arterioles in CDH.
Representative immunofluorescence staining images of all 4 groups show colocalization of Sma (red) and platelet 
derived growth factor β (Pdgfr-β; green) in the parenchyma of CDH lungs. Arrowheads indicate examples of 
capillaries with colocalization, A indicates airways, V indicates vessels. Scale bars represent 20 µm.
Discussion
Our study shows that antenatal treatment of CDH pups with the PDE5 inhibitor sildenafil 
starting at the clinically relevant time point results in reduced lung hypoplasia and reduced 
vascular abnormalities. Administration of sildenafil was started at the canalicular stage of 
lung development in the rat, which corresponds with the time point when human CDH can 
be detected by routine ultrasound at 20 weeks of gestation. The diaphragm of the rat is 
already formed and the major pulmonary vessels are already developed at the time the 
administration of sildenafil was started. Therefore we did not observe a reduction in the 
incidence of CDH, or an improvement of the pulmonary vascular volume in the major 
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branches of the vascular tree. However, sildenafil improved the body weight and LW/KW 
ratio, indicating a better lung growth development compared to untreated CDH pups. 
Furthermore, the alveolar airspaces increased in diameter, which could be related to the 
formation of the primary and secondary septa later in prenatal lung development. Moreover, 
sildenafil reduced the thickening of the smooth muscle cell layer in arterioles normally 
present in CDH, and prevented the frequently observed aberrant differentiation of pericytes 
in CDH as indicated by the loss of the co-localization of α-Sma and Pdgfr-β in capillaries 23, 36.
Table 4: Overview of studies with antenatal sildenafil treatment in the nitrofen rat model
Our study Luong  
et al 24
Kattan  
et al 39
Lemus-Varela 
et al 40
Yamamoto  
et al 41
100 mg/kg
Oral 24 h
E17.5 – E20.5
100 mg/kg
Subcutaneous 24 h
E10.5 – E20.5
45 mg/kg
Oral 12 h
E14 – E22
100 mg/kg
Oral 24 h
E16 – E20
100 mg/kg
Subcutaneous 24 h
E11.5 – E20.5
Fetal body weight CDH: significantly 
decreased
CDHsil: significant 
improvement
CDH: significantly 
decreased
CDHsil: no 
improvement
Lung weight
 
CDH: decreased 
lung/kidney weight
CDHsil: significant 
improvement
Cosil: decreased 
lung/kidney weight
CDH: decreased lung/
body weight
CDHsil: no 
improvement
Cosil: no significant 
differences
CDH: decreased 
lung/body weight
CDHsil: significant 
improvement 
Morphology CDH: decreased 
alveolar airspaces
CDHsil: significant 
improvement
Cosil: No significant 
differences
CDH: increased mean 
linear intercept
CDHsil: significant 
improvement
Cosil: no significant 
differences
CDH: decreased 
alveolar 
airspaces
CDHsil: no 
improvement
CDH: decreased 
alveolar airspaces
CDHsil: significant 
improvement
Vasculature CDH: decreased 
vascular volume
CDHsil: No 
improvement
Cosil: decreased 
vascular volume
CDH: less pulmonary 
vessels
CDHsil: significant 
improvement
Cosil: less pulmonary 
vessels
CDH: less 
arterioles
CDHsil: 
significant 
improvement
Vessel wall CDH: increased SMC§ 
layer
CDHsil: significant 
improvement
Cosil: increased SMC§ 
layer
CDH: no significant 
differences
CDHsil: no significant 
differences
Cosil: no significant 
differences
CDH: increased 
SMC layer
CDHsil: 
significant 
improvement
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In this study we proved the placental crossing of sildenafil into the fetal circulation with 
higher levels of plasma sildenafil and lower levels of plasma DMS in the pups compared to 
the mother. Sildenafil is known to be catalyzed by hepatic CYP3A4 and CYP2C9. Prenatal 
and early postnatal CYP-mediated N-demethylation is less prominent when compared to 
adults, which causes less clearance of sildenafil. This reduced clearance in fetuses results in 
a longer terminal half-life 37. The dose of sildenafil chosen for this study was 100 mg/kg/d, 
which was based on a previous study on the pharmacokinetics of sildenafil in rats. Since the 
metabolism in rats is  faster than in human, this dose is a lot higher than the normal dose 
used in the clinical setting. Although the oral bioavailability of sildenafil in female rats is only 
44%, which is similar to humans (38%), it is preferred over other methods keeping in mind 
the potential clinical application 38.
Luong et al21 had previously shown that antenatal sildenafil crosses the placenta without 
affecting the PDE5-expressing organs of the pups in the nitrofen-rat model. Consistent with 
our study, they show improvement in lung structure in the nitrofen-induced rat model after 
antenatal sildenafil. However, Luong et al treated rats for 10 days, starting already at day 
10.5 of gestation, which is only one day after the start of lung development in rats and can 
therefore be seen as prophylactic 24. Furthermore, an increase in the number of arterioles 39, 
a decrease in vascular remodeling 40 and improvement in pulmonary vascular response and 
lung growth 41 were shown after antenatal treatment with sildenafil of different duration in 
the nitrofen rat model. Improvement in parenchymal and lung abnormalities after antenatal 
sildenafil was shown in a rabbit model of CDH 42 and in a lamb model, downregulation of 
eNOS was shown to be normalized after antenatal treatment with tadalafil, another PDE-5 
inhibitor 43. However, the treatment strategies in all these studies were already initiated very 
early during pregnancy, at a time when human CDH would not yet be detectable and before 
CDH symptoms and pathology develop. A summary of the relevant sildenafil studies in the 
nitrofen rat model is shown in Table 4.
We found that sildenafil caused a decreased LW/KW ratio, increased muscularization of the 
arterioles and decreased pulmonary vascular volume in healthy control rats. Differences 
in lung structure in control rats and rabbits treated with sildenafil were also reported by 
Luong et al 24 and Russo et al 42. The pathophysiology of these side-effects is still not clear, 
but might involve the increase in cGMP after PDE-5 inhibition, since increased cGMP can 
also lead to toxicity and interfere with normal cellular proliferation 44. Extreme vasodilation 
caused by increased cGMP might also have a deleterious effect on the development of the 
pulmonary vasculature. However, sildenafil has been used as a treatment for preeclampsia in 
pregnant women with no significant adverse effects in both mother and fetus during follow 
up of 30 days post-delivery 45. Furthermore, recently a trial has started for the antenatal 
use of sildenafil in pregnancies complicated by early-onset extreme fetal growth restriction 
(STRIDER; NCT02277132 (clinicaltrials.gov)) 46.
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In the present study we focused on pulmonary vascular development, since pulmonary 
hypertension in CDH is the major cause of morbidity and mortality. The major strength 
of this study is the timing of the sildenafil treatment at day 17.5 of gestation, which 
corresponds to 20 weeks of gestation in human pregnancy, when CDH is detectable by 
routine ultrasound in many countries. Sildenafil has never been tested in a clinical trial as 
an antenatal treatment to target the pulmonary vascular growth. However, the possibility 
of prenatal diagnosis of CDH offers a unique opportunity to treat fetuses antenatally. So far, 
sildenafil is only used postnatally as a treatment for severe pulmonary hypertension and in 
some of the most severe CDH patients who are resistant to current therapies, in an attempt 
to prevent extracorporeal membrane oxygenation (ECMO). Therefore, it is not possible to 
directly compare the pathological changes seen in these patients with the effects of the 
antenatal sildenafil treatment in the CDH rat model. 
The potential to treat CDH already antenatally might be a big improvement in the management 
of this disease in humans. So far the approach for antenatal modulation of the severity of 
pulmonary hypoplasia is through mechanical interference with pulmonary fluid drainage. 
To this effect antenatal tracheal plugging has been advocated 47, 48. An alternative approach 
can be the provision of antenatal sildenafil in selected high risk prenatally diagnosed CDH 
fetuses. However, even for postnatal sildenafil no solid safety data are available 49. Even 
more for antenatal sildenafil (STRIDER; NCT02277132 (clinicaltrials.gov)) questions remain 
on safety, dosage as well as repeated prescription and optimal timing of the drug. 
In conclusion, our study demonstrates that antenatal treatment with sildenafil started 
at a clinically relevant time point improves bodyweight, decreases lung hypoplasia and 
attenuates vascular remodeling in nitrofen-induced CDH in rats. Antenatal use of sildenafil 
might improve morbidity and mortality in CDH patients by improving lung structure. 
However, it is important to determine the optimum dosage for this therapy in a potential 
phase I trial.
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Abstract 
Patients with congenital diaphragmatic hernia (CDH) often suffer from severe pulmonary 
hypertension and the choice of current vasodilator therapy is mostly based on trial 
and error. Since pulmonary vascular abnormalities are already present early during 
development, we performed a study to modulate these pulmonary vascular changes 
at an early stage during gestation. Pregnant Sprague-Dawley rats were treated with 
nitrofen at day 9.5 of gestation (E9.5) to induce CDH in the offspring and subsequently the 
phosphodiesterase-5 inhibitor sildenafil and/or the novel prostaglandin-I receptor agonist 
selexipag (NS-304) were administered from E17.5 until E20.5. The clinically relevant start 
of the treatment corresponds to week 20 of gestation in human, when CDH is usually 
detected by ultrasound. CDH pups showed increased density of air saccules which was 
reverted after the use of only sildenafil. The pulmonary vascular wall was thickened and 
right ventricular hypertrophy was present in the CDH group and improved both after 
single treatment with sildenafil or selexipag, whereas the combination therapy with 
both compounds did not have additive value. In conclusion, antenatal treatment with 
sildenafil improved airway morphogenesis and pulmonary vascular development, while 
selexipag only acted positively on pulmonary vascular development. The combination of 
both compounds did not act synergistically, probably because of a decreased efficiency 
of both compounds caused by CYP interaction and induction. These new insights create 
important possibilities for future treatment of pulmonary vascular abnormalities in CDH 
patients already in the antenatal period of life.
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Introduction 
Congenital diaphragmatic hernia (CDH) is a rare developmental anomaly characterized 
by an incomplete diaphragm, lung hypoplasia and pulmonary hypertension (PH), which is 
often unresponsive to current vasodilator therapy 1. Although the postnatal therapeutic 
approach is highly protocolized 2 the pharmacotherapy of PH in CDH is mainly trial and error 
and is based on the modulation of three major vasoactive pathways: the nitric oxide (NO), 
endothelin (ET) and prostacyclin (PGI2) pathways. Inhaled NO (iNO) is the most frequently 
used drug followed by (i.v.) sildenafil, a phosphodiesterase-5 (PDE5) inhibitor acting on the 
same pathway by inhibiting the conversion of cyclic guanosine monophosphate (cGMP). 
Currently drugs acting on the PGI2 pathway are used only in a compassionate way, showing 
contradicting results 3-5. Although the ET pathway has shown to be affected in patients with 
CDH 6, 7, targeting this pathway is even more challenging because of the clinical availability 
of oral formulation only. A recent Cochrane review showed no improvement in patients with 
CDH after iNO treatment 8. However, properly designed trials are lacking while no systematic 
research has been performed into the different pathways involved. An overview of all studies 
performed in humans using postnatal vasodilator therapy in CDH is presented in Table 1
Table 1: Studies on vasodilatory drugs in CDH
Compound Pathway Patients Effect Reference
Inhaled NO Nitric Oxide 34 No effect Kinsella et al., 1997 35
53 No effect in mortality and ECMO NINOS, 1997 36
31 No effect in mortality and ECMO Clark et al., 2000 37
84 No effect in mortality and ECMO Finer et al., 2003 38
Sildenafil Nitric Oxide 9 Improved oxygenation index Bialkowski et al., 2013 39
7 Improved cardiac output
Reduced PVR
Noori et al., 2007 40
Milrinone Prostacyclin 6 Improved RV function
Improved oxygenation index
No effect on PVR
Patel et al., 2012 41
Prostacyclin Prostacyclin 9 Improved oxygenation index Bos et al., 1993 42
Bosentan Endothelin No studies performed
ECMO = extracorporeal membrane oxygenation, PVR = pulmonary vascular resistance, RV = right ventricle.
Furthermore, changes in the pulmonary vasculature, leading to PH, have previously been 
shown to be present already early during gestation 9, while treatment is only offered 
postnatally. Over the last years we and others showed improvement in lung development 
after antenatal treatment with sildenafil in different animal models of CDH 10-12. However, 
the pulmonary pathology in these animals was not totally reversed. Since CDH-associated 
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abnormalities may not be limited to only one pathway, antenatal targeting of more 
pathways could possibly provide new approaches for therapeutic strategies. Antenatal use 
of all endothelin receptor antagonists have shown to be teratogenic 13, 14. However, prenatal 
monotherapy with a slow-release synthetic prostacyclin agonist in a rat model of CDH 
showed improvement of the diminished development of alveolar and capillary networks 
15. Until recently most available prostacyclin analogues could only be administered by 
continuous intravenous infusion or inhalation, and had limited stability and a very short 
half-life 16 Selexipag is a novel highly selective long-acting oral PGI2 receptor agonist that 
has recently been approved for the treatment of PH in adults. The active compound of 
selexipag, NS-304, is hydrolyzed by the liver to its active metabolite ACT-333679, which has 
an even higher affinity for the PGI2 receptor 
17, 18.
Here, we analyzed for the first time the effects of antenatal treatment targeting both the NO 
pathway and the PGI2 pathway in the nitrofen-CDH rat model, starting at a clinically relevant 
time point. 
Methods 
Animal Model
Pregnant Sprague-Dawley rats received either 100 mg nitrofen dissolved in 1 ml olive oil or 
just olive oil by gavage on gestational age day E9.5. Administration of nitrofen at exactly this 
time point induces mainly left sided CDH in approximately 70% of the offspring, while all pups 
have PH 19. This study included only pups with an observable diaphragmatic defect. Pregnant 
rats were divided into 8 groups: control, nitrofen (CDH), control+sildenafil, nitrofen+sildenafil 
(CDH+sildenafil), control+NS-304, nitrofen+NS-304 (CDH+NS-304), control+sildenafil/
NS-304 and nitrofen+sildenafil/NS-304 (CDH+sildenafil/NS-304). Sildenafil (100 mg/kg/
day, Pfizer, New York, NY, USA) and NS-304 (1 mg/kg/day, MedChem Express, Monmouth 
Junction, NJ, USA) were dissolved in 0.8% ethanol in water and administered via oral gavage 
for 4 consecutive days from E17.5 to E20.5. At E21 pups were delivered by caesarean section 
and euthanized by lethal injection of pentobarbital (Figure 1). The dosage of sildenafil was 
based on our previous study 10, whereas for NS-304 a dose study was performed.
All animal experiments were approved by an independent animal ethical committee and 
according to national guidelines.
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Figure 1 Schematic overview of the study design
Overview of study design showing interventions at different time points. X-axis shows days during gestation. 
Flashes indicate time point of intervention, cross indicates time point of termination. The different treatments are 
placebo, sildenafil, NS-304 and sildenafil + NS-304. n= 2 litters for control and nitrofen with placebo (n= 26 and 24 
pups, respectively) or sildenafil (n= 15 and 24 pups, respectively), n= 3 litters for control and nitrofen with NS-304 
(n= 35 and 37 pups, respectively) or sildenafil+NS-304 (n= 36 and 37 pups, respectively).
Lung Morphology
Fetal rat lungs were isolated, fixed overnight in 4% PFA and embedded in paraffin. Serial 
5 µm thick sections were made through the middle of the left lobe and stained with 
haematoxylin and eosin (HE). Sections were imaged at 40x magnification using a BX41 
research stereomicroscope system (Olympus; Tokyo, Japan). Four non-overlapping images 
in three different sections of each lung were acquired. Major airways and vessels were 
excluded from analysis. The airspace size was automatically quantified using the two 
following measures: the D2-score, as previously described 
10, and the mean linear intercept 
L
m
. Approximate value of the latter was calculated as proposed by Muñoz-Barrutia et al 20, 
using both horizontal and vertical test lines. However, previous comparisons between both 
methods have shown a higher accuracy of the D2-score 
21.
Immunohistochemistry and Immunofluorescence Staining
Immunohistochemistry (IHC) was performed on 5 µm paraffin sections of lungs according 
to standard protocols, using the Envision™ detection system (Dako Cytomatic, Glostrup, 
Denmark) 22. Primary antibody used for IHC was smooth muscle actin (α-SMA; MS-113-P1; 
1:1200, Thermo Scientific, Fremont, CA, USA). Antigen retrieval with Tris-EDTA buffer (10 
mmol Tris, 1 mmol EDTA; pH 9.0) was used.
Primary antibodies used for immunofluorescence staining were smooth muscle actin 
(α-SMA; MS-113-P1; 1:500, Thermo Scientific) and Ki-67 (1:100, Abcam, Cambridge, UK). 
Secondary antibodies against mouse (α-SMA) and rabbit (Ki-67) were used. Negative 
controls were performed by omitting the primary antibody. Antigen retrieval with Citric Acid 
buffer (11.2 mmol; pH 6.0) was used.
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA isolation of whole lungs, cDNA synthesis and subsequent qPCR analysis were performed 
as previously described 22. Primer combinations for the qPCR reactions are listed in Table 2. 
Actb was used as housekeeping gene.
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Table 2: Primer sequences
Gene Sequence (forward 5’- 3’) Sequence (reverse 5’- 3’)
Ptgir CACGAGAGGATGAAGTTTACCA AATCCTCTGATCGTGAGAGGC
Ptgis CATCAAACAGTTTGTGGTCCT CAAAGCCATATCTGCTAAGGT
eNos CATACTTGAGGATGTGGCTG CCACGTTAATTTCCACTGCT
Pde3 CCAGCAACCGAATATTGACCA AATCTGAAAGTTCCAGTTGCTC
Pde5 TCAACAACGGATAGCAGAACTC CCCTGTTCATTAGATCAGCGG
Prkg2 ACTAGGCATTATCTACAGAGACC TCCAAAGTCAACCAACTTAAGG
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Pdgfr-β AACGACCAGTTCTACAATGCC CATGATCTCATAGATCTCGTCGG
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
Cardiovascular measurements
Lungs and heart of pups were perfused through the right ventricle with Microfil contrast 
agent (Microfil, Flow Tech; Carver, MA, USA) and imaged with a micro Computed Tomography 
(micro-CT) scanner (Quantum FX, PerkinElmer; Waltham, MA, USA; pixel size 10–295 µm). 
Subsequently, images of the hearts were analyzed with Dataviewer (Skyscan, Bruker, 
BioSpin, Ettlingen, Germany).
Statistical analysis
Data are presented as means (SD). For the results of the dose study, one-way analysis of 
variance (ANOVA) was applied to compare bodyweight and lung-to-kidney weight ratio 
(LW/KW) between dose levels (placebo, 0.1, 1 and 10 mg/kg), followed by Tukey’s method 
for post-hoc multiple comparisons. For the data of the intervention study, two-way ANOVA 
with factors disease (control versus CDH) and treatment (placebo, sildenafil, NS-304 and 
combination of sildenafil and NS-304) was used to compare the results of the experiments 
between groups. The interaction effect of disease and treatment was included in the model 
in case this effect was statistically significant. The normality assumption of the ANOVA 
models was assessed by creating histograms of the model residuals. The analyses were 
performed using SPSS 21.0 for Windows (Armonk, NY, USA: IBM Corp.). All statistical tests 
were two-sided and used a significance level of 0.05.
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Results 
Dose study
We first established an effective antenatal dose of NS-304 by analyzing the effects on the pups 
and monitoring possible side-effects of this compound. Therefore we started a dose study in 
control rat pups using 3 different dosages based on previous studies in adult rats 23, 24. 
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Figure 2 Dose study of NS-304
A: Bodyweight is significantly increased after treatment with NS-304 at 1 mg/kg (p=0.036) and 10 mg/kg (p=0.009) 
(n= 12, 13, 10 and 14, respectively). Lung-to-kidney weight ratio is significantly increased in all treated groups 
(p=0.001, p=0.005 and p<0.001, respectively) (N = 13, 14, 11 and 15, respectively). B: Representative images of H&E 
staining on lung and kidney show no abnormalities in all groups. Representative images of the liver show vacuoles 
in all samples. Scale bars represent 200 µm (lung), 500 µm (kidney) and 50 µm (liver). C: Representative images of 
Oil-Red-O (ORO)-staining showing steatosis of the liver after use of 8% EtOH, but not after use of 0.8% EtOH. Scale 
bars represent 20 µm. * p<0.05, ** p<0.01, *** p<0.001. Bars represent means (SD).
124 TREATMENT WITH SILDENAFIL AND SELEXIPAG IMPROVES VASCULARITY IN CDH
0.02
0.04
0.06
0.00Lu
ng
/b
od
y 
w
ei
gh
t (
ra
tio
)
2
4
6
0
Lu
ng
/k
id
ne
y 
w
ei
gh
t (
ra
tio
)
***
**
***
**
A B
C D
B
od
yw
ei
gh
t (
gr
am
s)
******
***
***
***
Pla
ceb
o Sil NS
Sil+
NS
0
1
2
3
4
5
0.10
Lu
ng
 w
ei
gh
t (
gr
am
s)
0.15
0.20
0.25
0.05
0.00
***
***
Pla
ceb
o Sil NS
Sil+
NS
Pla
ceb
o Sil NS
Sil+
NS
***
***
**
Pla
ceb
o Sil NS
Sil+
NS
***
Figure 3 Body and lung weight
A: Bodyweight is decreased in pups with CDH (p<0.001). Sildenafil increases bodyweight significantly in both control 
and CDH pups (both p<0.001), where NS-304 and the combination of both compounds only increases bodyweight 
in control pups (both p<0.001). N= 39, 37, 35 and 36 in the control groups and 19, 31, 14 and 21 in the nitrofen 
groups, respectively. B: Lung weight is significantly decreased in CDH pups (p<0.001) with no difference after 
treatment. N= 53, 50, 26 and 27 in the control groups and 24, 32, 10 and 16 in the nitrofen groups, respectively. 
C: The lung-to-body weight ratio is significantly decreased in CDH (p<0.001) with improvement only after NS-304 
(p=0.003). N= 33, 35, 26 and 27 in the control groups and 17, 28, 10 and 16 in the nitrofen groups, respectively. 
D: Lung-to-kidney weight ratio is significantly decreased in CDH (p<0.001) and improved in all treatment groups 
(p=0.002, p<0.001 and p=0.004, respectively). N= 44, 50, 24 and 27 in the control groups and 23, 32, 10 and 15 in 
the nitrofen groups, respectively. Weights of pups from our previous experiment 10 were included to enlarge the 
data. * p<0.05, ** p<0.01, *** p<0.001. Bars represent means (SD). White bars represent control pups, grey bars 
represent CDH pups. Sil means sildenafil, NS means NS-304.
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Pups of mothers treated with NS-304 did not show any malformations of face, palate, limbs or 
other organs. Bodyweight was increased in pups treated with 1 and 10 mg/kg/day and LW/KW 
was increased in all treated pups (Figure 2A). No differences in histology were observed in both 
lungs and kidneys between all dose levels (Figure 2B). The livers of all pups showed steatosis, 
which was resolved after adjusting the percentage of ethanol in which the compound was 
dissolved from 8% to 0.8% (Figure 2C). Based on this dose study the optimal dosage of NS-304 
was found to be 1 mg/kg/day. The dosage of sildenafil was based on our previous study 10.
Lung morphology
In accordance with our previous study 10, CDH pups had a decreased bodyweight, which 
increased after treatment with sildenafil. Lung weight was also reduced in CDH pups, but 
this did not improve after treatment of sildenafil, NS-304 or the combination of sildenafil 
and NS-304 (Figure 3A, B). Both lung-to-bodyweight ratio (LW/BW) and LW/KW were 
significantly reduced in CDH pups. LW/BW increased only after treatment with NS-304, 
where LW/KW increased in all three groups receiving treatment (Figure 3C, D).
In correspondence with our previous results 10, the density of the air saccules was 
increased in lungs of CDH pups (Figure 4A). Statistical analyses showed a significant positive 
correlation between disease and treatment for the D2-score, the Lm and the number of air 
saccules (p=0.005, p=0.024 and p<0.001, respectively). The lower D2-score and Lm in CDH 
were significantly higher in the pups treated with sildenafil, while NS-304 alone or the 
combination of sildenafil and NS-304 were not significantly different (Figure 4B, C). The 
number of air saccules was increased in CDH and diminished after treatment with sildenafil 
or the combination of sildenafil and NS-304 (Figure 4D). Combined, these results show 
a therapeutic effect on the formation of air saccules after antenatal targeting mainly by 
sildenafil.
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Figure 4 Disrupted lung morphogenesis is partly resolved after sildenafil treatment
A: Representative images of H&E stained lungs. Scale bars represent 50 µm. B: Mean saccular airspace diameter 
(D2-score) is significantly decreased in CDH (p<0.001), with a significant increase after treatment with sildenafil only 
(p=0.001). C: The mean linear intercept (L
m
) is significantly decreased in CDH (p<0.001), with a significant increase 
after treatment with sildenafil only (p=0.048). D: The average number of air saccules in 1 image per lung was 
increased in CDH (p<0.001) and decreased after sildenafil (p=0.036) and combination therapy (p=0.017). For each 
group, 4 non-overlapping images on 3 different sections for 5 different animals were used. * p<0.05, ** p<0.01, *** 
p<0.001. Bars represent means (SD). White bars represent control pups, grey bars represent CDH pups. Sil means 
sildenafil, NS means NS-304.
Since NS-304 acts on the IP-receptor (Ptgir), we checked the expression of this receptor 
and its synthase at mRNA level. We found an increase in Ptgir and a decrease in Ptgis in 
CDH with only a trend to improvement after treatment in case of Ptgir (Figure 5A, B). The 
expression of endothelial NO synthase (eNos), an important enzyme in the production 
of vasoactive NO, was increased in CDH and did not change after treatment (Figure 5C). 
Phosphodiesterase-3 (Pde3), which hydrolyses and thus inactivates the secondary messengers 
cyclic adenosine monophosphate (cAMP) and cGMP, was not expressed differently in control 
and CDH, but was decreased after treatment with NS-304 in both control and CDH (Figure 5D). 
Phosphodiesterase-5 (Pde5), the enzyme which hydrolyses cGMP is inhibited by sildenafil, 
and its downstream target protein kinase G2 (Prkg2) were both increased in CDH. Prkg2 was 
decreased in CDH in all treatment groups (Figure 5E, F). All these changes in the expression of 
these factors in both therapeutic pathways confirm the importance of these pathways in CDH. 
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Figure 5 RNA expression levels of rate-limiting factors in the NO and PGI2 pathways 
A: Quantitative PCR shows a significant increase in Ptgir in CDH (p<0.001) with no differences after treatment. 
B: Ptgis is decreased in CDH (p<0.001) with no improvement after treatment. C: eNos expression is increased 
in CDH (p=0.041) and shows no improvement after treatment. D: No differences were found in Pde3 between 
control and CDH pups, but treatment with NS-304 decreased Pde3 expression in both control and CDH (both 
p=0.030). E: Pde5 is increased in CDH (p=0.007) with no improvement after treatment. F: Prkg2 is increased in CDH 
(p=0.013) and decreased after treatment with sildenafil, NS-304 and the combination of both (p=0.045, p=0.002 
and p<0.001, respectively). N= 6 for all groups. * p<0.05, ** p<0.01, *** p<0.001. Bars represent means (SD). White 
bars represent control pups, grey bars represent CDH pups. Sil means sildenafil, NS means NS-304. No interaction 
model was used for Ptgir, Ptgis, eNos, Pde3 and Pde5.
Pulmonary vasculature
Next, we analyzed the pulmonary vascular development by whole mount imaging 
after infusion of a contrast agent (Figure 6A). This revealed a decrease in the 
vascular branching and total vasculature volume in CDH. None of the applied 
treatment modalities showed significant improvement (Figure 6B), as we previously 
reported after prenatal sildenafil monotherapy 10. However, histological analysis of 
the lungs revealed an increased thickening of the smooth muscle layer of the small 
pulmonary vessels (25-50 µm) in CDH pups, comparable to our previous results 
10. This augmented thickness of the vascular wall was significantly reduced after 
treatment with sildenafil as well as with NS-304 alone or the combination of both. 
Remarkably, all treated control groups showed an increase in thickness of the 
medial smooth muscle layer (Figure 6C,D). Immunofluorescence staining showed 
an increase in Ki67/Sma double-positive cells in the small pulmonary vessels in 
CDH pups, which was reversed to normal in all three treatment groups, indicating 
reduced proliferation of these cells after treatment (Figure 6E, F). 
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Figure 6 Both sildenafil and NS-304 reduce muscularization defects in CDH
A: Schematic image of injection through the right ventricle. B: Representative images of Microfil-injected 
pulmonary vessels show decreased branching and volume in CDH with no improvement after treatment with NS-
304 or the combination of sildenafil and NS-304. C+D: Representative images of immunohistochemistry staining 
show increased expression of Sma and an increased thickening of the vascular wall of small pulmonary vessels 
(25-50 µm) in CDH (p<0.001) and control lungs treated with all compounds (all p<0.001). In CDH this thickening 
is decreased after all treatments (all p<0.001). n= 34, 30, 33 and 34 in the control groups and 32, 33, 38 and 33 in 
the nitrofen groups, respectively. E+F: Representative images of immunofluorescence staining show an increase in 
Ki-67/Sma double-positive cells in small pulmonary vessels in CDH (p<0.001) with improvement to normal in all 
treated groups (p<0.001, p<0.001 and p=0.001, respectively). n=12 for all groups. Scale bars represent 10 µm. ** 
p<0.01, *** p<0.001. Bars represent means (SD). White bars represent control pups, grey bars represent CDH pups. 
Sil means sildenafil, NS means NS-304.
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Since we found reduced muscularization of the pulmonary vasculature in CDH lungs after 
antenatal vasodilator therapy, we checked the effect of the treatment on the heart. Since 
right ventricular hypertrophy is an indication for pulmonary hypertension postnatally 25, we 
measured the myocardium of the right ventricle in relation to the total diameter of the 
heart. This showed a significant increase in CDH with reversion to normal after treatment 
in all 3 groups (Figure 7A, B) showing a potential effect of treatment on the already higher 
pulmonary vascular resistance before birth. 
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Figure 7 Prenatal treatment improves cardiovascular defects 
A + B: Representative images of with Microfil filled hearts show increased thickness of the right ventricle wall in 
relation to the total diameter of the heart (p<0.001). This thickening improved after treatment with sildenafil, NS-
304 and the combination of both (p=0.001, p=0.023, p<0.001, respectively). Scale bars represent 2mm. n= 5, 3, 5 
and 4 in the control groups and 2, 3, 2 and 4 in the nitrofen groups, respectively. * p<0.05, ** p<0.01, *** p<0.001. 
Bars represent means (SD). White bars represent control pups, grey bars represent CDH pups. Sil means sildenafil, 
NS means NS-304.
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Discussion
In this paper we confirm that antenatal treatment with sildenafil, starting at a clinically 
relevant time point, results in a partial reversal of the abnormal development of the lung 
morphology and pulmonary vasculature in the nitrofen-induced CDH rat model. However, 
we show for the first time that the novel PGI2 receptor agonist selexipag improves the 
pulmonary vasculature. Combination therapy with both compounds did not have a 
synergistic effect. This is the first study combining therapies targeting both the NO and PGI2 
pathway for antenatal use in CDH.
In accordance with our previous work 10, sildenafil increased bodyweight and LW/KW ratio 
and improved the lung morphogenesis in CDH pups. LW/KW ratio was even reversed to 
normal after treatment with selexipag, but sildenafil did not have a synergistic effect when 
combined with selexipag. This may be explained by a combined inducing effect of sildenafil 
and selexipag on the activation of CYP3A4. of activity. This is supported by a phase 3 study 
on selexipag, which predicted a 30% lower exposure to the active metabolite ACT-333679 
when used in combination with a PDE-5 inhibitor 26. Furthermore, it is known that the 
clearance of drugs by CYP3A4 is increased during pregnancy 27. A recent study showed no 
measurable levels of radioactivity in fetal tissues after the use of selexipag in a pregnant rat 28. 
However, they only measured radioactivity after just one single dose. The saccular airspaces 
did not increase after the use of selexipag and, when added together with sildenafil, it only 
seemed to reverse the positive effects of sildenafil, suggesting the enhanced clearance 
of both compounds. In contrast to the lung morphology, selexipag caused a decrease in 
muscularization and proliferation of the smooth muscle layer and a reduced myocardial 
thickness of the right ventricular wall. These effects were also observed after the use of 
sildenafil as well as the combined sildenafil/selexipag therapy. The increased proliferation 
of Sma positive cells in CDH might relate to the pulmonary hypertension in these pups and 
was previously shown by others as well 15. Hypertrophy of the right ventricular wall has 
been known to be an early sign of PH postnatally followed by right ventricular dilatation 
and eventually heart failure 25. Normally, early during gestation the right and left cardiac 
ventricles are approximately identical in size, whereas later in pregnancy the right ventricle 
becomes slightly more dilated 29. However, in case of right ventricular outlet obstruction 
the myocardial mass can already increase antenatally 30. A previous study in adult rats 
with monocrotaline-induced PH showed reduced hypertrophy of the pulmonary arterial 
wall and less thickening of the right ventricle after the use of selexipag 23. These combined 
results indicate a potential effect of this drug on the severity of the PH. Reduced pulmonary 
vascular pathology was also observed in a prophylactic study by Umeda et al, who applied 
a prostacyclin agonist antenatally in CDH 15. They showed an increased LW/BW ratio and 
reduced thickening of the medial wall of pulmonary arteries, as we show as well. In contrast 
to our results, they found an improvement of the alveolar and capillary networks with an 
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increased mean linear intercept at E21. These differences can possibly be explained by the 
thromboxane inhibitory activity of their compound or the early start of treatment at day 
E9.5, when development is still at an earlier stage and deviations in lung development have 
not yet started. The major advantage of our approach is the start of our treatment at E17.5, 
a phase of lung development comparable to 20 weeks of gestation in human when CDH can 
be detected, which makes it potentially more clinically relevant. Furthermore, we used an 
orally available approved medicine for our treatment, which could be extrapolated easier to 
clinical use. As previously described by our group 10, pulmonary vascular volume is decreased 
in CDH. Apart from sildenafil, selexipag and combination therapy with both compounds did 
not increase vascular volume and branching. This may well be expected since the majority 
of the pulmonary vessels is already developed at the start of treatment and treatment will 
therefore mostly affect the vascular remodeling. 
Confirming the results previously shown by us and others 10-12, sildenafil caused unanticipated 
differences in lung structure in healthy controls, with a thickening of the smooth muscle layer 
in the pulmonary vessels. However, selexipag induced similar effects in healthy subjects, 
which strengthens the idea that inducing vasodilation in already healthy vessels might be 
deleterious for the development of the pulmonary vasculature 10.
The possibility of early detection of CDH by ultrasound makes this disease suitable for 
antenatal therapies. Some studies have already been performed in the nitrofen rat model 
on the antenatal use of sildenafil alone 10, 11 or in combination with steroids 31, 32 or the 
endothelin antagonist bosentan 33. However, the combination with a prostacyclin agonist, 
which can safely be used antenatally, has never been studied in this disease. Although 
antenatal treatment with selexipag or the combination of selexipag and sildenafil did not 
seem advantageous over monotherapy, at least in the nitrofen rat model, the addition of a 
second drug might still be of interest because of the variable response to vasodilator therapy 
of CDH patients in the clinical setting 1 (Table 1). The variability between patients and the 
altered expression of different vasoactive factors in CDH strengthens the need for ongoing 
evaluation of the developmental sequences of the pathways involved and subsequent, a 
more precision medicine approach.
We analyzed for the first time the feasibility and effects of antenatal use of the novel PGI2-
receptor agonist selexipag in the nitrofen-induced CDH rat model. The positive effects on the 
pulmonary vasculature show that the compound successfully entered the fetal circulation. 
Embryotoxicity studies in rats and rabbits have shown no malformations, irregularities 
or neurological differences after the use of selexipag during pregnancy 26, 34. Indeed, no 
malformations or abnormalities in histology were seen in different organs in our study. 
In conclusion, this study demonstrates improvement of lung morphogenesis after antenatal 
treatment with sildenafil monotherapy and a reduction in vascular remodeling after 
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antenatal treatment with both sildenafil and selexipag monotherapy, where no synergistic 
effect was present after combination of both compounds. This knowledge creates important 
possibilities in the therapy of pulmonary hypertension in CDH patients. Ideally future 
research has to reveal antenatal differences in expression of vasoactive factors in specific 
individual CDH patients before clinical trials on precision medicine with these compounds 
can be performed.
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Congenital diaphragmatic hernia a vascular disease of the newborn
Congenital diaphragmatic hernia is a congenital abnormality, which occurs approximately 
in 1:2500 live births. CDH is associated with a defect in the diaphragm, a variable bilateral 
pulmonary hypoplasia and pulmonary hypertension (PH), which still leads to mortality 
and potential life-long morbidity 1. The severity of the defect in the diaphragm and the PH 
fluctuates per patient and the response of the patient to the treatment modalities also differs 
from patient to patient. This leads to difficulties in the choice of the optimal treatment of 
these critically ill newborns. Development of a standardized treatment protocol in the past 
decade has increased the survival chances of CDH patients significantly2 +referentie? The 
development of new treatment modalities awaits a better understanding of the disease, 
which requires new insights in how and when during development the structural changes 
associated with PH arise and which molecular mechanisms are involved in these changes. 
In order to reveal the molecular pathways involved in the development of the structural 
changes in PH it is important to first understand how the pulmonary vasculature normally 
develops. Although many studies have been performed both clinical and experimental using 
a variety of animal models such as sheep, rabbits and rodents 3-5 very few have focused on 
early pulmonary vascular development
Development of the pulmonary vasculature in CDH
The pathological changes in the pulmonary vasculature of PH associated with CDH are 
characterized by thickening of the smooth muscle cell layer in the tunica media and 
muscularization of the small capillaries, a process called neo-muscularization 6. Moreover, 
these structural vascular changes as well as the expression of markers associated with more 
contractile smooth muscle cells are already present early in lung development 7. Indicating 
that these pathological changes in CDH are caused by aberrant developmental processes, 
making the PH associated with CDH an early developmental anomaly.
Description and function of pericytes
Pericytes are prime candidates to underlie the structural changes in PH. Pericytes are 
located around the vessels and are in direct contact with the endothelial cells located in 
the capillaries 8. During angiogenesis, the process where the vasculature expands through 
sprouting of endothelial cells to form new tubules, pericytes are recruited in a PDGF-
depended manner 9-11.
Fluctuations and alterations in the number of pericytes that surround the vasculature 
(pericyte coverage) have been linked to multiple pathological conditions such as diabetic 
renopathy, cancer biology, pulmonary fibrosis and pulmonary hypertension in the adult 8, 
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12-14. To study the potential role of pericytes in the vascular pathological conditions, it is 
necessary to understand the biology of these cells. We used a cell based approach and 
in Chapter 2 we first characterized the pericyte population during lung development in 
CDH and age matched controls. Analysis of multiple markers at different gestational ages 
revealed that NG2 and PDGFRβ were the most specific in identifying pericytes in the lung 
in mice and human respectively. The diversity in the specificity of the pericyte markers 
indicates the variance in the nature of these cells. In the developing lung pericytes most 
likely differentiate from a mesenchymal pool of cells. Suitable markers to identify this 
progenitor pool are not yet revealed. Next steps will be to characterize the mesenchymal 
pool and identify the signaling pathways involved in the differentiation of the mesenchymal 
cell pool into pericytes during lung development. Characterization of the progenitor pool 
will give an even earlier target to influence the vascular growth and may also be helpful in 
early diagnosis of CDH, assuming that this pool is also affected in CDH. 
The role of pericytes in PH associated with CDH
In chapter 2, we hypothesized that pericytes are potential candidates to be the precursor 
cells for the smooth muscle cells due to their location and function. Confocal microscopic 
analysis in combination with Fluorescence-activated cell sorting (FACS) analysis showed an 
increase in pericyte coverage from E15 onwards in CDH. Firstly, this confirms the hypothesis 
that pericytes are the source of the hypermuscularization and neomuscularization in PH. 
Secondly, it shows for the first time that not only the number of smooth muscle cells is 
higher in CDH, but also the number of the possible precursor cell, the pericyte, is higher 
(Chapter 2). Increased pericyte coverage is shown to be a consequence of downregulation 
of BMPR2 and an upregulation of WNT/ β-Catenin signaling 15. An increased number of 
pericytes is associated with a decrease in functional pericytes. This leads during the active 
growth of the pulmonary vasculature to improper stabilization of newly formed tubes and 
an incomplete capillary bed
The differentiation of pericytes into multiple cell types such as chondrocytes, adipocytes 
and smooth muscle cells has been shown in vitro 16-18, indicating the multipotent nature of 
pericytes. However, it has been shown recently that pericytes do not differentiate into other 
cell types in vivo 19. The observation in chapter 2 that pericytes express more Smooth muscle 
actin (ACTA2) in CDH at E18 indicates that they start to differentiate into smooth muscle 
cells in a malignant manner, leading to the excessive muscularization of the pulmonary 
vessels. The increase of pericyte coverage and their aberrant differentiation is also observed 
in the mouse model for arterial pulmonary hypertension in the adult 12, however the role 
of perciytes in the developmental disease CDH and its associated PH has not been studies 
before.
Unraveling the cellular changes that lead to the underdeveloped capillary bed in CDH 
could help to develop new treatments. Previous studies and therapies have focused on the 
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postnatal treatment of the hypertension associated with CDH. Given our data that clearly 
show an early developmental process, a new approach could be to interfere with the 
altered behavior and maturation of pericytes in the early onset of lung development. The 
observation of increased pericyte coverage and disturbed angiogenesis could potentially be 
translated to other diseases.
For instance, alterations in pericyte coverage also plays a distinctive role during vascular 
growth and thereby angiogenesis in tumors 20, 21. Both an increase as well as a decrease 
in pericyte coverage in tumor vasculature is observed22, 23. Moreover, an increase, but 
not a decrease, in pericyte coverage has been linked to resistance to therapy and poor 
clinical outcome for patients (reviewed in Ribeiro et al 24). However, a decreased number 
of pericytes have been linked to increased vessel permeability and thereby favors tumor 
cells to metastasize. The, observed increased pericyte coverage in CDH may increase the 
resistance to PH therapy and thereby be comparable to the effect in tumor biology. Indeed 
there is one case report in the literature on the positive effect of Glivec 25 a well-known 
anticancer drug that rescued a patient with CDH 26.
Further support of disturbed angiogenesis in CDH as described in chapter 2, came from the 
observation of decreased Collagen IV (COLIV) expression at E15 and E18. COLIV is a major 
component of the basal membrane between endothelial cells and pericytes. The expression 
of COLIV indicates integrity of the basal membrane 27 28.
The diaphragmatic hernia in CDH is the result of an underdeveloped diaphragm 29. Reduced 
COLIV expression could also lead to a higher vulnerability of the tissue. The severity 
and thereby the size of the diaphragmatic defect could be a result of the reduced COLIV 
expression.
Thus, the observed increased number of pericytes early during lung development in CDH 
gives a new insight into the development of the pathological changes in the vasculature in 
CDH.
Molecular analysis of the structural changes in the pulmonary vasculature in 
CDH
To further investigate which genes are involved in the disturbed development of the 
pulmonary vasculature in CDH, the transcriptome of the endothelial cells and pericytes was 
analyzed as described in Chapter 3. Besides the endothelial and pericyte population, the 
epithelial cells and mesecnhymal cells were also used for RNA sequence analysis. Analysis of 
the four different populations at E13 revealed that there was high similarity in the GO terms 
between the endothelial and pericyte population. Moreover, detailed analysis of the ROBO/
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SLIT pathway and the angiopoietin pathway revealed differentially expression of some 
members of these pathways by endothelial cells, of other members by the pericytes, and of 
a number of members in both populations This indicates that signaling between endothelial 
cells and pericytes early in lung development is affected in CDH, and that multiple pathways 
are involved which could explain the heterogeneity of the clinical presentation and the 
degree of the pulmonary hypoplasia of CDH.
The role of KLF4 in the development of the pulmonary vasculature in CDH 
Since the development of the pulmonary vasculature is mostly based on two cell types, 
the endothelial cells and pericytes, we further focused on genes of the endothelial cell 
population. A novel gene, which has not been linked to CDH before is Kruppel like factor 4 
(Klf4) which we identified by RNA sequence analysis.
KLF4 is shown to be an upstream regulator of NOTCH signaling 30, which is active during 
angiogenesis, regulating the competition between the tip and the stalk cell to be the 
guidance cell to form new tubes 31. Decreased KLF4 expression in CDH could thus lead to 
disturbed NOTCH signaling and thereby causing reduced sprouting of endothelial cells. A 
lower number of sprouting endothelial cells lead to an arrest in growth of the capillary 
network of the pulmonary vasculature, which we describe in Chapter 2.
Thus, decreased KLF4 expression may be a key in the mechanism that underlies the 
underdevelopment of the pulmonary vasculature in CDH. Revealing these mechanisms could 
help to intervene early with pulmonary vascular growth in CDH patients, thereby preventing 
the development of severe pulmonary hypertension. KLF4 has been described as a regulator 
of dedifferentiation of perivascular cells in pulmonary arterial hypertension in adults 32. 
However, we did not find differences in expression of KLF4 in the pericyte population or in 
the mesenchymal population. The pathology of pulmonary arterial hypertension in adults 
is different from the pathology of PH in the newborn. Moreover, in adult pulmonary arterial 
hypertension an increase in proliferating endothelial cells is observed while no signs of 
increased apoptosis were observed. Endothelial cells in pulmonary arterial hypertension 
are indeed hyperproliferating and in that manner similar to cancer cells. Moreover, 
proliferating endothelial cells associated with pulmonary arterial hypertension have been 
used as a histological hallmark for pathology 33. Although we did not observe differences in 
proliferating endothelial cells in PH associated with CDH, alterations in specific endothelial 
gene expression were observed. This indicates that endothelial cells in CDH are intrinsically 
different, similar to endothelial cells in pulmonary arterial hypertension.
Furthermore, pulmonary hypertension associated with CDH is caused by a developmental 
defect and pulmonary hypertension in adults is due to other causes34 35. An alternative 
explanation may be that the aberrant pulmonary vasculature in CDH is primarily caused 
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by ‘malignant’ differentiation of multipotent cells and less by dedifferentiation of smooth 
muscle cells. 
Targeted therapy influencing the behavior of endothelial cells during angiogenesis could 
lead to more appropriate vascular growth. Therapy of CDH patients will have to go through 
the mother. Finding cell surface markers that are specific for the endothelial cells in the 
lung of the CDH patient will help to develop targeted therapy. Moreover, drugs developed 
for specific cell surface markers only expressed on ‘pathological’ endothelial cells could be 
downstream or upstream of KLF4 and thereby influence the KLF4 activity.
Retinoic acid and pulmonary vascular development
Retinoic acid signaling is of high importance during embryogenesis. It has been shown to 
be essential for limb development, neuronal differentiation and organogenesis 36. Likewise, 
the importance of proper retinoic acid signaling is shown for normal lung development. 
The inhibition of retinoic acid signaling by the chemical compound BMS493 resulted 
in reduced budding and branching of the early lung buds 37. The role of the retinoic acid 
pathway in the development of CDH has been shown in multiple studies in mice, rat and 
human 38, 39. Furthermore the expression of retinoic acid receptors has been thoroughly 
studied during the development of the diaphragm, in the pleuroperitoneal folds and the 
primordial diaphragm 5. Indeed, retinoic acid signaling is active in the structures from which 
the diaphragm develops and inhibition of the retinoic acid signaling results in diaphragmatic 
defects. The timing of the administration of the chemical compounds is crucial. Moreover, 
the timing determines the sidedness of defect in the diaphragm 5. The chemical compounds 
that are used to induce CDH interfere with the retinoic acid pathway. When CDH inducing 
compounds are administered, the activity of Aldehyde dehydrogenase 1 family, member A2 
(RALDH2) is inhibited. The RALDH2 enzyme is required for the conversion of retinaldehyde 
into retinoic acid. Thus, retinol is present in the serum and is transported by the Retinol 
binding protein 4 (RBP4), it then binds the extracellular receptor Stimulated by retinoic acid 
gene 6 (STRA6). Then retinol gets internalized and through enzymatic conversion steps is 
converted into retinoic acid. Retinoic acid is secreted and taken up by retinoic acid responsive 
cells where it is transported to the nucleus and binds to the retinoic acid receptors thereby 
activating retinoic acid responsive genes 40.The inhibition of the enzyme results in less 
retinoic acid and reduced activation of the retinoic acid receptors 40.
Studies related to retinoic acid signaling and CDH have been performed both in rodent 
models and with patient material. Moreover, newborns with CDH show significant lower 
levels of the retinol binding protein compared to controls 39. Further evidence of the 
involvement of retinoic acid signaling in CDH comes from retinoic acid receptor knockout 
studies41. Retinoic acid receptor knockout mice show only 25% of CDH in their offspring. The 
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low numbers of CDH in the retinoic acid receptor knockouts supports the idea that reduced 
activity of the retinoic acid pathway is not the only molecular mechanism, which is causing 
CDH. The effect of retinoic acid inhibition on the growth of the pulmonary vasculature has 
not been studied before. In Chapter 2 we found for the first time the effect of the inhibition 
of retinoic acid on the development of the pulmonary vasculature in the mouse CDH model. 
The cellular effects were determined which included an increase in pericyte coverage in 
the pulmonary vasculature in early lung development. However this observation,  did not 
link any molecular mechanisms to the effect of retinoic acid pathway inhibition. Studying 
the transcriptome of different cell population revealed which cells express retinoic acid 
receptors and new candidates that are important for the development of the pulmonary 
vasculature, but it could not directly be linked to the retinoic acid pathway. This may 
be because the whole transcriptome analysis was performed 4 days after the nitrofen 
administration. Nonetheless, this not only shows the difficulty of understanding the retinoic 
acid pathway, but also indicates the complexity of the natural history and variability of CDH. 
Genes whose expression is regulated by retinoic acid receptors may have other activators 
and are therefore called retinoic acid responsive genes. Thus, their expression is related to 
retinoic acid activity, but not exclusively.
Previously, it has been shown that a decreased active retinoic acid led to an increase in active 
Transforming Growth Factor β (TGFβ)37. The idea that TGFβ signaling becomes more active 
in our studies is an interesting finding in relation to our finding that pericyte differentiation 
is accelerated in CDH. Moreover, in our model the inhibition of retinoic acid could lead to an 
increase in TGFβ signaling. TGFβ signaling is a major regulator of a wide range of signaling 
pathways 42. The finding of reduced COLIV expression in chapter 2 could be an effect of 
disturbed TGFβ signaling. Furthermore, increased activity of the TGFβ signaling pathway 
could be the molecular pathway which leads to disturbed differentiation of pericytes into 
smooth muscle cells and the hyper –and neomuscularization. However, the decrease in 
retinoic acid signaling and thereby the increase in TGFβ signaling is probably a direct effect, 
creating a signaling cascade from which the effects are observed later in development. It is 
likely that this imbalance in signaling pathways in the onset of lung development hampers 
the pulmonary vascular development.
Diaphragm development in CDH
The other pathological characteristic of CDH is the incomplete diaphragm. Many studies 
have focused on either the lung or the diaphragm and not the combination of the two 
structures. The diaphragm and lung develop from different embryonic structures. The major 
diaphragmatic components, the muscle layer and the connective tissue surrounding it, 
develop from three major structures, the septum transversum, the pleuroperitonial fold and 
the somites 29, 43. These structures are all mesodermally derived and thereby have the same 
origin as pericytes. Pericytes in the developing diaphragm have not been studied in detail, 
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During the development of the pulmonary vasculature in congenital diaphragmatic hernia multiple events lead 
to pathological changes in the pulmonary vasculature. Moreover, a cascade of activation and/or inhibition of 
signaling pathways lead to a decrease in newly formed capillaries and thereby an underdeveloped capillary bed, 
neo-muscularization of capillaries and hyper- muscularization.of the mid-sized vessels.
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however they have been characterized in the postnatal diaphragm 44. Thus, pericytes are 
present in the diaphragm and share their origin with the developmental structures of the 
diaphragm. This makes them attractive candidates to understand not only the pulmonary 
vascular abnormalities but also the diaphragmatic defects. Thus further studies should be 
done to add insights in the role of pericytes in the development of the diaphragmatic defects 
in CDH. Lineage tracing studies could help to reveal whether pericytes in the diaphragm 
and pericytes in the lung have the same cellular origin, and are perhaps even derived from 
the same progenitor pool. In the CDH rodent model, the retinoic acid pathway is inhibited 
at E8 and one the targets may be the pericyte progenitor pool. During development 
this progenitor pool will invade the lung and diaphragm and differentiate into pericytes. 
However, the microenvironment and the local signaling cascades in the lung and diaphragm 
are different, resulting in organ-specific responses in the pericytes, which may explain the 
multiple pathological characteristics of CDH. Thus in the lung the signaling cascade will 
result in pericyte hypermuscularization whereas the effect in diaphragm may be opposite 
and leads to insufficient muscularization or uneven muscularization leading to rupture of 
the diaphragm 45
New possibilities for treatment of pulmonary hypertension in CDH rat model
Progress in medicine has resulted in early detection of CDH by ultrasonography usually 
during population screening around 20 weeks of gestation. However, the severity of clinical 
postnatal symptoms remains difficult to predict. This is due to the different gradations 
of pulmonary vascular resistance of CDH patients postnatally and their unpredictable 
responsiveness to current treatment modalities such as nitric oxide (NO). The impaired 
responsiveness to NO may be due to rapid degradation of the intracellular messenger cyclic 
guanosine monophosphate (cGMP) by phosphodiesterase-5 (PDE5) 46. Binding of cGMP to 
PDE5 stimulates the phosphorylation and activation of PDE5 by cGMP-dependent protein 
kinase G (PKG), which results in the conversion of cGMP into GMP 47. Sildenafil is a potent 
PDE5 inhibitor, leading to an accumulation of cGMP and thus the continuous activation of 
PKG. PKG has several physiological substrates, which are involved in smooth muscle cell 
(SMC) relaxation by lowering intracellular calcium 48, 49. Sildenafil also reduces inflammation, 
improves early postnatal survival, prevents pulmonary vascular remodeling in different 
experimental animal models of pulmonary hypertension without CDH 48, 50, 51, and prolongs 
survival and improves lung structure in a neonatal hyperoxia rat model 52.
To study the effect of sildenafil in the CDH rodent model pregnant rats were treated with 
nitrofen at E9.5 and received sildenafil later in gestation. The administration of sildenafil 
during the canalicular stage of lung development resulted in an improved body weight 
and lung to kidney ratio. Furthermore, the alveolar airspaces increased in diameter, which 
could be related to the formation of the primary and secondary septa later in prenatal lung 
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development. Moreover, sildenafil reduced the thickening of the SMC layer in arterioles 
normally present in CDH and prevented the frequently observed aberrant differentiation 
of pericytes in CDH as indicated by the loss of the colocalization of ACTA2 and PDGFRβ in 
the capillaries. However, the control group also showed decreases of the alveolar airspaces. 
The effect in the control group indicates the importance of the balance in the NO pathway. 
Another compound what has been tested for prenatal therapy of CDH in the nitrofen rat 
model is ONO -1301RS. The compound was proven to reduce lung hypoplasia and did not 
affect heart and kidney function. However, the limitation of compound studies is that the 
organs are analyzed post mortem. These analyses will not show any side effects, which may 
occur during birth and postnatal life. It therefore would be beneficial before using these 
compounds in the clinic to study the effect on post-natal function of organs in pups. 
In conclusion
Here, we present new insights into the development of the pulmonary vasculature in the 
retinoic acid deficient mouse model and although the general concept of lung development 
in human and mouse is comparable53, little is known about the differences and the involved 
signaling pathways. Therefore, a next step would be to study how these cells behave during 
human lung development. A possibility to study this is to use in vitro culture systems, like 
3D organoids or a ‘lung on a chip’ principle. The lung on a chip provides a method to culture 
multiple cell layers and thereby create an artificial environment to mimic airflow. These 
cell culture approaches give the possibility to culture patient material, which may help to 
identify the affected processes in lung development associated with CDH. Using multiple 
cell types will give insight in cell -cell interactions during human lung development. The 
lung on a chip technique and organoid cultures with patient material are useful for drug 
discovery and can serve as a diagnostic tool since this culture system provides a method 
to test multiple drugs directly. In addition, an immediate read out can be made of patient 
response to the drug. 
A targeted approach for therapy development for CDH should be based on the knowledge of 
developmental processes and mechanisms. This thesis describes new detailed insights into 
the development of the pulmonary vasculature in CDH, revealing increased pericyte coverage, 
which is the first sign of developing pulmonary hypertension. We furthermore show that 
during early lung development (E13), the endothelial cell population in CDH shows the biggest 
difference in gene expression compared to other sequenced populations. Down regulation of 
KLF4 in CDH may explain the reduced extension of the capillary network in CDH. 
This work is a first step in revealing the early molecular and cellular mechanisms, which 
underlie pulmonary hypertension in CDH. New studies can be designed with this knowledge 
and provide opportunities to treat pulmonary hypertension associated with CDH from 
future perspectives to actual therapy.
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Summary
Congenital diaphragmatic hernia (CDH) is a life-threatening congenital disease which 
occurs approximately 1:2500 life births. CDH is characterized by a defect in the diaphragm, 
pulmonary hypoplasia and pulmonary hypertension (PH). 
The PH associated with CDH is the cause of long term hospitalization and life-long medical 
treatment. The difficulty of treating CDH lays in the fact that CDH patients respond differently 
to therapy for PH. 
PH is characterized by a thickening of the smooth muscle cells layer within the tunica media 
of the arterioles, this is a process called hyper-muscularization. The small capillaries in the 
distal end of the lung are also muscularized, a process what is called neo-muscularization. 
Previous it has been showed that these changes occur already early during development. 
Pericytes are prime candidates to underlie the muscularization of the vasculature in the PH 
associated with CDH. During growth of the pulmonary vasculature pericytes are recruited 
in a PDGFβ dependent manner by endothelial cells to stabilize newly formed tubules. As a 
consequence of the interaction between pericytes and endothelial cells, the pericytes start 
to release Collagen IV (COLIV), a key component of the basement membrane (BM). 
To study the role of pericytes in the development of PH a mouse CDH model was established. 
First, NG2 was identified as the proper marker for pericytes during lung development. An 
increase in pericyte coverage was observed with Fluorescence- activated cells sorting and 
confocal microscopy analysis of immunofluorescent labeled whole mount lung samples 
from E15 onwards in the CDH mouse model. Reduced expression of COLIV was observed, 
indicating that the basal membrane between pericytes and endothelial cells is affected in 
CDH. Furthermore, pericytes in CDH intent to express more smooth muscle actin (ACTA2) 
and loose proliferation and migration capacity. 
Samples of CDH patients confirmed that an increase in PDGFRβ expression, and thus an 
increase in pericytes, is linked to aberrant expression of COLIV at young gestational ages. 
Thus, the increased pericyte coverage is an important factor in the pathogenesis of CDH 
and a lack of COLIV in the BM leads to reduced stabilization of the vessel bed and therefore 
insufficient development of the pulmonary vasculature. 
For further understanding of the pathogenesis of PH associated with CDH whole 
transcriptome analysis on FACS sorted cells was performed at E13 in the CDH mouse 
model. The transcriptome of four different populations, the epithelial, the mesenchymal, 
the endothelial and pericytes were analyzed. The analysis of the RNA seq revealed high 
overlap in the differentially expressed genes between the endothelial cell population and 
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the pericyte, indicating that the signaling between endothelial cells and pericytes is affected 
causing the aberrant vascular development in CDH. Detailed analysis of the RNA sequence 
data revealed that the expression of the gene Kruppel like factor 4 (Klf4) is reduced in the 
endothelial cell population in CDH. The reduced expression of KLF4 was confirmed with 
whole mount fluorescent analysis. KLF4 acts upstream of NOTCH and therefore members 
of the NOTCH signaling pathway were further analyzed. This confirmed disturbed NOTCH 
signaling indicating that the aberrant vascular development in CDH is a result of decreased 
KLF4 expression resulting in disturbed NOTCH signaling
To explore the new possibilities to treat PH associated with CDH sildenafil was administered 
to pregnant female rats after they received nitrofen at E9.5, in the canalicular phase of 
lung development. The administration of sildenafil resulted in improved body weight and 
improved lung to kidney ratio. Furthermore, the alveolar airspaces increased in diameter, 
which could be related to the formation of the primary and secondary septa later in prenatal 
lung development. Moreover, sildenafil reduced the thickening of the SMC layer in arterioles 
normally present in CDH and prevented the frequently observed aberrant differentiation of 
pericytes in CDH as indicated by the loss of the colocalization of ACTA2 and PDGFRβ in the 
capillaries. However, the control group also showed decreases of the alveolar airspaces, 
Indicating the presence of unwanted side effects in the control group.
A targeted approach for therapy development for CDH should use the knowledge of 
developmental processes and mechanisms. This thesis describes new detailed insights 
into the development of the pulmonary vasculature in CDH, revealing increased pericyte 
coverage, which is the first sign of developing pulmonary hypertension. We furthermore 
show here that during early lung development (E13), the endothelial cell population in 
CDH shows the biggest differences in gene expression compared to the other sequenced 
populations. Down regulation of KLF4 in CDH may explain the reduced extension of the 
capillary network in CDH. 
This work is a first step in revealing the early molecular and cellular mechanisms, which 
underlie pulmonary hypertension in CDH.
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Samenvatting
Congenital hernia diafragmatica (CHD) is een levensbedreigende ziekte die ongeveer 1:2500 
geboortes plaats vindt. CHD wordt gekarakteriseerd door een defect in het diafragma, long 
hypoplasia and pulmonaire hypertensie (PH). De PH die geassocieerd wordt met CDH is de 
oorzaak van lange termijn ziekenhuis opname en levenslange behandeling van de PH. De 
behandeling van de PH die gepaard gaat met CHD is moeilijk, dit komt doorrdat patienten 
verschillend reagageren op dezelfde behandeling.
PH wordt gekarakteriseerd door een verdikking van de gladde spiercellen in de tunica media 
van de arteriolen, dit process wordt hyper muscularizatie genoemd. De kleine capilalairen 
zijn ook gemusculariseerd, dit proces wordt neo muscularisatie genoemd. Eerder is al laten 
zien dat deze veranderingen al vroeg in de otnwikkeling zijn te vinden. 
Pericyten zijn geschikte kandidaten om aan de grondslag van de muscularisatie te liggen 
geassocieerd met PH en CDH. Pericyten zijn nodig tijdens de groei van de vaatboom van 
de long. Pericyen worden aangetrokken door endotheel cellen in een PDGFβ afhankelijke 
manier om nieuw gevormde buisjes te stabilizeren.  Door de interactie tussen de endotheel 
celle en de pericyten gaan de pericyten Collageen IV produceren, dit is een van de hoofd 
componenten van het basale membraan. 
Om de rol van pericyten in de ontwikkeling van PH te bestuderen werd er gebrukt gemaakt 
van een muis model voor CDH. Als eesrte werd NG2  geindentificeerd als de meest gechikte 
marker voor pericyten tijdens de long ontwikkeling. Verder werd een toename in het aantal 
pericyte in verhouding met het aantal endotheel cellen. Deze observatie werd gemaakt in het 
muis  model voor CDH vanaf E15 doormiddel van Fluorescent-activated cell sorting (FACS) 
en analyse van complete longen die fluorescent gelabeled waren. Er werd vermidenderde 
expressie van Collageen IV geobserveerd. Dit suggereert dat het basale membrane tussen 
de pericyten en de endotheleel cellen aangedaan is. Verder werden in het CDH muis model 
meer pericyten gevonden die Aplpha smooth muscle actin tot expressive brachten en deze 
pericyen verloren hun capiciteit om te prolifereren en migreren. Preparaten van human 
CHD patienten bevestigden de eerdere bevindingen uit het muis model. In de humane 
preparaten werd meer expressie van PDGFRβ gevonden (dus meer pericyten) en minder 
expressie van Collageen IV vroeg tijdens de ontwikkeling. Samengevat, de vermeerdering 
van pericyten is een belangrijke factor in de pathogenesis van CHD. De vermindering van 
Collageen IV in het basale membraan leidt tot verminderde stabilizatie en daardoor minder 
uitgebreide ontwikkeling van de groeiende vaatboom in CHD.
Om de pathogenese van PH beter te begrijpen werd het complete transcriptoom van FACS 
geisoleerde cellen op E13 geanalyseerd in het muis CHD model. Het transcriptoom van de 
epiteel, de mesenchymale cellen, de endotheel cellen en de pericyten werd geanalyseerd. 
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De analyse van de RNA sequence onthulde een grote overlap tussen de anders gereguleerde 
genen in CHD tussen de endotheel populatie en de pericyten. Dit suggereert dat de signalering 
en communicatie tussen endotheel cellen en pericyten aangedaan is en dat dit de oorzaak 
is van de verminderde vaatgroei in CHD. Gedetialleerde analyse van de RNA sequence data 
onthulde verder dat het gen Kruppel like factor 4 (Klf4) verminderd tot expressive komt in 
de endotheel populatie in CHD. Dit werd verder bevestigd met de analyse van complete 
immunofluorescent gelabelde longen. KLF4 reguleert de signaal route van NOTCH. Hierdoor 
werden leden van de NOTCH signaal route verder geanalyseerd. Deze analyse bevestigde 
dat leden van de NOTCH signaal route veranderd tot expressie komen in CHD. Dit te samen 
laat zien dat de onder onwikkeling van de long vaatboom in CHD wordt veroorzaakt door 
verminderde Klf4 expressie en de ontregelde NOTCH expressie. 
Om verdere mogelijkheden voor de behandeling van PH te onderzoeken werd sildenafil 
gegeven aan zwangere ratten die op E9.5 nitrofen hadden gehad.  De toediening van sildenafil 
resulteerde in de pups met een verbetering van het lichaamsgewicht en verbetereing van de 
long tot nier ratio.  Verder werd er een vergroting van de alveolaire ruimte geobserveerd, 
wat relateert aan de ontwikkeling van de eerst en tweede septa later in de long ontwikkeling. 
Behandeling met sildenafil resulteerde verder in een vermindering in de verdikking van de 
gladde sper cel laag om de arteriolen en verder voorkwam behandeling met sildenafil verdere 
differentiatie van pericyten. Desalniettemin, de groep die geen nitrofen had ontvangen 
maar wel sildenafil, de controle groep, lie teen vernauwing van de alveolaire ruimte zien. 
Dit suggereert dat behandeling met sildenafil ongwilde bijeffecten kan induceren. 
Therapeutische studies naar de ontwikkeling van de behandeling van CHD moet gebruik 
maken van de kennis die beschikbaar is over onwtikkelings processen en moleculaire 
mechanismens. Dit proefschrift beschrijft een gedetialleerd inzicht over de ontiwkkeling 
van de longvaatboom in CHD. Het onthuld een verhoging in de pericyte/endotheel ratio, 
wat het eerste teken is van de ontwikkeling van pulmonale hypertensie. Verder laten we 
voor het eerst zien dat gedurende de vroege ontwikkeling van de long (E13), de endotheel 
populatie in CHD de meeste grote verschillen heeft in gen expressie in CHD. Verminderde 
expressive van KLF4 in CHD kan de verminderde groei van het capillaire network verklaren 
wat gerelateerd is met CHD. Dit proefschrift is een eerste stap in het onthullen van de 
vroege moleculaire en cellulaire mechanismen die ten grond slag liggen aan de pulmonale 
hypertensive geassocieerd met CHD.
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Dear Emma, thank you so much that you’re willing to take part in my committee. Furthermore, 
I am very grateful that you have given me the opportunity to come to work at the Gurdon 
with you. I am looking very much forward to the coming years. I have great respect for your 
great knowledge and great mind.
Lieve Evelien, geniet ervan want hier begint jouw pagina, wel met 1,5 regel afstand. 
Allereerst, natuurlijk zoals ik je al eens heb verteld als ik niet met Maarten was dan was ik 
met jou ;). Verder ben ik enorm blij dat jij ervoor hebt gekozen om je PhD ook in Rotterdam 
te doen anders was ik nooit zo’n had goede vriendin erbij gekregen. Voor jouw inzicht in de 
wetenschap en je kritische en nuchtere houding heb ik enorm veel respect. Tijdens koffie 
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pauzes hadden we daardoor ook vaak best een wetenschappelijke discussie J . Maar we 
hebben ook veel leuke borrels gehad. Ik zeg alleen Boudewijn en dan weet jij de rest. En 
etentjes, het vieren van je 29ste verjaardag in een prive restaurant was toch ook wel een 
hoogte puntje. 
Je verdiend ook mijn dank voor je hulp tijdens onze verhuizing naar Cambridge, want dat 
was ook best een dingetje maar ook hier ben je een enorme steun voor mij en ik denk ook 
voor Maarten geweest.  Ik hoop nog vaak een biertje met je te drinken in Cambridge. De rest 
van de pagina zal ik je wel toe sturen maar als laatste wil ik natuurlijk bedanken dat je mijn 
paranimf wilt zijn, ik weet hoe leuk je dat vindt ;).
Lieve Daphne, ontzettend bedankt dat jij mijn paranimf wilt zijn. Wij zijn ongeveer 
tergelelijkertijd begonnen en tegelijk klaar. Tijdens die jaren heb ik heel prettig met je 
samengewerkt. Samen op woensdagmiddag (soms tot s avonds) ratten ontleden. Verder 
heb ik genoten van onze reizen naar Kaapstad en Toronto. In de jaren zowel op werk als 
daarbuiten heb ik veel respect gekregen voor je nuchtere en altijd positieve (we zijn er echt 
bijna op de tafelberg ) houding.  Ik wens je heel veel suces (met de huisartsenopleiding) en 
geluk samen met Paul.
Alle collega’s van 1034 wil ik natuurlijk bedanken! Allereerst Petra, ontzettend bedankt voor 
je werk tijdens mijn verlof en natuurlijk daarna! Ik wens je heel veel succes en geluk in New 
York. Lieve Marjon, hartelijk bedankt voor je rol als lab moeder de afgelopen jaren, je hebt 
altijd veel intresse getoond en was altijd in voor een praatje. Anne dankjewel voor het delen 
van je verhalen over het moederschap. Lieve Mieke, jij bent altijd een enorm licht geweest 
op en buiten het lab. Superknap hoe jij altijd iedereen op zijn/haar gemak hebt weten te 
stellen. Beste Bob, bedankt voor de small talk op het lab of tijdens de lab etentjes. Dear Koji, 
it was very nice to work with, although it was only for a few months. It was very nice to get a 
little insight into the Japanese culture. I wish you and your family all the best for the future. 
Beste Jennifer, heel erg veel succes met het opzetten van je onderzoek in Rotterdam. Beste 
Gabriella heel veel success met je promotietraject. 
Dear Marta, I have had a wonderful time sitting next to you in the office. You were always 
there to do some chatting and we did have some fun outside the lab as well. I wish you all 
the best in Heidelberg and hopefully I can visit you in the near future.
De overige collega’s van cel biologie, Niels, Shreya, Nuo, Kerstin, Gert, Ser, Sylvia, Nienke, 
Derk Raymond, Andrea, Danny en Judith en Petros en Mariek voor het leveren van de 
nespresso!!
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Gert en Gert-Jan van het imaging centre. Heel erg bedankt voor de hulp de afgelopen jaren. 
Het is enorm leuk en enthousiastmerend om met mensen samen te werken die zo van hun 
vak houden. 
Beste Ingrid (Berger) heel erg bedankt voor je flexibele hulp met de sort.
Bedankt Wilfred van IIcken en Zeiliha Ozgur voor de hulp met het opzetten en het uitvoeren 
van het RNA sequencen
Lieve Mette, derde zus, ontzettend bedankt dat je de tijd hebt genomen  voor het ontwerpen 
van de kaft en de uitnodiging. De dingen die jij maakt zijn zo tof!
Lieve papa en mama heel erg bedankt voor jullie vertrouwen en intresse vanaf het begin van 
mijn studie tot en met het hele promotietraject.  
Lieve lieve zussen, jullie staan altijd voor me klaar en zijn een enorme steun (niet alleen 
tijdens het promoveren). Jullie hebben altijd voor de nodige afeleiding gezorgd (weekendje 
paardrijden, etentjes en ((whatsapp audio)borrels). Ik mis jullie hier enorm en hopelijk 
komen jullie vaak naar Cambridge. 
Lieve broers, bedankt voor alle feesten en partijen de afegelopen jaren.
Lieve Annemarie, jij verdiend een special plekje in het dankwoord. Onze wandelingen 
zorgden er tijdens dit traject voor dat ik de dingen ook van een heel andere kant kon 
bekijken, wat ik zeer inspirerend vond.
Lieve schoonfamilie, bedankt voor de nodige afleidingen (in de vorm van weekendjes en 
vakanties ) de afgelopen jaren.
Lieve Nicoline, jij bent al meer dan mijn halve leven een hele goede vriendin. Ook al zien we 
elkaar soms meer dan anders. Jij staat altijd voor me klaar voor een verdiepend gesprek. 
Lieve Renate, met je positiviteit en nuchtere houding ben je altijd een gewelig gezelschap 
geweest voor afleiding. Ik heb ontzettend genoten van onze ‘vrije’ periode en vind het super 
leuk dat we nu het moederschap delen.
Lieve Benedine (en Steef), ontzettend bedankt voor alle gezellige weekenden die we eerst 
met z’n vieren en nu met z’n zevenen hebben beleefd. Benedine, jij hebt me geleerd de 
dingen te benoemen zoals ze zijn.
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Lieve Djaja, jij bent mijn lievelings en de herinneringen aan onze ISN periode en onze hebben 
me altijd kunnen op vrolijken. Ook al zie ik je niet meer dagelijks je bent altijd in mijn hart.
Lieve lieve Maart, natuurlijk maakte ik een grapje toen ik zei dat ik je niet in mijn dankwoord 
zou noemen. Jij verdient een heel eigen boekje als dankwoord. Om te beginnen heb je altijd 
de tijd genomen om alle presentaties en alles in mijn presentaties recht te zetten en dan 
nam je ook de tijd  naar het oefenen te luisteren. Je luisterde altijd naar mijn soms minder 
interessante gezwets over werk en kon je dat altijd in perspectief plaatsen. Ik heb enorm 
veel respect voor jouw positiveit en geduld.  Zoals op de eerste pagina home is wherever 
I’m with you. Ik ben zo blij dat jij met mij het Cambridge avondtuur hebt aan willen gaan. 
Zoals we al meer dingen hebben meegmaakt, samen kunnen we alles! Jij en muppie zijn het 
allermooiste in mijn leven!!!
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